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"Metals: We know so much and we know so little" 
Arthur Furst 1977 
III 
Abstract 
A study into the applicability of laser ablation inductively coupled plasma-mass 
spectrometry (LA ICP-MS) coupled with native polyacrylamide gel 
electrophoresis (PAGE) to metal speciation in proteins is described in this thesis. 
Chapter one of the thesis outlines the various roles played by metal ions in clinical 
samples. Health risks can arise from anthropogenic metal enrichment and metallo-
drug therapy is identified as a key source. The use of platinum and gold metallo-
drugs is discussed in detail. Speciation of metals in clinical samples is examined, 
concentrating on some of the techniques currently employed and their limitations. 
Particular attention is paid to the techniques employed in the study. The aim of the 
study is outlined - to develop an alternative speciation strategy for the study of 
metals in proteins. The reagents and instrumentation used are described in chapter 
two along with all experimental procedures. 
Chapter three describes the method development and determination of the 
analytical performance of the technique. The technique is used to study platinum 
speciation of protein samples enriched in vitro, the metal distribution profiles 
obtained are shown. The technique is next applied to the analysis of in vivo 
samples obtained from platinum therapy patients and a control source. Chapter 
four outlines the application of the technique to analysis of gold enriched samples 
both in vitro and in vivo from chrysotherapy patients. The gold distribution 
profiles obtained are shown and discussed. Chapter five looks at multi-element 
distribution and interactions occurring in serum. Elements naturally occurring at 
trace levels in serum, such as Cu and Fe, are studied in vivo. Other, lower level 
metals are studied following in vitro enrichment. 
Chapter six concludes the study. It discusses how the technique was found to be 
applicable for metal speciation of clinical samples by meeting the criteria laid out 
at the start of the study. Recommendations for future work are also outlined. 
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Chapter 1: Introduction 
1.1 Role of Trace Elements in the Human Body 
Within the human body there exist a multitude of elements at a variety of 
concentrations (see Appendix 1.1). Some of these elements play important 
biological roles whilst others serve no apparent function. Surprisingly just four 
elements; carbon. oxygen. hydrogen and nitrogen make up over 99 % of the total 
number of atoms present in the bodyl. These four elements are known as the bulk 
elements and are present at the glkg level. A further 0.9 % is made of a group 
known as the macro-nutrients. These seven elements are found in the body at g/kg 
level. All the bulk elements and macro-nutrients are essential to the body. The 
remaining 0.1 % of the body mass is made up of a number of elements ranging in 
concentration from mg-J.1g/kg, these are known as the trace elements. Very little is 
known about the exact biochemical behaviour of most of the trace elements. Table 
1.1 shows a classification of elements commonly found in the human body. 
Class 
Bulk Elements 
Macro-nutrients 
Essential Trace Elements 
Possibly Essential Trace Elements 
Non-Essential Trace Elements 
Elements 
C,H,N,O 
Ca, C~ K, Mg, Na, P, S 
Co, Cr, Cu, F, Fe, I, MIl. Mo, Se, Zn 
Ni, Si, Sn. V 
Ag, AI, As, Au, B, Ba, Cd, Ge, Hg, Li, 
Pb, Pt, Rb, Sb, Sr 
Table 1.1: Classification of elements present in the human body 
Merti first classified the trace elements into two groups; those which have been 
established as essential for life and health, and those for which proof of 
essentiality does not (yet) exist. To avoid confusion a definition of essentiality 
was drawn Up3, it states that an element is regarded as essential when deficient 
intake consistently results in an impairment of function and when supplementation 
with physiological levels cures the impairment. Using epidemiological surveys 
and animal experiments the trace elements found in the human body have been 
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classified. Non-essentiality is however, hard to determine due to the extremely 
low concentrations involved and the problems of contamination. Elements 
previously considered to be non-essential have been found to play important 
biological roles as a result of advancement in analytical techniques. It is, 
therefore, prudent to add a third category containing elements, which may 
possibly be essential. The biologically important elements tend to be the lighter 
elements, which are most abundant on earth. These elements tend to be 
bio-available as a result of their solubility in water. All the essential elements 
should be provided in the diet to prevent deficiency symptoms developing. 
The absolute and relative concentrations of elements are crucial for a healthy 
existence. No element is inherently toxic or beneficial, they all elicit a biphasic 
response. Each element has its own specific curve of biological response against 
concentration, see Figure 1.1. 
Optimal 
+ Excess 
Essentiality 
Concentration 
Toxicity 
-
Figure 1.1: Curve 0/ Biological Response vs. Concentration. Solid line - essential 
elements, dotted line - non-essential elements. Figure adapted/rom" 
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The balance of elements in a healthy body is very delicate since the difference 
between beneficial and toxic levels for some essential elements can be quite small. 
Disorders can occur if this delicate balance is upset and so diagnostic screening of 
body fluids and tissues is often used. Concentrations of essential elements in the 
body are under homeostatic control, but for non-essential elements there are no 
such controls. Extremes in concentration of any element, even the essential 
elements, can lead to illness or even death, see Table 1.2. Recommended Daily 
Allowances (RDA) have been drawn up as a guideline to help minimise the 
occurrence of such toxic effects5• 
The adequacy of a diet is determined not only by the concentration of an element 
in the food, but also the bioavailability of that element, that is its ability to be 
absorbed and utilised by the body. The bioavailability of different elements can 
vary greatly, Na and K are readily absorbed by the body, whilst strongly 
hydro stable elements are hardly absorbed at all. For non-essential elements, levels 
in the body reflect the levels in food and water. Modem day activities such as 
mining and industrialisation have resulted in the increased release of metals into 
the environment, therefore increasing the likelihood of toxicity problems. 
The roles played by essential elements in the human body are many and varied. 
Some elements are of structural importance, such as Si in cartilage and F in bone. 
Once in the body most metal cations are bound to proteins, the ability of an 
element to bind to these proteins (and enzymes) determines the type of role it will 
play. Charge carriers are typically metals with weak protein binding ability, such 
as Na and K. Medium strength binders, such as Ca and Mg, are used to stabilise 
structures. Strong protein binders, like Cu, Zn and Mo, tend to be used as redox 
catalysts in enzymes. Trace elements also function as integral components of 
vitamins and hormones. Some biological processes are very specific in their metal 
ion requirements meaning only certain metals of specific oxidation states can 
fulfill the requirements of a catalytic or structural role. Other processes are much 
less specific in their requirements such that one metal ion can replace another, 
although this can be at the expense of biological activity. 
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Element Deficiency Symptom Excess Symptom 
Ca Bone Deformities Cataract, 
Tetany Gall Stones 
Athersc1erosis 
Co Anaemia Cardiac Failure 
Anorexia Hypothyroidism 
Growth Depression 
Cr Impaired Gluoose Tolerance Lung Cancer 
Elevated Serum Lipids Contact Dermatitis 
Corneal Opacity 
Cu Anaemia Wilson's Disease 
Kinky Hair Syndrome Liver Cirrhosis 
Defective Melanin Production Neuropathy 
Defective Keratinisation Hypertension 
Ataxia 
F Dental Caries Fluorosis 
Fe Anaemia Haemochromatosis 
General Weakness Siderosis 
Liver Cirrhosis 
I Goiter Goiter 
Cretinism Thyrotoxioosis 
K Nephropathy Addison's Disease 
Muscular Weakness 
Respiratory Failure 
Li Manic Depression Hypothyroidism 
Epileptiform Seizures 
Mg Convulsions Anaesthesia 
Mn Skeletal and Cartilage Defects Ataxia 
Gonadal Dysfunction Manganism 
Psychiatric Disorders 
Motor Neurone diseases 
Mo Growth Depression Anaemia 
Defective Keratinisation Gout-like Syndrome 
Hypercipurinaemia 
Na Addison's Disease Hypertension 
Stomach Cramps Fluid Retention/Swelling 
Ni Growth Depression Lung Cancer 
Impaired Reproduction Contact Dermatitis 
Se Liver Necrosis Selenosis 
White Muscle Disease Dermatitis 
Endemic Cardiomyopathy Arthritis 
Osteoarthropathy Hair Loss 
Si Growth Depression Silioosis 
Bone and Cartilage Defects 
Sn Impaired Digestion Visual Defects 
Growth Depression Electroencephalographic 
Abnormalities 
V Growth Depression Mucosa Membrane Irritation 
Failure to Reproduce 
Zn Anorexia Pancreatic and Renal Damage 
Growth Depression Anaemia 
Sexual Immaturity Skeletal and TIssue Lesions 
Hypogonadism Perinatal Mortality 
Skin Lesions 
Hyperkeratosis 
DePression of Immune Response 
Table 1.2: Symptoms of deficiency and excess of some essential elements. 
Table adaptedfrom6 
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A large number of complex interdependencies exist between the elements present 
in a human body. An example of some interdependencies is shown in Figure 1.2. 
Trace elements can exert stimulatory or antagonistic effects upon one another. 
Elements of similar ionic radius and electronic configuration are likely to 
compete, see Table 1.3. Such interactions can include substitution at an active site 
on an enzyme or competition for binding to a transport or storage protein. As a 
result of these interdependencies an excess of one element can interfere with the 
biological activity of another, for some elements such interferences are well 
documented whilst little is known about others. The presence of complexing 
agents in the body, such as EDT A, can affect the delicately balanced homeostasis. 
TI Mg 
K 
/ 
Ba 
r 
S Al ~ 
Si 
Mo 
Figure 1.2: 1nterdependencies 0/ elements in the body. Figure adapted/rom7 
Knowledge of these elemental interactions can be useful, an example of such a 
case is the use of Se to protect against the toxicity of some heavy metals. Se has a 
high affmity for Hg, Cd and Ag readily complexing these elements and so 
decreasing their biological activity. 
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An excess of Can produce a deficit of 
Cd Se, Zn 
Ca Zn 
Fe Cu,Zn 
Mo Cu 
Zn CU,Fe 
Table 1.3: Competition between some essential elements, table adapted/rom8 
1.2 Metabolism of Trace Elements in the Human Body 
Metals are absorbed into the body by ingestion, inhalation or more rarely by 
resorption through the skin. Once absorbed metals and their compounds enter the 
blood where they are mostly bound by blood cells and/or plasma proteins. This is 
a rapidly reversible process. Plasma protein binding can be specific as in the case 
of transferrin (Fe) and ceruloplasmin (eu) or non-specific as in the case of 
albumin - the most abundant serum protein. The bloodstream then distributes the 
metals throughout the body. Serum is an important channel of transport for many 
metabolic entities and so helps maintain metabolic stability within the human 
body. High molecular mass blood cells and proteins bound to metal ions cannot 
cross the capillary walls and so the transfer of metal ions to body tissues is 
dependent upon the diffusible fraction, that is the fraction not bound. Metals can 
be lost from the body in two ways via the liver or via the kidneys. The manner in 
which metals are excreted depends upon the individual metal. Sodium and 
potassium go through the kidneys (i.e. excreted in the urine) along with very small 
amounts of copper and zinc. In general, however, most of the trace metals are lost 
via the liver (i.e. in the faeces). Figure 1.3 illustrates the possible pathways of 
ingested trace metals. 
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1 
7 
Diet 
M 
2 
Plasma 
1-----+,- . M ------< ;: 
M : , 
M 
Figure 1.3: Metal ion absorption and excretion 
1) Metal intake 5) 
2) % Absorption 6) 
3) Transfer tolRelease from tissue 7) 
4) Storage 
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Urinary excretion 
Re-excretion by bile 
Faecal excretion 
Metal cations found within the body are mostly bound to proteins. The role that 
each metal ion serves is, therefore, dictated by its ability to bind to these proteins, 
and in particular enzymes. Metals with weak binding ability, such as sodium and 
potassium, act as charge carriers. Medium strength binders, such as calcium and 
magnesium, act to stabilise structures whilst those with very strong binding 
abilities, such as copper, zinc and molybdenum, act as redox catalysts. Metal 
toxicity is attributed to metals binding with enzymes and other molecules 
preventing normal biological functioning. 
To understand further the biologicaVtoxic roles of trace metals it is necessary to 
take a closer look at serum proteins and the possible binding interactions that can 
occur with trace metals in the body. In general all proteins are able to bind metals 
on their surface. Proteins are macromolecules, which serve a variety of critical 
biological functions. The building blocks of proteins are amino acids, polymerised 
by condensation reactions as shown in Figure 1.4. 
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I I 
:NH-2 -C-COOH 
I 
+ :NI-t---C-COOH 
I 
R R' 
I ~ I 
· :NHi-i-C-,-i-cOOH + H20 
R H R' 
Figure J. 4: Condensation of amino acids to form polypeptides and proteins 
The tenn 'metal binding' is somewhat misleading. The subject of metal 
adsorption by serum proteins was poorly understood until Langmuir wrote two 
papers clarifying the subject9, 10. It is now known that a considerable amount of 
metal binding occurs on the surface of the proteins, with covalent bonds 
(relatively rare but very strong - 40-140 kcaVrnole) occurring only in the centre of 
the protein. When dissolved, proteins are in a colloidal state and so have an 
enormous surface area for adsorption (1 cm3 serum = 100 m2 protein surface) II • 
Despite the fact that most protein-metal interactions are not true bonds the tenn 
'bond' is still widely used. 
To understand in detail the effects of trace metals on living systems it is necessary 
to know the nature of the protein binding sites. There are 20 naturally occurring 
amino acids, each with a different functional group, R (see Appendix 1.2). The 
amino acids most likely to bind trace elements in serum are aspartic acid, glutamic 
acid, cysteine (S donor) and histidine (N donor)12 and possibly lysine (N donor)13. 
Important information about metabolic homeostasis can be obtained from the 
identification of specific ligand-protein interactions in serum since protein binding 
controls the distribution of trace metals to tissues, the rate and mechanism of their 
release and also regulates the metabolism/loss of trace metals. Some typical metal 
binding sites are given in Table 1.4. 
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Metal Ligand 
Fe2+, Fe3+ 0, N, S, 
alkaline earth metals 0 
lanthanides 0 
Ae+, Cr3+ 0 
di-positive first row transition metals N 
Mn2+ ::::) Cu2+ N 
Zn2+ NorS * 
Cd2+, CH3Hg +, Pb2+ S 
Table 1.4: Favoured metal binding ligands. * Depending on chelation 
The toxic action of trace elements may be due to the protein complexes formed in 
the serum. Changes in the molecular structure of proteins result in the appearance 
of acute metal poisoning. The metals may block active sites, break hydrogen (H) 
bonds or change the conformation and solubility of the proteins. Toxicity tends to 
increase with decreasing electron configuration stability, hence, heavy metals are 
potentially the most toxic elements. This can be explained by the increased 
affinity of heavy metals for amino, imino and sulphydryl groups all of which 
make up the active centres of enzymes and proteins. The exact proteins affected 
by such heavy metal toxicity are not known. 
The chemical forms of trace elements in the body determine their physiological 
behaviour, much work has been done in this field by Comelis14, IS. These different 
chemical forms are known as species and their study is known as speciation. The 
official definition of speciation currently under discussion at IUP AC states that; 
"Speciation analysis is the process leading to the identification and determination 
ofthe different chemical and physical forms of an element existing in a sample,,16. 
A prime example of metal toxicity being determined by valence state is the 
element arsenic, As(V) is relatively harmless whereas As(III) is highly toxic. 
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Toxicity can also be affected by biomethylation. Metallic mercury does little harm 
to man, but RHg+ compounds, particularly methylmercury cations, are extremely 
toxic due to their ability to cross the blood-brain barrier. Hence, when analysing 
biological samples there is a need for speciation, that is a need to know where the 
element is located and what form it exists in. Total elemental concentration very 
rarely yields adequate information to determine biological status. 
1.3 Anthropogenically Enriched Elements in the Human Body 
In recent years levels of elements previously rare in the biosphere have increased, 
mainly due to industrialisation. Industrialisation has led to the widespread 
pollution of air and water. This has, in turn, led to pollution of the food chain. As 
a direct result the occurrence of pollutant trace metals in the human body has 
increased. Zn smelting has led to a hundred fold increase in Cd levels17, whilst the 
widespread introduction of the automobile has led to an increase in Pb 
emissionsl8 • Many occupations now carry a risk of exposure to such elements and 
their associated toxic effects. As a result clinical screening is used to warn of such 
risks. Whilst at the moment there are no known biological roles for elements such 
as Ta and Zr the increased presence of such elements as contaminants in the 
environment may lead to their incorporation into biological system. This leads to 
the need for increased knowledge on the function of such elements in the body 
and also the future need for toxicological studies. 
Another source of increased metal exposure is the use metallo-drugs in medicine. 
Metallo-drugs are being utilised increasingly, one of the problems associated with 
their use is the poor characterisation with respect to in vivo toxicity. The mode of 
action, identification of target sites and potential toxicity of the compound are all 
important details concerning the development of metallo-drugs. The effect of a 
drug upon biological processes in the body is dependent upon the active site ofthe 
drug. Most modem drugs incorporate metal ions as part of their active site (See 
Table 1.5) and so the mode of action is determined by the type of metal present. 
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Element Compound Use 
Ag Ag( sulfadiazine) Antibacterial 
Al KAI(S04n. 12H20 Astringent Antacid 
Al AI(OH)3 Antiperspirant 
As A~03 Antileukaemic 
Au Au(thioglucose ) Antiarthritic 
B BI2HIISHr Neutron Capture Therapy 
Ba Ba salts X-ray Diagnosis 
Bi K3[Bi(citraten] Antiulcer, Antacid 
Ca CaC03 Antacid 
Ce Ce(N0 3)3 Bum Wounds 
Co Coenzyme BI2 Pernicious Anaemia 
Cu CuC03 Dietary Supplement 
F SnF2, NaF Anticaries 
Fe [Fe(Me4phenhr Antimicrobial 
Fe Na2[Fe(N0)(CN)~] Vasodilator 
Gd Gd(chelate) Magnetic Resonance Imaging 
Ge carboxyethy\ Ge(IV) Anticancer 
La La carbonate Kidney Disease 
Li Li2C03 Manic Depression 
Mg MgO Laxative, Antacid 
Mn Mn(chelate) Magnetic Resonance Imaging 
N N20 Anesthetic 
Os tetroxide Antiarthritic 
Pt cis-Pt(NH3nCh Anticancer 
Ru [Ru(Me4phenMacac )t Antimicrobial 
S Na2S2~ Cyanide Antidote 
Sb NaSb(gIuconate) Antileishmanial 
Se Se~ Antiseborrhoeic 
Sn Sn(protoporphyrin)-( Ch) Jaundice Treatment 
Tc Tc propyleneamineoxime Diagnostic Radio Imaging 
Xe Xenon gas Anaesthetic 
Zn ZnC03,F~03 Skin Ointment 
Zn Zn sulfate Wound healing 
Zr Zr lactate Antiperspirant 
Table 1.5: Metallo-drugs in common use. Table adaptedfroml9. 
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The general rules governing which metals bind to which biological sites (as in 
Table 1.4) hold true for metallo-drugs. Heavy metal complexes tend to act by 
binding to nucleic acid bases and phosphate groups, and so alter their structure. It 
is thought that many metallo-drug side effects do not result directly from the 
mode of action of the drug but are instead caused by their incidental interactions 
with proteins. Metallo-drugs can be administered in a number of ways; orally, 
intra-venously, parenterally or topically. Once administered the drugs enter the 
blood stream. As with all trace metals entering the circulatory system they are 
reversibly bound to plasma proteins (rapid) or to blood cells (slower). An 
equilibrium is set up between the bound and unbound forms of the drug, the 
unbound form is, in general, pharmacologically active. Availability of the drug to 
the tissues is determined by the position of equilibrium that governs the amount of 
free (unbound) drug able to diffuse freely between the blood and body tissues. 
The formation of such a bound drug complex acts to prolong drug action by 
reducing the amount of free drug available for metabolisation. The complex acts 
as a depository for the drug by slowing down elimination. The more strongly the 
drug is bound the lower the pharmacological activity due to lower drug 
concentration reaching the tissues, but these levels will be maintained for longer 
periods of time than is the case with more weakly bound drugs. Protein-drug 
binding can also act to protect the body from drug metabo lisation in the liver and 
kidneys. Generally only the free drug is metabolised as the protein binding sites 
usually have a greater affinity for the drug than the metabolising system. 
1.3.1 Platinum Drugs 
Heavy elements rarely occur naturally in biology, that is to say most heavy metals 
are 'unnatural' in man. This does not mean that they do not occur or have 
potential uses. Prior to 1969 most cancer research was centred on the potential 
carcinogenicity of metals and their salts, rather than potential anticancer 
properties. This is hardly surprising, as medical scientists tended to regard all 
heavy metal compounds as non-selective poisons. There are, however, a number 
of metal complexes used in cancer chemotherapy, with a family of neutral 
platinum complexes being the most important. 
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The anti-tumour activity of platinum ammine complexes was discovered quite 
fortuitously by Rosenberg in 196520 whilst studying the effect of an 
electromagnetic field on cell division. A weak alternating current was passed 
through Escherichia coli using inert Pt electrodes in a nutrient medium containing 
ammonium chloride. The cell division was inhibited whilst cell growth was 
unaffected leading to filamentous growth of the cells21 . The effect on the cells was 
found to be due to electrolysis products of the Pt electrodes within the cell 
medium, specifically a substance known as Peyrone's chloride22, first synthesized 
in 1845. 
Platinum based drugs have been in use since the early 1970's and cisplatin is now 
one of the most widely used anticancer drugs23. In tumour cells genetic control of 
the cells life span is lost, resuhing in the uncontrollable growth of the tumour 
tissues. Anti-tumour drugs are, therefore, designed to interfere with this cell 
proliferation by blocking synthesis of DNA, RNA or proteins in the cell nucleus. 
Reactions involving the drug occurring in other regions, such as with serum 
proteins, can lead to toxic side effects. These drugs will also damage any normal 
cells undergoing division, especially susceptible are the dividing cells found 
within hair follicles and bone marrow. Such side effects limit both the size and the 
frequency of dosage administered. It should be noted that most of the agents that 
chemically modify DNA are themselves mutagenic. They must be considered as 
potential carcinogens and so need to be handled with the utmost care. 
The compound cis-diamminedichloroplatinum(II), is commonly known as 
cisplatin, and its chemical structure is shown in Figure 1.5. It is the parent 
compound of a family of platinum drugs and is used in the treatment of ovarian, 
cervical, bronchial, lung, testicular, endometrial, bladder and prostate cancers as 
well as head and throat tumours. Evidence shows the anti-tumour activity of 
cisplatin to be due to it reacting and inhibiting the replication of cellular DNA24. 
The trans isomer is found to have no anti-tumour activity and is toxic. Despite its 
wide field of applicability, the use of cisplatin is severely limited by its numerous 
side effects, in particular nephrotoxicitys, which may be attributed to the 
inactivation of essential proteins by chelation of platinum to thiol residues26. This 
theory is backed up by the fmding that the chelating agent diethyldithiocarbamate 
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(DDTC) is capable of reducing cisplatin related toxicities without affecting the 
efficacy of the drug27• This is possible because DDTC is capable of reversing 
cisplatin-protein interactions but is incapable of reacting with bio-complexes 
involving cisplatin and guanine bases28• It is also possible to reduce the severity of 
the nephrotoxicity, with no effect on the activity of the drug, by hydrating the 
patients prior to treatment29• The use of cisplatin has a number of other 
disadvantages besides its high toxicity such as the need for administration by 
intravenous injection and the possibility of patient resistance. Cisplatin resistance 
is thought to be due to a number of factors which include decreased drug 
transport, increased cell detoxification due to increased metallothionein levels 
(known to detoxify heavy metals) and alterations of the apoptotic cell death 
pathwaYo. 
Of the second generation platinum drugs available the most popular is diammine 
(I, I-cyclo butanedicarboxylato )-platinum(II), commonly known as Carboplatin, 
see Figure 1.5. Carboplatin shows a similar activity to cisplatin, and is less toxic31 
with respect to the peripheral nervous system and the kidneys - despite the dose 
levels being higher. The dose limiting side effect for carboplatin is 
myelosuppression (bone marrow damage). The co-planar structure of carboplatin 
is thought to be responsible for the delay in its degradation into potentially 
detrimental derivatives. Since evidence to date suggests cisplatin and carboplatin 
have the same mechanism of action32 and produce the same DNA lesions it can be 
inferred that the differences in toxicity of the two drugs are due to their different 
pharmacokinetics and distribution properties. 
l-J NIII", "",ICl ~~ "'pf" 
~N~ ~Cl 
Carboplatin Cisplatin 
Figure 1.5: Commonly used platinum anti-tumour drugs 
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Third generation drugs are currently under development. In these the platinum 
complex is coupled to a functional carrier molecule, which improves the 
selectivity of the drug for the tumour tissue. Cytotoxically active carriers, such as 
doxorubicin, can synergistically contribute to the efficacy of such platinum 
drugs33• Synthetic, water-soluble, polymeric carriers designed for the binding of 
antineoplastic co-ordination compounds of the cisplatin type, can be resistant to 
serum protein binding. This may lead to a reduction in toxic side effects. 
Knowledge about the mode of action of cisplatin and the other platinum drugs 
could lead to information about the mechanisms of toxicity and the structure-
activity relationship. This information could then be used to develop more potent, 
less toxic platinum analogues. It might also be used to improve the scope of 
activity to include other forms of cancer, such as breast cancer. Figure 1.6 shows 
the metabolic pathway for cisplatin 
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Figure 1.6: Metabolic pathway for cispiatin (Adaptedfrom Ref34) 
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Cisplatin is thought to be cytotoxically active due to its ability to selectively bind 
to biological molecules, something that is not possible with the trans isomer. The 
chloride ligands are found to be labile whilst the Pt-amine linkage is found to be 
very stable against nucleophilic attack. Upon injection cisplatin enters the blood 
stream. The relatively high chloride ion concentration in human serum (-100 
mM)3S limits the amount of aquation as chlorine substitution reactions are slow. 
The drug, therefore, remains reasonably intact as it is transported around the body 
in the blood stream. Whilst in the blood stream reactions with blood proteins may 
occur, a likely candidate for platinum binding are thiol groups ofproteins36, which 
are known to have a high affmity for platinum. It has been show that 24 hours 
after injection of cisplatin virtually all the platinum is bound to plasma proteins37, 
38. Transferrin is thought to act as a carrier for delivering platinum drugs to cancer 
cells39 and so maintaining cytotoxicity. However, it has been found that blood 
platinum binds mainly to albumin resulting in a decrease in the biological activity 
of cisplatin40, and also to globulin41. 
Once in the blood stream neutral drug compounds are readily able to penetrate the 
cell membranes. The chloride ion concentration of the intracellular fluid is often 
relatively low (-4 mM) and so substitution reactions will occur leading to the 
aquation of the platinum drugs. Aquation is the step necessary to activate the drug. 
The aquated complex is more labile than the original complex (due to water being 
a better leaving group with respect to Pt(II) than the chloride ion) and it is able to 
react with a variety of biological ligands, forming covalent bonds with proteins, 
DNA, RNA and other nucleophiles in the ce1l42. After reaching the tumour cells 
cisplatin binds with DNA causing cell death by apoptosis (programmed cell 
death). After interaction with cell DNA the degradation products of cisplatin are 
excreted via the liver and kidneys. Carboplatin has been found to aquate at a 
slower rate than cisplatin32, this could explain the reduced toxicity associated with 
carboplatin therapy. 
The precise mechanism of action of cisplatin is still the subject of research. It is 
generally accepted that the anti-tumour effect of Pt(II) complexes is due to its 
interaction with DNA. Cisplatin binds to the DNA molecule of tumour cells and 
so prevents cell replication. There are a number of possible modes of platinum 
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binding to DNA as shown in Figure 1.7. In theory the cationic Pt(II) species can 
bind to all sites with lone pairs, but the Guanine N7 sites are the most easily 
oxidisable DNA sites and as such tend to be favoured over other sites. The 
bonding of Pt to two N atoms of the same DNA strand43, with Guanine as the 
preferred linkage44, 45, is thought to be responsible for the anti-tumour activity. 
Such an intra-strand linkage is not possible for the trans isomer of cisplatin, giving 
a possible explanation for its inactivity46. 
dlelate coordination 
to a guanine base 
1.2-intrastrand cross-linking 
DNA-protein cross-iinlGnt 
Figure 1.7: Modes of platinum-DNA binding,figure adaptedfrom34 
Platinated DNA can be analysed by a number oftecbniques such as NMR, X-ray 
crystallography and electron microscopy. The results of analysis show the 
favoured sites of interaction. It can also be determined that cisplatin unwinds the 
DNA, shortening it by up to 50 % of the original length, and can cause binding 
and kinking of the DNA helix47• Cisplatin damages DNA in a way that healthy 
cells can repair but which cancerous cells cannot. Despite this a number of 
toxicities are observed with cisplatin use. Cisplatin is found distributed throughout 
the kidney, causing it to be toxic above critical levels. Such toxicity may be due to 
the inhibition of enzymes through co-ordination of platinum to sulphydryl groups 
in the proteins. 
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Most of the current research has been done into the interaction of platinum drugs 
with DNA48,49, as this is the mechanism whereby this class of platinum complex 
exerts its specific activity. Next comes research into total platinum serum levels50, 
51. Relatively few studies into platinum-protein interactions are carried out52, 53, 
this is possibly due to the finding that in vitro cytotoxicity of cisplatin is reduced 
on binding to plasma proteins54• As already mentioned cisplatin is found to 
rapidly react with serum proteins forming complexes with no cytotoxic activity. 
Such platinum-protein interactions are thOUght to contribute to the toxic side 
effects, particularly those involving kidney damage. Knowledge of platinum-
protein complex formation is, therefore, important for toxicity studies and was the 
motivation for this study. 
In order to make meaningful correlations between platinum blood levels and drug 
efficacy andlor toxicity it is necessary to distinguish between free circulating 
(active) drug and protein bound (inactive) platinum. This can be achieved using 
uhrafiltration55, but for speciation information powerful separation tools such as 
HPLC are required. Chang et al. 56 reported the first analytical technique capable 
of quantifYing cisplatin in the presence of other platinum species. Cisplatin was 
isolated by HPLC using a strong anion exchange column. Since then a number of 
platinum speciation methods have been developed, these being summarised in 
Section 1.4. 
1.3.2 Gold Drugs 
Chrysotherapy, treatment with gold, gets its name from the Greek XpU(J'o~, 
meaning gold. Gold, unlike platinum, is an ancient metal and has a long medical 
histo~7. The tradition of eating gold foil appears to have started in ancient China 
and then spread to India. The Hindu religion's association of gold with 
immortality has meant that many modem-day Hindus and some Moslems also eat 
gold foil in their food. Arab scientists often experimented with various forms of 
gold in the first millennium AD. In the 8th century gold was recommended as a 
panacea, a view held as recently as 1500 AD by Paracelsus58• 
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By the mid 19th century gold therapy was favoured in homeopathy and gold was 
thought to protect against leprosy. In 1890 Kochs9 found that gold(l) cyanide, 
AueN, inhibits the bacteria causing tuberculosis. It was this work done by Koch 
that put chrysotherapy on a good footing and paved the way for the use of gold 
salts in the treatment of tuberculosis (TB), syphilis and a number of other 
pathogenic organisms. 
Due to the high toxicity of AueN it was unsuitable for widespread use and so in 
1917 Feldt60 first tested gold thioglucose (still used today) for the treatment ofTB. 
The first person to use chrysotherapy for non-TB purposes was Lande61 . He 
observed the relief of joint pain in patients he was treating with gold thioglucose, 
and hence suggested its beneficial effects in arthritis. The French physician 
Jacques Forestier is usually credited with the first treatment of rheumatoid arthritis 
(RA) by chrysotherapy62. Forestier used gold thiopropanol sodium sulphate, and 
suggested that the effectiveness of the drug lay in the combination of gold with 
sulphur. In 1934 Forestier recorded a 70-80 % success rate with 500 RA 
patients63. 
Au3+ is isoelectronic with Pt2+ and so it is of interest as an antineoplastic drug64• 
19SmAu is used for angiocardiography6s. There are a number of reviews on the 
various types of gold therapy in use66~8. The main application of gold containing 
drugs is in the treatment ofRA, which we will concentrate on here. The gold salts 
used are known to retard the progression of bone and articular destruction. All 
gold drugs are Au(I) compounds, since Au(III) is much more toxic to humans. 
The accumulation of high concentrations of gold in the bloodstream can lead to 
toxic side effects, and so the monitoring of gold in the serum and urine of patients 
undergoing such treatment is required. Gold drugs used to treat RA fall into two 
main groups, oral and parenteral. 
Only one of the more modem orally administered gold drug has found widespread 
acceptance, Auranofin, see Figure 1.8. Auranofin is a lipid-soluble monomer 
enabling it to be administered orally. It has a gold content of29 %. 
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Figure 1.8: Oral gold drug 
Parenteral drugs are administered by injection and are the older class of gold 
drugs. There are a number of parenteral drugs available, see Figure 1.9. Of all the 
parenteral gold drugs available to treat RA the most widely used is sodium 
aurothiomalate (Myocrisin). Myocrisin is a water-soluble polymeric compound 
that is insoluble in hydrophobic environments. It is, therefore, administered 
intramuscularly in the form of an aqueous solution, this prevents hydrolysis by the 
acidic gastric juices. It has a gold content of around 45 % in the powdered form. 
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Figure 1.9: Parenteral gold drugs 
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The use of gold thiolate compounds in the treatment of RA is limited by the 
occurrence of toxic side effects. The side effects resemble allergic reactions on 
skin and mucous membranes as well as gastrointestinal and renal problems. Such 
side effects occur in about one third of patients undergoing chrysotherapy with 
parenteral drugs, a lower toxicity is associated with oral drug treatment. It is 
assumed that some of the toxic side-effects are due to the formation of Au(III) 
compounds. Adverse side effects usually disappear after reduction or cessation of 
dosage. In more severe cases the toxicity of gold drugs may be reduced by the 
addition of sulphur-chelating agents such as penicillamine, or dimercaprol, since 
Au(l) is known to form thermodynamically stable complexes with sulphur 
ligands. 
Despite the many tens of millions of people that suffer from RA69 together with 
the fact that chrysotherapy, widely used for well over fifty years, has been proven 
to induce remission7o, the physiological or chemical mechanisms whereby gold 
drugs alleviate RA remain elusive71 -73• However, the pharmacokinetics of 
parenteral and oral gold drugs are known to differ widely74. Gold does not have 
well defined transport, storage or enzyme functions in the human body. A possible 
metabolic pathway of gold drugs is outlined in Figure 1.10. 
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Figure 1.10: Metabolic pathway of gold drugs 
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Immediately after administration myocrisin in the blood is associated mainly with 
serum proteins, whilst auranofin is equally distributed between the serum and 
erythrocytes. After 72 hours auranofin gold is also localised in the serum 
proteins7s. Au(l) has a high affmity for thiolate S, but binds only weakly to 0 and 
N ligands. As a resuh, cysteine rich proteins are targets for Au(I) binding, whilst 
the binding of Au(I) to DNA is weak76. In the bloodstream most of the gold from 
myocrisin is present in the serum, the majority of which (80-90 %) is bound to 
albumin", whilst most of the remainder is associated with globulins7s. For 
myocrisin, the gold content of each protein fraction, isolated by electrophoresis, 
differs from patient to patient, but remains constant for anyone patient as the level 
of drug in the serum increases during therapy79. These fmdings seem to imply that 
there are a number of gold binding sites of comparable strength in serum, which 
are not saturated at the gold levels achieved during therapy. Typical 
concentrations of gold in the blood of patients are in the range of 0.1-10 J.1g/mLso. 
The level of gold in the serum reflects the size of the administered dose, total 
elimination from the body can take over a year after cessation of therapy. 
Surprisingly no correlation has been found between serum gold levels and clinical 
response and/or toxicity. 
Blood plasma proteins playa role in drug delivery and targeting. Albumin carries 
70-95 % of circulating gold in blood of patients treated with gold anti-arthritic 
drugs81 , via Cys3482, 83. Plasma proteins, principally albumin, act as a major long 
term pool for a large proportion of the administered gold present in the blood. 
Some gold is absorbed on albumin, probably as the unchanged or partially 
metabolised drug. This gives rise to a more active pool of gold which will transfer 
more easily and so have more clinical relevance than the unbound gold. Myocrisin 
is also known to react readily with zinc metallothionein in vitro with gold 
replacing the zinc84• 
RA is an autoimmune disease involving the painful inflammation of tissue 
surrounding the joints. The areas of inflammation are found to accumulate 
macrophages and neutrophile polymorphs, the lysosomal enzymes that destroy the 
articular cartilage8s. Gold is found to accumulate preferentially in the inflamed 
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joints86, due to the phagocytosis of gold-albumin complexes. Gold is concentrated 
in the lysosomes, forming aurosomes, where it inhibits the lysosomal enzyme 
activity. This inhibition is thought to be due to the co-ordination of gold to the 
thiolate groups present in the enzymes87• 
The cause of the toxic side effects associated with chrysotherapy is poorly 
understood. It has been demonstrated that the observed toxicity may be due to the 
oxidation of Au(I) to Au(III) in vivo88-90• In inflammatory situations oxidation 
may be due to the in vivo presence of strong oxidants CIO- and H202. The aqua 
complex of Au(I) is unstable and disproportionates thus; 
3Au(I) ~ 2Au(O) + Au{lII) 
The Au(III) metabolites produced can, in turn, readily oxidise peptide and protein 
groups and di-sulphide bridges91 and so may lead to toxic side effects. 
Abraham and Himmel92 have reported on the oral administration of colloidal gold 
to RA patients not responding to conventional gold therapy. They found this 
treatment to be effective and found no clinical or laboratory evidence of toxicity. 
These findings are consistent with the theory that the active ingredient in 
chrysotherapy is Au(O) and the toxic side effects are caused by Au(III), generated 
from the oxidation of the Au(I) drug. There is, therefore, a need to develop new 
speciation tools with which to study Au speciation of patients undergoing 
chrysotherapy. Speciation data can then be used to further toxicity studies by 
helping to elucidate the toxic species and the mechanism of toxicity. This 
knowledge may then be used in the development of new, less toxic drugs. 
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1.3.3 Other Metal Based Drugs 
Many other metal based drugs are in use daily, Table 1.5 is in no way exhaustive 
as there are far too many metallo-drugs to mention in full. The table clearly shows 
that it is not only the elements essential to good health that are utilised in 
medicine. Lots of metal based drug therapy involves the use of exogenous metal 
ions, metals which are non-essential for life, such as Ag, AI, Ge, Li and Sb. A 
brief description of some of these metal-based drugs follows. Figure 1.11 shows 
the structures of some metal based drugs; the anti-tumour drug titanocene 
dichloride, an antimetastatic Ru drug and sodium nitroprusside used as a 
hypertensive agent during heart surgery. 
Cl 
2-
Cl 
Figure 1.11: Some examples of metal based drugs 
In their simplest form metal-based drugs are used as dietary supplements to treat 
the symptoms of essential element deficiency. Metal based drugs can also be 
administered to counter the effect of an excess of a chemically similar element in 
the body, although excess metal levels in the body are more frequently treated by 
chelating agents. 
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Some metals serve a wide range of therapeutic roles, for example the application 
of silver in medicine is widespread. It can be used as an anti-bacterial agent, in the 
treatment of gonococcal infections, and is even used in chewing gum for people 
wishing to give up smoking. 
Some metals have more specific roles, be they anticancer, antiinfective, 
antiarthritic or neurological. Lithium salts are used in the treatment of manic 
depressive (bipolar) psychoses and other neurological and psychiatric disorders. 
Manic depression is thought to be due to too much catecholamine-related activity. 
Treatment is needed to reduce the activity of dopamine or norepinephrine. 
Lithium carbonate is particularly effective in the treatment of manic depression as 
it counteracts both phases in the typically cyclic course. It provides mild sedation 
without the non-specific tranquilising effect of phenothiazines. Successful lithium 
treatment requires around 1 mmole Li+ IL blood, toxic side effects may be caused 
by 2 mmoles LtlL blood, whilst 8 mmoles LtlL blood can be fatal, giving 
lithium one of the narrowest therapeutic indexes of commonly used drugs. 
Lithium sahs commonly have a coordination number 6 which means they can 
easily replace sodium or magnesium in 6 co-ordinate holes, this is done in 
preference to remaining as the insoluble lithium salt. Lithium is not bound by 
proteins or metabolised and so virtually all of the lithium administered is excreted 
in the urine. 
Radionuclides have an increasingly important role to play in modem medicine. 
They are used not only as conventional therapeutic drugs, but also find 
applicability in diagnostic imaging. Magnetic resonance imaging (MRI) is also a 
popular diagnostic tool employing metal-based drugs. 
The use of metallo-drugs is a very exciting and promising area, creating a great 
deal of interest. It has only been possible to touch upon the subject briefly here, 
more detailed information on the role of metal ions in medicine can be obtained 
from recent reviews93,94. 
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1.4 Trace Element Determination and Speciation in Biological 
Systems 
In recent times there has been a growth in biological and clinical interest in trace 
element determination and speciation. This is due to a number of factors; 
• improved analytical techniques with low limits of detection 
• recognition of essentiality of elements previously considered non-essential 
• recognition of deficiency syndromes 
• widespread use of metallo-drugs with possible toxic side-effects 
• increased exposure to heavy metals due to industrialisation 
1.4.1 Trace Element Determination 
Humans are exposed to many naturally occurring and anthropogenic ally enriched 
metals, all of which are detrimental to health at high enough doses. To help reduce 
the likelihood of toxicity exposure regulations have been formulated. 
Determination of metal concentrations in human body fluids and tissues is 
necessary in order to assess current human exposure, it can also be used for the 
diagnosis and prognosis of diseases. Such an example is infectious hepatitis where 
the concentration of copper in serum is directly related to the severity of the 
disease. Monitoring of metal levels in the blood of patients undergoing metallo-
drug therapy is particularly important. Patients receiving lithium treatment may be 
monitored in this way to help prevent the build up of toxic lithium levels. 
Availability of biological samples is usually limited, and the metals of interest are 
usually at trace levels. As a result of these limitations a suitable technique for 
trace metal analysis of biological samples needs to be highly sensitive (- ngIL 
range) requiring J.11 samples with little or no sample preparation to avoid 
contamination. The analytical techniques which have been utilised in trace 
element studies include neutron activation analysis (NAA), X-ray fluorescence 
(XRF), voltammetry, inductively coupled plasma optical emISSIon 
spectroscopy/mass spectrometry (ICP-OES or ICP-MS) and atomic absorption 
spectrometry (AAS). Table 1.6 shows typical relative detection limits for some of 
these techniques. 
26 
Metal ICP-OES FlameAAS GFAAS Voltammetry ICP-MS TXRF NAA 
Ag 1.80 1.50 0.0]5 0.10 0.03 0.4 2.00 
Al 7.00 45.0 0.]5 0.03 0.]6 - 4.00 
As ]1.0 30.0 0.60 <0.20 0.04 0.20 0.05 
Au 3.00 10.0 0.30 ]0.0 0.06 0.20 0.005 
Be 0.20 3.00 0.0]5 - 0.10 - -
Bi 11.0 30.0 0.30 <0.10 0.04 0.20 20.0 
Cd 1.00 0.70 0.006 <0.0002 0.03 0.40 1.50 
Co 3.00 9.00 O. ]5 <0.005 0.0] 0.]0 0.03 
Cr 1.50 3.00 0.06 0.02 0.0] 0.40 20.0 
Cu 1.50 1.50 0.06 0.002 0.02 0.10 0.10 
Fe 1.50 7.50 0.06 <0.04 0.20 0.20 6.00 
Ga 11.0 150 0.20 0.004 0.08 - 0.06 
Ge 9.00 300 0.45 - 0.02 - 0.50 
Hg 7.00 300 1.20 0.005 0.02 0.20 0.03 
In 25.0 30.0 0.]5 - 0.06 - 0.0006 
La 2.30 3000 - - 0.01 - 0.06 
Li 1.20 0.70 0.06 - 0.10 - -
Mg 0.10 0.15 0.0]2 - 0.]3 - 25.0 
Mn 0.30 1.50 0.03 40.0 0.03 0.20 0.003 
Mo 2.00 45.0 0.]2 100 0.04 0.20 10.0 
Nb 8.00 3000 - - 0.02 - 200 
Ni 4.00 6.00 0.30 0.001 0.04 0.10 ]5.0 
Pb ]5.0 15.0 0.15 0.001 0.0] 0.20 3000 
Pd 9.00 30.0 0.75 0.02 0.06 - 0.]2 
Pt 7.00 60.0 1.50 <0.000] 0.08 0.20 1.00 
Sb ]1.0 45.0 0.60 0.10 0.06 0.50 0.20 
Se 20.0 150 0.60 0.02 1.00 0.20 l.l 
S. 10.0 30.0 0.60 <0.03 0.06 0.50 2.00 
Ta 8.00 ]500 - - 0.02 - 1.30 
Te 155 30.0 0.30 0.06 0.08 1.00 0.50 
n 8.00 - - 3.00 0.02 - 0.]6 
Ti 0.60 75.0 1.20 100 0.32 0.40 10.0 
TI 18.0 0.]5 0.]5 0.015 0.05 0.20 40.0 
U 26.0 45000 - 0.03 0.0] 0.002 -
V 1.20 60.0 0.60 100 0.03 0.20 0.15 
W 8.00 ]500 - 1000 0.05 - 0.045 
Z. 0.75 1.50 0.03 0.02 0.0] 0.10 2.50 
Zr 3.30 1500 - - 0.03 0.30 ]00 
Table 1.6: Typical relative detection limits/or various techniques. Values given in 
pg/L. Table adaptedfrom95 ' 
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NAA works on the principle of exciting the atomic nuclei by particle irradiation 
within a nuclear reactor. The number of excited atoms depends on the intensity of 
the irradiation and is directly proportional to the number of atoms present. After 
excitation the atoms decay and emit a- or 13- particles and/or 'Y-quanta 
characteristic of each isotope present. As an analytical method NAA is unique in 
that it involves the excitation of the atomic nucleus and so the elements are 
determined independently of their physical and chemical state. Despite it being a 
very sensitive technique requiring no sample pre-treatment, NAA does not find 
wide usage mainly due to the limited number of suitable nuclear research reactors. 
The technique also proves expensive, requiring specially trained and experienced 
staff, is time consuming and cannot be used for all isotopes due to lack of suitable 
daughter nuclides. Whilst not used as a routine technique NAA is one of the best 
methods for the certification of reference materials in the biological field96• 
XRF is a powerful multielement analysis technique requiring no sample pre-
treatment, it can be used to analyse solid samples directly. It uses the principle 
that atoms subjected to radiation eliminate electrons from the inner atomic shells. 
Electrons from outer shells drop into the free positions and so emit simple 
electromagnetic radiation, which is unique to each excited element. 
Voltammetry is based on Faraday's law that 1 mole ofa compound transformed in 
an electrode process is equivalent to the electric charge n x 96500C (where n is 
the number of electrons transferred). This makes vohammetry potentially a very 
sensitive and selective technique. However, there are certain drawbacks to the 
method. The metals for determination need to be completely dissolved in a non-
interfering analyte solution of sufficient conductivity. Even residual traces of 
organic matter can severely interfere and so biological samples must be totally 
decomposed before analysis. Samples must also be degassed as dissolved oxygen 
can interfere with resuhs. Since each metal has a certain redox potential at a 
certain working electrode it is often possible to do sequential simultaneous 
determination of several metals. 
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OES is based on the generation of radiation by a host of transitions, resulting in 
complex spectra. The radiation intensity is directly proportional to the atom 
concentration. In order to determine elemental concentrations from the multitude 
of lines proper optical resolution is necessary. OES is well suited to multielement 
determinations. Inductively coupled plasma is a common excitation source for 
OES, and such systems can offer sequential or simultaneous multielement 
determination at the J.1g/L level. ICP-OES is a widely used technique due to its 
ability to perform rapid multielement determinations with relatively low limits of 
detection with possible automation. Electrothermal vaporisation allows direct 
sample insertion, which can improve detection limits. 
AAS is based on the principle that an atom absorbs radiation at the same 
wavelength at which it emits radiation. The sample is atomised in the light path of 
a specific radiation source. The amount of absorption is directly proportional to 
the number of atoms present. This gives an absorption spectrum, which is much 
simpler than the equivalent emission spectra. The two main types of AAS are 
flame atomisation and graphite furnace (GF). GF-AAS is considered accurate and 
precise and has been used as a reference method. With its multi-element 
capabilities and its relative cheapness, it has found numerous applications. Flame 
AAS is not as popular due to poorer limits of detection for many elements, the 
need to digest organic samples to minimise interference problems and lengthy 
analysis times. Almost all trace elements of interest in clinical chemistry have 
been determined in body fluids and tissue samples using AAS. 
MS works on the principle of gaseous ion production, either thermally or by an 
ion current. The ions or molecular fragments are separated by energy-mass 
focusing, using magnetic fields. The charged particles are then determined 
qualitatively or quantitatively. MS is a simultaneous multi-element technique, 
which has been used in combination with a number of techniques. For the 
determination of trace element concentration in biological samples ICP-MS is one 
of the most common techniques. 
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ICP-MS was introduced by Houk et al in 198097 and uses the high ionisation 
efficiency of inductively coupled plasma to ionise the samples. It has sub J.lg/L 
detection limits for many elements. ICP-MS is of particular interest for biological 
samples due to its rapid sample throughput and isotopic dilution capabilities. 
Limitations ofICP-MS include non-spectral interferences from the matrix effects 
and with the quadrupole mass spectrometers isobaric interferences are possible 
due to the nominal mass resolution. Isobaric interferences lead to complications in 
determining masses below 80 at low concentration. Some of these problems can 
be got around by keeping dissolved solids below 0.2 % for continuous 
nebulisation, and by using internal standards, matrix matching, standard additions 
or isotope dilution. High resolution MS can also be used for determination of 
elements below mass 80. 
Table 1.7 shows the applicability of the various techniques to total elemental 
concentration determination in biological samples. In clinical chemistry AAS 
tends to be favoured for the determination of trace metals due to practicability, 
time needed for analysis, cost of equipment and possibility for automation. 
Analytical Technique Element Matrix 
XRF PtYII·~ serum & urine 
NAA multi element 'W biological samples 
Voltammetry PtIUI• IUZ urine, hair & blood 
Glow Discharge MS Pb & PtIU~ urine 
AAS AU 'U4-'UO plasma 
ICP-MS Pt II17• IIU biofluids 
multi element II I. 112 serum 
Ag, Cd, Co, Pb & Sbl13 liver 
ICP-OES multi element 114·117 serum 
Table 1.7: Determination o/total elemental concentration in biological samples 
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The analytical procedure of choice depends on the trace metal of interest, the 
matrix and the concentration. AAS is generally limited to liquids and is suited to 
single element determinations. Since becoming commercially available ICP-MS 
has proved very effective in determining trace elements in biological samples. 
Table 1.6 shows ICP-MS is one of the most versatile and sensitive techniques 
available. Only NAA and voltammetry offer some limits of detection lower than 
ICP-MS. Both these techniques have problems with cost and sample 
preparation/applicability, respectively, which prevent their widespread use in 
biological analysis. Since ICP-MS is such a powerful, multielement technique 
which was used throughout the study it will be discussed here in more detail. The 
fIrst paper published on ICP-MS was in 198097, and in 1983 Perkin-Elmer SCIEX 
introduced the fIrst commercially available ICP-MS instrument. Today the 
technique is used daily in many laboratories as a routine analytical tool offering 
lower detection limits and higher productivity than optical ICP techniques. A 
further advantage of ICP-MS over AAS and ICP-OES is its ability to determine 
individual isotopes of elements. 
ICP-MS can measure most elements in the periodic table. The high temperature of 
the plasma ion source completely breaks apart the molecules of the sample and so 
ICP-MS detects only elemental ions. An advantage of ICP-MS over other 
inorganic techniques for elemental determination, such as ICP-OES and AAS, is 
its ability to determine individual isotopes of each element. ICP-MS tends to have 
less interference problems than ICP-OES and is faster than AAS when carrying 
out multielement determination. Detection limits are generally much lower than 
with ICP-OES and AAS, and with computer control an ICP-MS system can be run 
virtually 24 hours a day, 7 days a week. ICP-MS is a powerful multi-element 
technique for both qualitative and quantitative analysis. The sample, in aerosol 
form, is fIrst injected into the inductively coupled plasma. The resulting elemental 
ions are then extracted into the mass spectrometer for detection. A schematic of 
the HP4500 instrument used is shown in Figure 1.12. 
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Figure 1.12: Schematic of HP4500 ICP-MS 
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Most of the samples analysed by ICP-MS are liquids. The nebuliser converts the 
sample to an aerosol, which is passed through the spray chamber and into the 
plasma by the carrier gas. As well as conventional nebulisation a number of 
'hyphenated' techniques exist. These include microconcentric nebulisation 
(MeN), direct injection nebulisation (DIN), flow injection analysis (FIA) and 
laser ablation (LA) which is covered in detail in the next section. 
The plasma is generated by passing argon through the ICP torch, a series of three 
concentric quartz tubes encircled at one end by a water cooled, copper radio 
frequency (RF) load coil. The RF energy couples with the argon of the middle 
tube to produce the plasma. The outer tube carries a tangential flow of argon, this 
cools the torch to prevent it from melting and also positions the plasma. The 
sample aerosol is introduced into the plasma through the innermost injector tube. 
The sample punches a hole in the plasma and a toroidal plasma is produced with a 
central axial channel. This plasma formation ensures homogeneous sample 
introduction. The sample is first atomised and, on absorbing more energy, the 
atoms release an electron to form singly charged ions (doubly charged ions are 
also observed for some elements). In quantitative analysis it is important to have 
an efficient and reproducible excitation source. An ICP source achieves this 
thanks to the high temperatures present in the plasma, 6000 - 10000 K. The ions 
produced are extracted from the plasma into the interface region, see Figure 1.13. 
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Figure 1.13: Torch and interface region of ICP-MS 
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Mass Analyser 
An interface region is necessary to compensate for the high temperature and 
pressure differences that exist between the plasma region and the MS region of the 
instrument. The ion interface consists of two cones, an outer sampling cone, 
which is positioned in the analytical zone of the plasma. The skimmer cone is 
positioned several millimetres behind the sampling cone. The cones are typically 
made of nickel due to its high thermal conductivity, and robustness (although 
platinum can be used where nickel is inappropriate), and are water cooled to 
prevent damage from the heat of the plasma. The orifices of the cones are <lmm 
in diameter, large enough to prevent them clogging yet small enough to maintain a 
vacuum and minimise contamination of the mass spectrometer. The pressure 
difference between the plasma (atmospheric pressure) and the MS (high vacuum -
10-6 torr, 10-4 Pa) causes the ions in the plasma to be extracted through the cones 
into the ion lens region. 
The ion lens region is positioned immediately behind the interface and acts to 
focus ions into the quadrupole region. The positive ions produced in the plasma 
tend to repel each other and so lenses are needed to keep the ion beam from 
diverging. The HP4500 ICP-MS uses a unique type of lens system, known as the 
off axis system shown in Figure l.14. Two extraction lenses accelerate the ion 
beam before the Einzel lenses focus the ions. Next the Omega + and Omega -
lenses bend the focused ion beam allowing the quadrupole and detector to be 
positioned off axis. This off axis set up reduces the random background noise, and 
so gives a higher sensitivity. 
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The ion beam is next fed into the mass analyser which separates, by mass, the 
singly charged ions. The HP4S00 uses a quadrupole mass analyser as shown in 
Figure 1.15. This is basically a mass filter consisting of four parallel, hyperbolic 
Mo rods to which are applied a constant voltage and a RF oscillating voltage. A 
hyperbolic electric field is generated inside the quadrupole, which allows only 
ions of a specific mass to charge ratio (m/z) to pass through to the detector. Other 
ions do not have a stable path and are lost or neutralised by the quadrupole rods. 
PB + (U + Vcos rot) 
PB - (U + Vcos rot) 
Figure 1.15: Quadrupole mass analyser 
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Ions exiting from the mass analyser next enter the detector, which generates a 
measurable electronic signal proportional in intensity to the number of ions. 
Discrete dynode electron multiplier detectors are used in the HP4500, as shown in 
Figure 1.16. An ion enters the electron multiplier and hits the ftrst dynode. A 
flurry of electrons is generated which go on to hit the next dynode, in turn 
generating more electrons. The electrons generated are eventually detected by the 
collector. The signal obtained is amplified to give a measurable electronic signal. 
Collector 
Figure 1.16: Discrete dynode detector 
Computers with specially designed software are needed to control the plasma and 
mass spectrometer and also to interpret the data collected. HP 4500 software is 
specially designed and so is capable of a number of modes of analysis. Time 
resolved analysis is usually used with flow injection or laser ablation as it can 
monitor signal intensity as a function of time. For semi-quantitative analysis a 
calibration solution is made up containing as few as three elements, and the 
software calculates the approximate concentrations of the elements of interest. For 
full quantitative analysis the calibration standards much contain every element of 
interest. The ability to distinguish between different isotopes of the same element 
makes ICP-MS suitable for isotope ratio work (e.g. geological dating) and isotope 
dilution work (very accurate, used to certify CRM's). 
The major interferences experienced with ICP-MS are isobaric overlaps, oxides 
and other polyatomic species, doubly charged ions and matrix effects. Isobaric 
overlap occurs when isotopes of two different elements have the same m/z ratio 
such that they can not be resolved by the mass discriminator. Quadrupole mass 
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analysers typically operate at low resolution (l amu), more expensive high 
resolution ICP-MS systems are available at the cost of sensitivity. Such problems 
can be got around by using a different isotope of the element of interest or by 
using specially designed correction software. Interference from polyatomics can 
be more problematic. Oxides commonly appear, mainly from aqueous sample 
solutions and so these can be minimised by reducing solvent loading. Laser 
ablated samples rarely suffer from oxide interferences due to the lack of solvent. 
Polyatomic argon species also occur, these can cause interferences up to mass 80 
(40 Ar40 Arj. Argon polyatomics are often problematic when analysing biological 
samples as they can interfere with Cr and Fe. Such interferences are best 
controlled my manipulation of operating parameters. Doubly charged ions can 
occur for elements with sufficiently low ionisation potentials, i.e. Ca, Sr, and Ba. 
Doubly charged ions appear in the mass spectrum at half the mass of the parent 
singly charged ion. In general, interferences from doubly charged ions are few and 
can be avoided. Internal standards can be used to correct for matrix effects. Ideally 
internal standards should not occur naturally in the sample and should not be 
likely contaminants in the laboratory, Rh and In are popular choices. 
1.4.2 Separation 
In order to gain an insight into the activity of specific metals in the environment, 
especially those in contact with biological organisms, the total metal concentration 
of a sample is not always sufficient. In such cases it is useful to gain an indication 
of the metals various chemical and physical forms, as these determine its 
biological effect. This is the case in the majority of treatments involving metals. 
Analytical techniques are needed which can characterise the products of metallo-
drug metabolism and so a better understanding of the interactions of metallo-drugs 
with transport proteins and DNA can be achieved. Successful therapy often 
involves selectivity and so it is the concentration of one or more specific forms of 
the metal that is important rather than its total concentration. Table 1.8 shows how 
the biological effects of certain elements can depend upon their chemical 
speciation. 
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Element Predominantly Beneficial Potentially Toxic 
Species Species 
As As(V) compounds As(III) compounds 
Ba Chloride Nitrate 
C Widespread in biochemistry Cyanide ion 
Cr Cr(lll) compounds Cr(VJ) compounds 
Cu Carbonate Chloride 
Table 1.8: Dependence of biological effect on chemical species. Table takenfromllR 
Successful speciation of a biological sample involves a fractionation scheme 
whereby the concentrations of the element that are, for example, protein bound, 
bound to low molecular mass components and present as aquated ions, are 
estimated. There has been an increase of interest in speciation in recent years, as 
suitably sensitive analytical techniques have become more widely available. 
Speciation studies are important in a number of different fields, including 
biochemistryll9, environmental sciencel2o, food science l21 and hydrochemistryl22. 
An indication of the importance of speciation studies is reflected in the large 
number of review papers available on the subjectIS,123.126. 
Here we will concentrate on the importance of speciation in biological systems. 
Identification of specific ligand-protein interactions in serum can yield important 
information about metabolic homeostasis. Diagnostic information concerning a 
number of serum binding proteins is important in clinical diagnosis whilst the 
identification of drug transport proteins yields important therapeutic information. 
In occupational health speciation plays an important role, especially in the 
identification of potentially toxic chemical species in the workplace. 
A simple way of separating free and protein bound metal ions is by filtration. 
Depending on the grade of filter used a wide variety of biomolecules can be 
separated, see Table 1.9. 
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Size Mr Example 
100 Jlm Pollen 
10 Jlm Starch 
Blood cells 
Typical bacteria 
I Jlm 
Smallest bacteria 
1000 A 
DNA viruses 
100 kDa 
100 A Albumin 
10kDa Vit BI2 
I kDa 
lOA Glucose 
IA Water, NaCI ] 
Table 1.9: Variety o/filters available/or separation o/biomolecules 
Membrane Process 
Microfiltration 
(10 ~-0.02~) 
Ultrafiltration 
(0.03 ~-O.OOI ~) 
Reverse Osmosis 
(0.001 ~-O.OOOI ~) 
In ultrafiltration the sample is filtered using a filter with a known molecular 
weight cut off (MWCO) i.e. 30 kDa. The filtrate consists of small particles and 
molecules with molecular mass less than the cut off, whilst the large molecular 
mass fraction is retained by the filter. It is assumed that metal found in the flltrate 
is in the unbound (active if a drug) form. It is possible for metals to bind to low 
molecular mass fractions such as citrate and so for a true determination of 'free' 
and 'bound' levels more sophisticated methods of separation are needed. 
Chromatography works on the principle that different compounds travel at 
different speeds through a colUlllll, under distinct conditions. Discrete fractions 
are eluted to give sharp peaks in the time/concentration profile. There are a 
number of classes of chromatography available, from gas chromatography (GC), 
for the separation of volatile compounds to high-performance liquid 
chromatography (HPLC), for non-volatile compound separation. 
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A more sophisticated separation technique, capable of separating proteins, is 
electrophoresis. Electrophoresis is a technique that separates charged molecules 
by migration in an electrical field. Proteins carry a net charge at pH' s other than 
their isoelectric point (PI). The rate of protein migration depends upon the charge 
density, the higher the ratio of charge to mass the faster the migration. 
Electrophoresis is a well-established technique fIrst used by Tiselius127 in 1933 to 
analyse serum proteins. 
The pioneering work done by Tiselius was carried out in free solution, but this 
suffered from diffusion and convection currents. A support medium was 
introduced to minimise these effects such that the sample components remained in 
sharp zones. The earliest supports used were of fllter paper and cellulose acetate 
soaked in buffer. The next major advancement in support media was the 
introduction of starch gels, still used on occasion. Nowadays most electrophoresis 
is carried out on agarose or polyacrylamide gels. 
Electrophoresis units are available in horizontal or vertical orientation. Vertical 
mini gel units as shown in Figure 1.17 are available commercially for the 
separation of proteins. The mini gel system (gel length - 10 cm) is well suited to 
native protein separation as the small format reduces electrophoresis and 
processing time, thus minimising the likelihood of protein denaturation. 
Upper Buffer 
Sample Well 
Sample 
r-r---- Glass Plates 
Ht--f---- Resolving Gel -----l---lf-
Figure 1.17: Typical vertical mini gel system 
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Resolving gels are cast between glass plates, typically 1 mm apart, using plastic 
combs to form the sample wells. When the gel system is assembled the buffer is 
placed in the upper and lower chambers. In continuous systems the same buffer is 
used throughout. Discontinuous systems use different upper and lower buffers and 
include a stacking gel above the resolving gell28. The role of the stacking gel is to 
focus the sample loaded on the gel, but when separating serum proteins the 
stacking gel can cause the proteins to aggregate and precipitate out. This being the 
case continuous gels were used throughout. Sample buffer is added to the samples 
prior to loading. The sample buffer generally contains a tracking dye 
(bromophenol blue) which aids sample loading and moves with the solvent front 
thus indicating when electrophoresis is complete. The sample buffer also contains 
glycerol which, being more dense than the running buffer, allows the samples to 
sit in the wells and so prevents diffusion into the upper buffer. Once the samples 
are loaded into the sample wells the appropriate DC voltage is applied via 
platinum electrodes. 
Rapid separation is desirable to preserve protein band sharpness. The higher the 
voltage applied the faster the rate of migration, but the greater the Joule heating 
which can distort the protein bands. A compromise is needed to minimise the 
heating but maximise the migration rate. The design of the system is such that the 
upper buffer is between the gels being run and so can cool them and minimise 
heat gradients. The voltage is removed once the tracking dye has reached the end 
of the gel, that is, before the samples reach the electrode. This ensures the proteins 
are separated according to their electrophoretic mobility. 
After electrophoresis is complete the gels can be preserved by drying on filter 
paper or between sheets of cellophane. Proteins in the gel can be detected by 
staining. The sulphated trimethylamine dye Coomassie Brilliant Blue R-2S0 is the 
most common protein stain. An acid-methanol-dye mix is used to precipitate or 
fix the proteins in the gel. The dye then penetrates the gel and binds to the proteins 
within the gel. A destaining solution is used to remove surplus dye. After staining 
gels can be dried in the usual manner. 
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The electrolyte buffer used in electrophoresis is very important as it determines 
the power requirements and affects separation. Proteins vary in size, shape and 
charge. Being amphoteric, proteins take on the characteristics of the buffer. In 
acidic buffers (PH's below their pI) NH3+ groups are produced, whilst in alkaline 
buffers (PH's above their pI) COO- groups are produced, see Figure 1.18. 
When separating proteins there is no definitive buffer, but buffers of pH 8.6, such 
as Tris-HClIglycine129, are widely used in native PAGE as they render the proteins 
quite soluble and the proteins retain their native form. At pH 8.6 most proteins 
have a net negative charge and so will migrate towards the anode. 
COOH 
NH3 
pH<pI 
net positive charge 
coo-
NH3 
pH=pI 
no net charge 
Figure 1.18: Amphoteric nature of proteins 
coo-
pH>pI 
net negative charge 
Polyacrylamide gel electrophoresis (PAGE) is the most common matrix medium 
used for the separation of proteins. Its popularity lies in the fact that it is optically 
clear, chemically inert, electrically neutral, is stable over a wide range of 
temperature, pH and ionic strength, and is available in a wide range of pore sizes. 
Polyacrylamide gel is made up of long linear polyacrylamide chains crosslinked 
with bis-acrylamide (bis) to create a network of pores. Polyacrylamide gels are 
characterised by T %, the weight percentage of total monomer including 
crosslinker. T % gives an indication of the pore size, in general as T % increases 
the pore size decreases. A protein's ability to move through the gel depends on its 
size and structure relative to the pore size; as a rule, larger molecules tend to 
migrate more slowly than smaller ones. No single concentration will give 
maximum separation for the components of a complex protein mixture such as 
serum. Gradient gels can also be used, these have a linear pore gradient along the 
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length of the gel. T % increases, and so pore size decreases in the direction of 
migration. Gradient gels act as molecular sieves, the proteins are continually 
entering regions of the gel with smaller pore sizes and so the advancing edge 
migrates slower than the trailing edge resulting in sharper bands 130. Gradient gels 
are especially suited to complex protein mixtures as they increase the molecular 
mass range that can be separated on a single gel. 
Proteins can be separated in a number of ways. Native PAGE uses non-
dissociating buffers which separate the proteins in such a way that sub-unit 
interactions, biological activity and native protein conformation are all preserved. 
This approach is appropriate when studying metal speciation as any metal-protein 
interactions will remain intact. To maintain proteins in their native state it is 
essential that the pH of the buffer falls within a range for which the proteins are 
stable. Tris-HClIGlycine buffer is the buffer of choice for electrophoretic 
separation of most native proteins. In native PAGE the proteins are separated on 
the basis of both size and charge, see Figure 1.19. To achieve the best resolution 
as small a volume (as thin a zone) of sample as possible needs to be loaded. 
A) Before voltage applied 
B) After applying voltage 
':::-.:-V 
Figure 1.19: Electrophoresis on basis of protein mass and charge 
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One of the most popular gel systems for separating proteins is SDS-PAGE, 
described in 1967,131 it was introduced in its current form in 1970132. The proteins 
are denatured using a buffer containing the strong anionic, protein-dissociating 
detergent, sodium dodecyl sulphate (SDS) and a thiol reducing agent such as 
2-mercaoptoethanol. The proteins are dissociated into individual, rod shaped, 
polypeptide units which bind SDS in a constant weight ratio (1.4 g SDS/g 
polypeptide \33). SDS effectively masks the intrinsic charge of the polypeptide 
chains giving them a constant net negative charge per unit mass, hence proteins 
migrate as a function of their molecular mass. The high resolution achievable with 
SDS-PAGE relative to native-PAGE comes at the expense of protein activity and 
native structure. When studying metal-protein interactions protein denaturation is 
undesirable since it leads to the breakdown of disulphide bridges and hydrogen 
bonds. This can cause the proteins to uncoil exposing weak ligand binding sites 
previously inaccessible. In the case of albumin, an important transport protein, 
binding sites made up from the sub-unit arrangement are lost on denaturation. 
lsoelectric focusing (IEF) is a high-resolution electrophoretic method, which 
separates proteins in the presence of a continuous pH gradient. The pH gradient 
increases from anode to cathode and is formed using carrier ampholytesl34 or an 
immobilised pH gradient (lPG)13S. Proteins migrate according to their charge until 
they reach a pH at which they have no net charge (their isoelectric point - pi). At 
this point the proteins are focused into a narrow band\36. Typical pH ranges are 3-
10 while most protein pI's are in the range 4_6137, see Appendix 1.3. Small mobile 
ions in the sample (salts) can have detrimental effects on IEF as they can alter the 
net charge and pi of proteins and can slow down migration rates. As a result 
samples for separation by IEF should fIrst be desalted using dialysis or a desalting 
column. It is also possible to separate proteins by isoelectric focusing without the 
presence of a gel. This can be done using Bio-Rad's unique Rotofor system. 
Separation occurs entirely in free solution and so after separation the sample 
fractions can be easily collected, pooled and refractionated if required. The 
proteins remain in their native form as they remain in solution throughout the 
separation. 
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One dimensional (ID) electrophoresis gives only limited resolution and protein 
bands often overlap. In 1975 two dimensional (2D) electrophoresis was 
developed 138 with high-resolution capabilities. 2D electrophoresis generally 
combines IEF, separating proteins according to pI, and SDS, separating proteins 
according to molecular mass. This technique is capable of resolving up to 10000 
spots, but a drawback is that it is a technically demanding and labour intensive 
procedure. Despite 2D electrophoresis having the highest resolving power, ID 
electrophoresis is the more widespread technique. In many situations the 
resolution achieved with ID is fit for purpose and it is much easier to use with the 
added advantage of being able to run samples simultaneously for comparison. 
Quantitative analysis of metal ions associated with proteins is difficult when 
protein molecules are enclosed in the gel. Areas of the gel containing proteins of 
interest can be excised and digested before analysis, but this is at best a qualitative 
technique. Ahernatively proteins separated by PAGE can be recovered from the 
gel. This can be done either by Western blotting (poor or no protein transfer for 
high molecular mass proteins) or by electrophoretic elution. Simultaneous electro-
elution of multiple protein bands separated by electrophoresis can be achieved 
using the mini whole gel eluter, as developed by Bio-Rad. Proteins are 
electrophoretically transferred from the gel across a dialysis membrane, to be 
collected in one of 14 buffer filled chambers. A reasonable amount of protein is 
recovered in this way, although not all. Some protein remains in the gel, whilst 
proteins can also be lost by adsorption to the dialysis membrane. The protein 
concentration of the recovered fractions can be determined using standard 
biochemical techniques. 
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1.4.3 Hyphenated Approaches 
Speciation of biological samples typically involves a sample pre-treatment step 
followed by a selective biocompound separation step and finally a sensitive, metal 
specific, detection step. An inherent drawback with such hybrid systems lies in the 
fact that biological separation procedures were not originally designed to meet the 
requirements of trace element determinations and so they present a large 
contamination/element leaching hazard. Speciation studies generally assume that 
biomolecules and trace metals detected in the same fraction of a sample are 
associated with each other. 
Speciation of biological samples can be troublesome due to a number of factors; 
• 
• 
• 
• 
• 
• 
low metal concentrations 
small sample volume availability 
complex matrices 
poor specificity for biocompound separation 
contamination 
possible loss of integrity of metal-ligand binding 
As a result successful speciation techniques require; 
• high sensitivity, with respect to metal detection 
• good selectivity, with respect to biocompound separation 
• mild conditions, to maintain sample species integrity 
A landmark paper written in 1979 by Van Loonl39 regarding hyphenated 
techniques (as they later came to be known) led to a surge of interest in speciation. 
However, this is not to say speciation work was not carried out prior to this date. 
Despite poor limits of detection, proteins were being separated and analysed for 
metal ions as early as the 1960'SI40. 
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Early speciation work was done, in genera~ using gel electrophoresis to separate 
the metal species141 • Off-line detection could then be carried out directly on the 
gel. Alternatively proteins were extracted (blotted) from the gel prior to detection. 
Speciation by coupling chromatography to a suitable detection system has 
generally become a favoured approach. The separation technique used is 
determined by the physico-chemical properties of the analyte, e.g. GC favours 
volatile analytes. The choice of detection method is determined by the level of 
analyte in the sample, whilst the matrix dictates the sample preparation strategy. 
Table 1.10 lists techniques widely used. 
Separation Techniques Detection Techniques 
Supercritical Fluid Chromatography Fluorescence 
Liquid Chromatography Absorption Spectrometry 
Reversed Phase Graphite Furnace 
Ion Exchange Quartz Furnace 
Size Exclusion Flame 
Affinity 
Gas Chromatography Mass Spectrometry 
Packed Column Inductively Coupled Plasma 
Megabore Column Electrospray Ionisation 
Capillary Column 
Electro Chromatography Emission Spectroscopy 
Gel Electrophoresis Inductively Coupled Plasma 
Micellar Electrokinetic Microwave Induced Plasma 
Capillary Zone Electrophoresis Direct Current Plasma 
Field-Flow Fractionation 
Filtration Electrochemistry 
Dialysis Ion Selective Electrode 
Ultrafiltration Voltammetry 
Flow Injection Analysis Nuclear Magnetic Resonance 
Neutron Activation Analysis 
Table 1.10: Techniques widely used in metal ion speciation. 
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Capillary electrophoresis (CE) is becoming more widespread, although there are 
still a few problems associated with the interface when coupling to elemental 
detectors such as ICP-MS. In general the combination utilised is dictated by the 
nature of the compounds being separated. Table 1.11 shows a selection of 
speciation studies carried out on biological samples and the main metal species 
detected. 
Analytical Technique Element Matrix Species 
2D JEPI Fe, Zo, Cd, serum Fe-transferrin, Ca-albumin and 7 other 
Autoradiography Ni & Ca142 proteins, 9 Zo binding proteins, 4 Cu 
binding proteins and 2 Ni binding proteins 
Ni143 serum Several Ni binding proteins, including 
albumin 
Electrophoresis! Au· .... serum Au binding to albumin and globulins 
ET-AAS CU'145 serum Cu mainly bound to ceruloplasmin 
also Cl2-protein fraction 
HPLC I ET -AAS Se'4b serum Selenoprotein-P, glutathione and albumin 
HPLC I Flame-AAS Au '41 urine Au bound to albumin and high molecular 
mass species 
HPLC I HG-AAS As· .... serum Separate monomethylarsonic acid (MMA), 
As(III), As(V) and dimethylarsinic acid 
(DMA) 
HPLC I ICP-MS PtI4'/,13U serum Separation ofPt drugs and metabolites 
Zn151 serum Zn binding to transferrin and 
Cl2-macroglobulin 
AU152 urine Au drug/metabolite separation 
multi milk Preferential binding of elements to high 
element1S3 and/or low molecular mass fractions 
CE/ICP-MS II;)'> serum Separated iodine, thyroxine and 
triidothyroxine 
Electrophoresis! Ptl~~, I~D serum Inconclusive 
ICP-MS C0 1S7 serum Co bound to albumin, Clrmacroglobulin, 
Cll-lipoprotein, Cll-antitrypsin and 
PI-lipoprotein 
Table 1.11: Analytical techniques used in metal speciation o/biological samples 
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By using hyphenation it is possible to couple the high protein resolving power of 
gel electrophoresis with the high trace element sensitivity ofICP-MS. This can be 
achieved by ablating the dried electrophoresis gels using laser ablation, a well 
established solid sample introduction technique for ICP-MS. Since laser ablation 
was used throughout the study to interrogate dried gels it will be described here in 
further detail. 
Solution nebulisation is the main method of sample introduction used in ICP 
analysis. Unfortunately many samples are not suitable for nebulisation into ICP 
systems and the necessary sample digestion procedures can be time consuming 
and lead to sample contamination or loss. With this driving force methods for 
solid sample introduction were investigated. A number of techniques have been 
developed for use with Iep systems including direct sample insertionlS8, 
electrothermal vaporization (ETV)ls9, arc and spark ablation I 60, and laser 
ablationl61 . A particular interest in laser ablation developed due to the fact that, 
unlike alternative solid sample introduction systems, it is able to sample both 
conducting and non-conducting samples. This makes it applicable to a wide range 
of organic and inorganic solids of varying geometries, with little or no sample 
preparationl62. Laser ablation is also capable of sampling liquid samplesl63. 
Laser radiation has some special qualities other energy sources do not possess, it 
is monochromatic, unidirectional, intense, coherent, and has low beam 
divergence. As a result of these qualities laser ablation lends itself to a variety of 
applications including bulk analysis, micro features analysis, surface mapping and 
depth profiling. Coupling ICP with a laser ablation system has the advantage of 
separating the sample ablation step from the sample ionisation. Since the sample 
will be atomised and ionised in the plasma the ablated material may be in any 
chemical state, unlike laser induced plasma emission spectrometry (LIPS). By 
coupling ICP-MS to laser ablation the amount of interference due to oxide and 
hydrogen molecular species can be reduced due to the lack of water being 
introduced into the ICP compared to solution analysis l64. 
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Laser Ablation has been used with ICP-OES systems since 1978165, and in 1985 
Gray made the ftrst major investigation into its use with ICP_MS I66• Gray used a 
ruby laser emitting a beam with approximately a 1 mm diameter, emitting at a 
wavelength of 694 nm. ICP-MS studies progressed to using the neodymium-
yttrium aluminium garnet laser (Nd:YAG), at its fundamental IR wavelength of 
1064 nm167• 
Simuhaneous independent parallel research carried out at British Geological 
Survey I 68, and Memorial University, Newfoundlandl69, showed that superior 
performance could be achieved by using the frequency quadrupled Nd: Y AG 
operating in the far UV at 266 nm. Others have since confrrmed this using 
Nd:YAG lasers and Excimer lasers. Excimer lasers (UV) use gas-ftlled cells 
instead of the usual rod. A choice of output wavelengths is available depending 
upon the type of gas used. (Le. XeCI: 308 nm, KrF: 248 nm, ArF: 193 nm). These 
days commercial laser ablation systems typically use frequency qUadrupled 
Nd:YAG lasers, operating in the Q-switched mode. Nd:YAG lasers tend to be 
favoured over Excimers as they are easier to operate, cheaper and more robust. 
This may change as Excimers become more reliable and user friendly. 
In laser ablation energy from a pulsed laser beam is focused on a target surface. 
The sample is vaporised due to interaction of the laser photons with the solid 
material. The vapour and particulates released from the sample surface are then 
swept into the plasma, via the Ar carrier gas flow, for atomisation and ionisation. 
The amount of material ablated depends upon the sample type, the surface 
conditions and also certain laser properties such as the energy and focus of the 
laser. The amount of ablated material reaching the ICP depends upon the 
geometry of the ablation chamber and its connection to the ICP. Signal intensity is 
directly related to the amount of ablated material transported into the ICP. 
Calibration curves can be constructed using matrix matched solid samples170 or 
even liquid calibration standardsl7l. The upper concentration limit is usually 
determined by the maximum amount of material the laser can ablate from the 
sample surface. 
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A transient signal is produced which needs to be monitored in the time resolved 
analysis mode. Precision can be degraded relative to conventional nebulisation 
due to heterogeneous sample surfaces and poor shot-to-shot reproducibility of the 
laser. This can sometimes be overcome by the addition of a suitable internal 
standard. The spatial resolution achievable depends on the wavelength and quality 
of the light used, decreasing the wavelength (i.e. going from IR to UV) can 
decrease the size of the craters produced, see Table 1.12, and can also increase the 
irradiance (power per unit area). The crater size also determines the limits of 
detection. 
Laser Emission Wavelength Crater Diameter 
Ruby,IR172 694nm 100~ 
Nd YAG, IRI73 lO64nm 30~ 
Frequency Doubled Nd:YAG, UV174 532nm 6-10~ 
Frequency Quadrupled Nd:Y AG, UVm 266nm -1~ 
ArF Excimer, UVI76 193nm sub-~ 
Table 1.12: Crater diameters produced by different lasers 
Several specific parameters determine the suitability of a laser for sample ablation 
including, lasing wavelength, sufficient power output, repetition rate, shot-to-shot 
reproducibility, ease of alignment and operation, thermal stability and cost. 
Nd: Y AG laser is widely used, especially when frequency quadrupled to emit at 
266 nm. UV emission is found to be better than IR for microanalysis as it 
produces a fine sample aerosol, has a high transport efficiency, less memory 
effects, and an improved signal stability. Since UV lasers have shorter wavelength 
emissions they are absorbed more efficiently. Unlike IR emission where the 
energy is mostly converted to thermal heating and melting of the sample, the high 
photon energy ofUV makes thermal heating negligible l77• Nd:YAG lasers can be 
thermally sensitive and so cooling systems are needed, but they are good lasers for 
micro-sample analysis as they are rugged, absorbed by most materials, easy to 
operate, small, inexpensive, have a high degree of reproducibility and a high pulse 
rate without loss of energy. 
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The key components for laser ablation include an excitation source (i.e. a rod of 
Nd doped YAG), a xenon flash lamp and a resonance cavity178. A schematic for a 
typical laser ablation system is shown in Figure 1.20. The excitation medium is 
housed in the resonance cavity, with a mirror positioned at each end of the rod. 
The xenon flash lamps, aligned parallel to the rod, act as an optical pump to excite 
the electrons. The mirrors are positioned an integral number of half wavelengths 
apart so that a system of standing waves can be established between them. One of 
the mirrors is half silvered to allow the emission of laser light from the cavity. The 
resonator is essentially monochromatic, as light of differing wavelengths is lost 
from the system. In order to produce an emission of 266 nm the output frequency 
of a Nd:YAG laser needs to be quadrupled. This is achieved by properly aligning 
two frequency-doubling crystals in the optical path of the laser. 
Resonance Cavity 
Q Switch Nd:YAG Crystal 
Xenon Flash Tubes 
Output Mirror 
Figure 1.20: Schematic of typical Q-switched Nd: YAG laser 
Laser 
Light 
The laser has two different modes of operation, ' fixed Q' and 'Q switching' mode. 
In the fixed Q mode the laser is pumped by the flash tubes and light is emitted 
when the threshold conditions for the laser are reached, typical pulse time IlS ' s. Q 
switching means changing the Q (quality factor) of the resonant cavity, defined as 
the energy stored in the cavity divided by the energy lost from the cavity per 
cycle. A high Q cavity will store energy well while a low Q cavity will emit stored 
energy well. Rapid extraction at high energy can be achieved by switching rapidly 
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from high to low Q. Q switching is achieved using a Q-switch, an electro-optical 
device containing a Pockells cell. When a voltage (i.e. 5 kV) is applied across the 
cell it becomes opaque. By placing the cell within the resonant cavity Q switching 
can be controlled. When the cell is opaque resonance cannot occur and the energy 
is stored, when the voltage is removed a short high intensity pulse of light is 
emitted, typical pulse time ns's. The style of crater produced depends upon the 
mode of laser operation, with Q-switching the craters are wide and shallow, whilst 
with fixed-Q mode produces narrow, deep craters179• 
In laser ablation the emitted light is focused upon a sample, a portion of which 
will be vaporised. The sample is mounted on a small stage, covered by a quartz 
window (transparent to the laser wavelength). Cell design is critical for efficient 
sample transport into the ICP. The cell volume should be kept small enough to 
minimise diffusion, but be large enough to prevent the sample sputtering onto the 
cell walls (which can lead to memory effects). In ICP the sample chamber 
effectively replaces the spray chamber, the AI carrier gas passes through the cell 
and transports the ablated sample into the plasma. The gas flow is diverted when 
the sample chamber is open to prevent the plasma being extinguished. The sample 
cell is mounted upon an x,y,z translation stage, powered by a stepper motor, to 
allow the sample to be accurately aligned (x,y) and the laser to be focused (z), see 
Figure 1.21. A CCD connected to a monitor can be used to provide a magnified 
view of the sample to assist in alignment. Sample illumination can be from above 
via a fibre optic system or by transmitted light in the case of thin section samples. 
Laser defocused 
Large crater 
Laser focused on sam pie surface 
Small crater 
Figure 1.21: Effect of laser focus on crater size 
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Laser defocused 
Large crater 
1.5 The Aim of This Study 
From a study of the literature available it is apparent that there is a need for an 
analytical technique capable of detecting metal species present in biological 
samples. Such a technique would fmd applications in a diverse selection of fields 
including environmental chemistry, clinical chemistry, pharmacology and 
associated health studies. It was decided to concentrate upon metal-protein species 
occurring in human serum. 
To achieve such a goal the analytical technique needs to fulfill certain criteria; 
• The separation technique needs to employ suitably mild conditions so as to 
maintain the integrity of metal-protein species throughout speciation 
• The technique needs to be able to separate the metal-proteins of interest 
• The technique needs to be suitably sensitive to detect the low metal 
concentrations present in serum samples 
• The technique needs to be able to cope with the small sample volumes 
available 
The good selectivity of native PAGE and the high sensitivity ofICP-MS present a 
novel technique for speciating metal ions in clinical samples when coupled using 
laser ablation. Figure 1.22 shows a diagrammatic representation of the technique. 
Gel Electrophoresis (pAGE) 
m 
p 
I 
Protein migration + -
Laser Ablation 
1 ········f ············ 1 I····· ·1 
+ 
ICP-MS 
Figure 1.22: Diagrammatic representation of metal speciation in serum 
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The aim of the study was to develop an analytical technique for the study of 
metal-protein binding in human serum Once developed the technique was to be 
used to study several metal-protein interactions occurring in vitro. The ultimate 
aim of the study was to apply such a technique to the analysis of clinical samples 
in the form of serum taken from patients receiving metallo-drug therapy. The 
following chapters will discuss all aspects of the work. 
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Chapter 2: Experimental 
2.1 Reagents and Materials 
2.1.1 Reagents 
Pure lyophilised forms of human serum album~ <X2-macroglobulin and 
transferrin (Fluka, Switzerland) were used for in vitro protein studies. Phosphate 
buffered saline solution (Sigma, UK) was used to reconstitute the proteins. 
Control serum samples were obtained from the Children's Hospital, Sheffield. 
Serum from patients undergoing platinum therapy was obtained from the 
Department of Clinical Oncology, Weston Park Hospital, Sheffield. Serum from 
chrysotherapy patients was obtained from the Department of Rheumatology, 
Royal Hallamshire Hospital, Sheffield. 
In vitro enrichment of proteins and serum was carried out using metallo-drugs, 
metals and colloidal gold. Cisplatin (David Bull Laboratories, Victoria) and 
carboplatin (Bristol Myers Pharmaceuticals, UK), were obtained from the Weston 
Park Hospital, Sheffield. Myocrisin (rnC Healthcare Limited, Dublin), was 
obtained from the Royal Hallamshire Hospital, Sheffield. Details of metallo-drugs 
used given in Appendix 1.3. Chloroplatinic acid standard (1000 mg/L as Pt), 
chloroauric acid standard (1000 mg!L as Au) and other inorganic metal stock 
solutions (1000-10000 mg/L) were purchased from BDH, UK. Colloidal gold (10 
nm, 0.01 % HAuC4) was purchased from Sigma. Bio-Lyte 3/10 ampholyte (40%) 
and pre-prepared IEF cathodic buffer were purchased from Bio-Rad, UK. Acetic 
acid, isopropanol, methanol and sodium hydroxide were all purchased from BDH, 
UK, whilst hydrochloric acid and phosphoric acid were purchased from Sigma, 
UK. The following reagents were purchased from Fluka, Switzerland. 2-
mercaptoethanol, acrylamide:bis solution (37.5:1), ammonium persulphate 
(AMP), bromophenol blue, Coomassie brilliant blue R-2S0, crocein scarlet 7B, 
glycerol, glycine, phosphate buffer saline solution (PBS), sodium dodecylsulphate 
(SDS), N,N,N'N' -tetramethylethylenediamine (TEMED), Tris base and triton 
X 100. 
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2.1.2 Materials 
10 well, Tris 4-15 % gradient ready gels (Bio-Rad, UK) were used for routine 
native gel electrophoresis. 2D-prep, Tris 4-15 % gradient ready gels (Bio-Rad, 
UK) were used for electrophoresis of samples for electro-elution. lOwell, IEF pH 
3-10 ready gels (Bio-Rad, UK) were used for isoelectric focusing of samples. 
VectaSpin Micro filters with a 30 kDa molecular weight cut off (Whatman 
International, UK) were used in ultra-centrifugation of serum samples. 
2.1.3 Preparation of Electrophoresis Buffers and Gels 
The gels for electrophoresis need to be made in house when not using pre-cast 
gels. Below are the recipes used to cast 7.5 % and 15 % continuous gels as well as 
the recipe used to cast enriched gels. The exact procedure followed is described in 
section 2.2.3. Preparation of the many buffers needed in electrophoresis is also 
given in this section. 
Continuous Gels 
7.5 % 15% 
Deionised Water 4.95 mL 3.45mL 
1.5M Tris-HC~ pH8.8 2.5 mL 2.5mL 
AcryllBis (37.5:1) 2.5mL 4.0mL 
10% AMP * 50 J.l.L 50 J.l.L 
TEMED** 5 J.l.L 5 J.l.L 
Pt Enriched Gel 
15 % 
Deionised Water 3.35 mL 
PtC4 (lOO J.l.g/mL Pt) 0.10 mL 
1.5M Tris-HCI, pH8.8 2.5 mL 
AcryllBis (37.5:1) 4.0mL 
10% AMP * 50 J.l.L 
TEMED** 5 J.l.L 
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Multi Element Enriched Gels 
0.0 mg/L 0.1 mg/L 0.25 mg/L 0.5 mg/L 1.0 mg/L 2.0 mg/L 
Oeionised Water 4.45 mL 4.35mL 4.2mL 3.95 mL 3.45 mL 2.45mL 
I.5M Tris-Hel, pH8.8 2.5mL 2.5mL 2.5mL 2.5mL 2.5mL 2.5mL 
AcryVBis (37.5:1) 2.5mL 2.5mL 2.5mL 2.5mL 2.5mL 2.5mL 
Internal Standard 500~ 500 Jll 500 Jll 500 Jll 500 Jll 500 Jll 
Spike Solution O.OJ.lL 100 Jll 250 Jll 500 Jll 1.0mL 2.0mL 
10% AMP 75 Jll 75 Jll 75~ 75 Jll 75 Jll 75~ 
TEMEO** 7.5~ 7.5~ 7.5~ 7.5 Jll 7.5~ 7.5 J.lL 
• Ammonium Persulphate .. N,N,N' ,N' -tetramethylethylenediamine 
Internal Standard - 15 mgIL Be, 10 mgIL Rh, 10 mg/L Tl 
Spike Solution - 10 mgIL stock of elements of interest 
1.5M Tris-HCI, pH8.8 
Tris base 
Deionised Water 
27.23 g 
80mL 
4.45mg/L 
O.OmL 
2.5mL 
2.5mL 
500 Jll 
4.45 mL 
75~ 
7.5 J.lL 
Adjust pH to 8.8 with 6 N HCl. Make to 150 rnL with de ionised water. Store 4°C. 
O.SM Tris-HCI, pH6.8 
Tris base 
Deionised Water 
6.0 g 
60mL 
Adjust pH to 6.8 with 6N HCl. Make to 100 mL with de ionised water. Store 4°C. 
Native Sample Buffer 
Deionised Water 
0.5 M Tris-HCl, pH6.8 
Glycerol 
Bromophenol Blue 
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4.9 rnL 
1.0 rnL 
2.0mL 
0.1 rnL 
Native Running Buffer (xlO Conc)/ Electro-elution Buffer (xlO Cone) 
Tris Base 15.0 g 
Glycine 72.0 g 
Deionised Water 
SDS Sample Buffer 
Deionised Water 
0.5 M Tris-HCI, pH6.8 
Glycerol 
10 % (w/v) SDS 
~-mercaptoethano I 
1.0 % Bromophenol Blue 
SDS Running Buffer (xIO) 
make up to 500 mL 
2.9mL 
1.0mL 
2.0mL 
1.6mL 
0.4 mL 
0.1 mL 
As native Running Buffer (xlO) adding 5.0 g SDS before making up to 500 mL 
IEF Sample Buffer 
50 % Glycerol (v/v) 
IEF Anode Buffer 
Phosphoric Acid 
Deionised Water 
Rotolor Buffer 
Cathodic 
0.1 MNaOH 
SDSlNative Stain Solution 
Methanol 
Acetic Acid 
Coomassie Blue R-250 
Deionised Water 
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4.2mL 
makeup to 1 L 
400mL 
100mL 
1.0 g 
500mL 
IEF Stain Solution 
Isopropanol 
Acetic acid 
Coomassie Blue R-250 
Crocein Scarlet 
Deionised Water 
SDSlNativelIEF Destain Solution 
Methanol 
Acetic Acid 
Deionised water 
2.2 Electrophoresis 
2.2.1 Equipment 
270mL 
100mL 
0.4 g 
0.5 g 
630mL 
400mL 
100mL 
500 mL 
Vertical electrophoresis of mini-gels was carried out using a Mini Protean II 
powered by a PowerlPac 3000 (Bio-Rad, UK). 
Figure 2.1: Bio-Rad Mini Protean II System 
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Electro-elution of mini-gels was carried out using a Mini-Whole Gel Eluter 
powered by a PowerlPac 3000 (Bio-Rad, UK). 
Figure 2.2: Bio-Rad mini whole gel eluter 
Serum samples for liquid IEF separation were first desalted using Sephadex G-
25M columns (Pharmacia Biotech, UK). Liquid IEF separation was then carried 
out using a Rotofor system powered by a PowerlPac 3000 (Bio-Rad, UK). 
Figure 2.3: Bio-Rad Rotofor IEF system 
Following electrophoresis polyacrylamide gels were dried using a Geldryer 
Minidry (Biometra Ltd. , UK). 
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2.2.2 Sample Preparation 
Powder free polyethylene gloves were worn at all times when handling samples 
and/or gels to prevent contamination and the transfer of proteins from the skin. 
Ultrapure 18 MIl Milli-Q deionised water (Milli-Q, Millipore, France) was used 
throughout. All chemicals used were of the highest purity available. 
When studying metal species in biological samples great care was taken over the 
sample preparation step. The very needle used to extract whole blood can be a 
source of contamination Fortunately with the disposable butterfly type needles 
used very little contamination has been reported l80• Anti-coagulants used in the 
collection of plasma, such as Li-heparin and K-EDTA, are possible contamination 
sources. With the anti-coagulant K-EDTA there is the added complication that 
EDT A, being a strong complexing agent, may disrupt metal-protein bindingI81. As 
a result serum samples were used throughout the study. Unlike plasma, serum 
lacks fibrinogen but contains all the proteins and substances not involved in 
clotting. 
Whole blood (-60 mL) was extracted into clean tubes containing no anti-
coagulant. The blood was then transferred into clean universal tubes. To isolate 
the serum, whole blood was left to coagulate naturally at room temperature for 
around 20 minutes. Once the clotting was complete centrifugation was used to 
separate the red blood cells from the serum (1000 g/3000 rpm, 4°C, 10 minutes). 
The dense red blood cells settle at the bottom of the centrifuge tube and the straw-
coloured supernatant is the serum. The serum fraction was pipetted off and 
aliquotted into clean Eppendorf tubes. 
Serum samples were stored at -20°C for up to 6 months. When required the 
serum samples were removed from the freezer and allowed to thaw naturally at 
room temperature. After thawing, the serum samples were spun on a vortex 
spinner for a few minutes to re-homogenise the serum. After thawing any unused 
sample was discarded as repeated freezing and thawing can denature the proteins. 
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The average concentration of protein in human serum is 70 J.lg/J.lL, after sample 
enrichment (l part spike to 9 parts serum) and addition of sample buffer (1: 1) the 
concentration of serum proteins loaded onto the gel was -31.5 J.lg/J.1l. Pure 
proteins, albumin, transferrin and <X2-macroglobulin, were acquired in the 
lyophilised form. The lyophilised proteins were stored at 4 °C until required. They 
were then reconstituted to the required concentration using phosphate buffered 
saline (PBS), which is isotonic to serum and has a physiological pH of 7.47. 
Protein samples were diluted to approximate physiological concentrations (see 
Appendix 1.4) in order to be comparable with human serum. The concentration of 
the albumin stock solution was 250 J.lg/J.lL. This was diluted using phosphate 
buffered saline to yield a concentration of 50 J.lg/J.lL. After sample enrichment, 
and addition of sample buffer the concentration of the albumin samples loaded on 
the gel was 22.5 J.lg/J.lL. The concentration of the transferrin stock solution was 20 
J.lg/J.lL. This was diluted using phosphate buffered saline to give a transferrin 
concentration of 3 J.lg/J.1l. After sample enrichment, and addition of sample buffer 
the concentration of the transferrin samples loaded on the gel was 1.35 J.lg/J.lL. 
The concentration of the <X2-macroglobulin stock solution was 20 J.lg/J.lL. This was 
diluted using phosphate buffered saline to yield a sample concentration of 4 
J.lg/J.1l. After sample enrichment, and addition of sample buffer the concentration 
of the <X2-macroglobulin samples loaded on the gel was 1.8 J.lg/J.lL. 
In vitro studies were carried out using serum and protein samples. Enriched 
samples were compared to un-enriched samples. Elements used to enrich protein 
samples included Pt, Au, La, Cr, Ni, Ga, Pb, Co, Cd, Zn, Cu, Fe and V. Spike 
solutions were obtained by diluting the appropriate metal standard solution with 
ultra-pure water to the desired concentration. Since the standard metal solutions 
are generally made up in acid care was taken to ensure the pH of the fmal spike 
solution was pH 7 ±l. This was necessary to prevent denaturation of the serum 
proteins from exposure to extreme pH values. Samples were enriched by adding 
10 J.1l of an appropriate spike solution to 90 J.1l of sample. To correct for protein 
dilution the un-spiked samples were prepared by adding 10 J.lL ultra-pure water to 
90 J.1l sample. 
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After enrichment the samples were homogenised using a vortex spinner. Samples 
were then left to equilibrate for at least 3 hours at room temperature or 
alternatively for 24 hours at 4 ac. 
In general, platinum studies were carried out using protein and serum samples 
enriched with 5 Jlg/mL Pt. Stock solutions of cisplatin (650 J.lg/mL Pt) and 
carboplatin (5255 Jlg/mL Pt) and an inorganic Pt(IV) solution (1000 J.lg/mL stock 
in HCI), were diluted to give 50 Jlg/mL spike solutions. The spike solutions were 
used to enrich the samples as described above. Gold studies were, in general, 
carried out using protein and serum samples enriched with 2 Jlg/mL Au. Gold has 
lower detection limits with ICP-MS than Pt due to it being mono-isotopic, hence 
enrichment was possible at a lower level. Stock solutions of myocrisin (26830 
J.1g/mL Au), colloidal Au (57.97 J.1g/mL Au) and an inorganic Au(III) solution 
(1000 Jlg/mL stock in HCI) were diluted to give 20 Jlg/mL Au spike solutions. 
The spike solutions were used to enrich the samples as described above. Studies 
of other metal ions were carried out using protein and serum samples enriched 
using inorganic metal solutions (1000-10000 Jlg/mL stock) see Appendix 1.5. The 
samples were enriched using spike solutions as described above. 
Ultrafihration of protein and serum samples was carried out using micro filters 
(Whatman International, UK) with a molecular weight cut-off of 30 kDa and a 
thermostatically controlled microcentrifuge system. The samples were centrifuged 
at 13000 rpm and a steady 4 ac was maintained, for approximately 15 minutes or 
until sample filtering was complete. 
2.2.3 Experimental Procedures 
Gel Preparation 
Polyacrylamide gels of different concentrations were cast to compare protein 
separation after electrophoresis. Polyacrylamide gels enriched with various 
elements at a range of concentrations were also cast to optimise and calibrate the 
LA ICP-MS system. Gels were cast in the following way, all the reagents except 
ammonium persulphate (AMP) and N,N,N' ,N' -tetramethylethylenediamine 
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(TEMED), were placed in a clean universal tube and degassed. The casting stand 
was prepared with glass plates and 1 mm spacers. Immediately prior to casting 
fresh AMP and TEMED were added to the monomer solution. The solution was 
mixed thoroughly and then carefully poured into the gel mould. The comb for 
forming sample wells was added and the gel was left to polymerise for 1 hour. 
Once polymerised the comb was removed and the sample wells were rinsed out 
with ultra-pure water. Pre-cast 4-15 % Ready Gel™ plates (Bio-Rad) with 10 
sample wells were used to separate samples in general, these were stored at 4 °C 
prior to use. 
Electrophoresis 
ID native PAGE was used to separate serum proteins on the basis of size and 
charge, using the Mini-PROTEAN® II electrophoresis cell (Bio-Rad). The gel(s) 
was loaded into the electrophoresis chamber. The upper and lower buffer 
chambers were then filled with the native running buffer, Tris-Glycine pH 8.6. 
Bubbles in the running buffer were carefully eliminated to ensure good electrical 
contact. Next 5 J.!L of pre-prepared sample mixture were loaded into the sample 
wells using specially designed elongated micro-pipette tips (Alpha Labs. UK). A 
constant 200 V voltage was applied to the gel. Gels were run for 45 minutes or 
until the tracking dye contained in the sample buffer reached the end of the gel, 
the exact time taken depending upon the experimental conditions. After 
electrophoresis the gels were carefully removed from the electrophoresis system 
and were rinsed in fresh running buffer. 
SDS PAGE was carried out in much the same way as native PAGE, the main 
difference being the buffers used. SDS sample buffer was added to samples in the 
ratio 2:1. The diluted sample was then heated to 95 °C for 5 minutes. The running 
buffer was added to the upper and lower chambers as described above and 7.5 J.1L 
of sample mixture were loaded per sample well. A larger sample volume was 
loaded compared to native PAGE to maintain the protein loading concentration. A 
constant voltage (200 V) was applied until electrophoresis was complete, the gel 
was then removed and rinsed. 
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IEF separation was carried out using pre-cast 5 % gels with a 3-10 pH range. An 
equal volume of sample buffer was added to the samples for electrophoresis. After 
loading the gels in the system the upper (cathodic) and lower (anodic) sample 
buffers were added. 5 J.1L of sample mixture were then loaded into the sample 
wells. Next a stepwise voltage profile was applied to the gel(s). 100 V was applied 
for 1 hour, next 250 V was applied for a further hour and fmally 500 V was 
applied for the final 30 minutes. The total run time was 2.5 hours. 
Electro-elution 
Samples for electro-elution were run as ID native PAGE but using 2DIPrep gels. 
These gels consisted of a single large 450 J.LL sample well and a 15 J.l.L standard 
well. 75 J.1L of sample mixture were loaded into the sample well and the gel was 
run as previously described. After electrophoresis the gel was removed and 
equilibrated in elution buffer for 20 minutes to minimise swelling during elution 
and to allow the exchange of buffers. The relevant portion of the gel was then 
excised. 
Careful assembly of the Mini Whole Gel Eluter system, (Bio-Rad) is essential for 
the efficient elution of proteins, see Figure 2.4. The eluter must be level, well 
aligned and free from air bubbles. To assemble the system the bottom electrode 
was placed in the base. Next two sheets of filter paper soaked in elution buffer and 
a pre-soaked (over night) sheet of dialysis membrane were placed on the 
electrode. Air bubbles were worked out with a roller. The elution chamber core 
was then inserted and the hex screws finger tightened. Buffer was added until all 
the chambers were covered, avoiding air bubbles. The excised gel was placed in 
the elution chamber with the protein bands lying parallel to the channels. Two 
sheets of filter paper soaked in buffer were laid on top of the gel and air bubbles 
again worked out using a roller. Excess buffer was blotted off and the aspiration 
ports were dried before sealing. Finally the upper electrode assembly was placed 
on top of the chamber and clamped into place. A constant current of 100 rnA was 
applied for 30 minutes. The sealing tabs were then removed carefully to avoid 
disturbing the samples and the fractions were collected using disposable plastic 
transfer pipettes. After collection the fractions were analysed by FI ICP-MS. 
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Figure 2.4 Schematic of Mini Whole Gel Eluter System (Bio-Rad) 
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Liquid IEF 
IEF can be carried out entirely in solution using the Rotofor® System (Bio-Rad). 
Before separation samples need to be de-sahed by passing 1 mL of serum through 
disposable PD-I0 Sephadex G25 M columns, followed by subsequent 1 mL 
aliquots of ultra-pure water, till a volume of 19 mL was acquired. 1 mL ofa 2 % 
ampholyte 3/10 solution in ultra-pure water was then added to the sample. The 
fll'st step in setting up the Rotofor system was the assembly of the electrolyte 
chambers. Once assembled the chambers were filled with their respective buffers. 
The anode electrode assembly was then positioned over the ceramic cooling 
fmger, followed by the membrane core and then the focusing chamber. Finally the 
cathode electrode assembly was added. The collection ports in the focusing 
chamber were sealed. The sample, 18 mL, was then loaded through the filling 
ports, ensuring no air bubbles were present, then the ports were sealed. Whilst 
fractionating the proteins the system was cooled, via the cooling fmger, to prevent 
protein denaturation. A constant 12 W was applied to the system for 3-5 hours. 
Progress was monitored by observing the voltage increase. When the voltage 
stabilised the run was complete. The system was left to run a further 30 minutes 
before harvesting the fractions with the harvesting equipment attached to a 
vacuum pump. 
The 20 fractions acquired can be analysed in a number of ways. A form of 2D 
electrophoresis can be achieved by separating the fractions using conventional 1 D 
native PAGE, loading 25 J.1L of recovered sample per lane. The fractions were 
analysed by FI ICP-MS. Prior to analysis fractions were diluted 1: 1 with a 1 % 
HCI solution containing 20 J.1g1mL of the internal standards Sc, Ir and Rh. 
Gel Manipulation 
Once run, polyacrylamide gels can be stained to show the position of proteins on 
the gel. Staining is a two step procedure, staining and destaining the gel. For 
staining the gel is immersed in the stain solution and gently agitated for 1 hour (45 
minute maximum for IEF staining). The gels are then immersed in the destain 
solution and gently agitated for 2-3 hours. During the destaining process, the 
destain solution needs to be replaced frequently, until the background is clear. 
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Electrophoresed gels, stained or not, can be dried in two ways. Gels for analysis 
by laser ablation (preferably not stained) need to be dried on a solid support. The 
gels were placed carefully on a sheet of blotting paper and covered with heatproof 
Saran wrap. The gel was then placed on the mini-gel drier, the rubber cover 
carefully placed over it and the vacuum applied. Gels were dried at 40°C for 
around 2 hours (too rapid drying can cause the gels to crack). Stained gels were 
dried between sheets of cellophane as this method minimised gel cracking and 
aided viewing. Gels were soaked in 2 % glycerol solution along with two sheets 
of cellophane. The first sheet of cellophane was placed on a sheet of glass. The gel 
was carefully placed on top, then covered with a second sheet of cellophane 
taking care to remove any air bubbles. A second glass sheet was placed on top and 
clamped together and left over-night to dry out. 
Individual lanes from gels dried on blotting paper were cut out, and carefully cut 
in half to allow mounting in the laser ablation chamber. The two pieces of gel 
were mounted in the ablation chamber using double sided adhesive tape, see 
Figure 2.5. The Saran wrap covering the gel was easily peeled off prior to 
ablation. 
Gellane cut into two sections 
Ar gas "\-__ _ 
Ar gas to le p 
or purge 
1-----, 
-
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Figure 2.5: Sample o/polyacrylamide gel mounted in laser ablation chamber 
68 
2.3 Laser Ablation ICP-MS 
2.3.1 Instrumentation 
Laser ablation of polyacrylamide gels was carried out using the LSXIOO and the 
LSX200 (CETAC Technologies, Omaha, USA). 
Figure 2.6: LSX200 Laser ablation system 
Following laser ablation elemental detection was carried out using a HP4500 ICP-
MS (Hewlett Packard, USA). 
Figure 2. 7: HP4500ICP-MS 
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2.3.2 Experimental Procedures 
Laser Ablation 
The ablation systems used in this study were the CETAC LSX-I00 and the 
CETAC LSX-200. The LSX-I00 laser is a frequency-quadrupled Nd:YAG laser 
operating at 266 run. A near-Gaussian beam profile with a 8 ns pulse duration is 
emitted. The diameter of the craters produced is controlled by the focus of the 
laser. The sample cell is mounted on a motorised, x,y,z translation stage. Samples 
can be viewed via a CCD camera image displayed on a monitor. Motorised zoom 
control allows magnification from 20 - 128x. Sample aerosol is transported to the 
plasma via Tygon tubing. Windows based software controls the system and allows 
the sample to be analysed in the following ways, bulk analysis, feature analysis, 
surface mapping and depth profiling. The software is also used to adjust the key 
laser parameters, which are shown in Table 2.1. 
Parameter LSX-IOO LSX-200 
Shot Rate 1-20 Hz 1-20 Hz 
Scan Rate 1-100 J.1m1s 1-100 J.1m1s 
Number of Shots 1-100 shots 1-100 shots 
Focus ±2000 steps * N/A 
Aperture Size N/A 1-7** 
Power 1-20·· 1-20** 
Table 2.1: Key parameters for LSX100 and LSX200 
*1 step = 1.25 JDfl ·*arbitrary units, 
A schematic of the LSX-200 is shown in Figure 2.8. The LSX-200 laser uses a 
frequency quadrupled Nd:YAG laser operating at 266 nm. A flat-top laser beam 
profile yields a laser pulse width < 6 os and features Q-switched laser frequency 
selection and variable pulse repetition rate from 1-20 Hz. The diameter of the 
craters produced is controlled by the polarizing beam attenuator (10-300 J.1m, see 
Appendix 1.6). An energy probe is incorporated into the system, which measures 
laser energy directly using a post-attenuated beam. 
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The sample cell is mounted on a motorised, x,y,z translation stage with <1 mm 
resolution. Samples can be viewed with a binocular microscope or by a CCD 
camera image, using transmitted or reflected light. Motorised zoom control allows 
magnification from 80 - 800x. Sample aerosol is transported to the plasma via 
Tygon tubing. Windows based software controls the system and allows the sample 
to be analysed in the following ways, scanning, rastering, single point analysis, 
depth profiling, single line scanning and single line rastering of the sample. 
Platinum enriched gels were used to determine the best laser parameters to 
achieve stable, sensitive, representative signals. The parameters were 
systematically altered whilst monitoring signal response. The optimal conditions 
for the two types of laser ablation systems used are shown in Table 2.2. 
Parameter LSXIOO LSX200 
Laser Energy 0.65 mJ 0.8 mJ 
Laser Shot Rate 20Hz 20Hz 
Apertu re Size N/A 260 flm 
Laser Defocus 
-3000 flm N/A 
Scan Rate 50 flmls 50 flmls 
Table 2.2: Optimised laser ablation parameters 
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When analysing lanes from dried polyacrylamide gels the gels were mounted in 
the laser ablation chamber as shown in Figure 2.5. The centre of the gel at the 
base of the sample well (the top of the sample lane) was found and the gel was 
ablated along the length of the gel (parallel to the lane). Once the end of the upper 
half of the gel lane was reached ablation was halted and the centre of the lower 
half of the gel was located. Ablation was then resumed in the direction of the 
solvent front until the end of the gel was reached. 
There are two main modes of ablation that can be used when interrogating dried 
polyacrylamide gels, a) point ablation and b) line rastering, as shown in Figure 
2.9. The first involves firing the laser at discrete, evenly spaced sites along the 
length of the gel. It is necessary to leave a crater width space between subsequent 
shot sites to avoid surface contamination by previously ablated material. The line 
rastering mode involves firing the laser continuously whilst slowly scanning along 
the length of the gel lane. This is achieved using the programmable translation 
stage upon which the ablation chamber is mounted. 
a) 
I 0 0 0 0 0 0 0 0 0 t oo 0 ' 0 0 0 0 oooej 
Protein Migration 
b) line rastering 
Figure 2.9: Alternative modes of gel interrogation 
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a) point ablation, laser fired shotwise whilst rastering along length of the gel 
b) line rastering, laser fired continuously whilst rastering along length of the gel 
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ICP-MS 
The operating parameters for the ICP-MS were optimised on a daily basis by 
ablating a 'National Institute of Standards and Technology' reference glass, NIST 
SRM612, containing many elements at known concentrations (see Appendix 1.7). 
The software was set for the ICP-MS to monitor rnIz values 59CO, 139La, and 
232Th, all present in the glass, in a time resolved fashion. The laser parameters 
were set such that the largest crater possible was produced, with high lasing 
energy, slowly rastering across the surface of the glass whilst ablating 
continuously. The ICP-MS parameters were varied until a stable, sensitive signal 
was achieved for the three masses of interest whilst maintaining low oxide and 
doubly charged ion concentrations. Typical ICP-MS operating parameter for laser 
analysis are given in Table 2.3. 
Parameter Value 
RFPower 1300W 
Reflected Power OW 
Coolant Gas Flow 16.0 Llmin 
Auxiliary Gas Flow 1.0 Llmin 
Carrier Gas Flow 1.5 Llmin 
Sample Depth 6.2 mm 
Extraction Lens (1) -155 V 
Extraction Lens (2) -64 V 
Einzel Lens (1) -100 V 
Einzel Lens (2) 6V 
Omega Bias -40 V 
Omega + 15 V 
Omega - -3 V 
Plate Bias -10 
Pole Bias -10 
Integration Time 0.1 s 
Table 2.3: Typical HP4500 parameters 
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2.4 Flow Injection ICP-MS 
2.4.1 Instrumentation 
Flow injection ICP-MS was carried out using a Gilson Miniplus 3 peristaltic 
pump (Gilson. UK) with a 6 port rotary flow injection valve (Omnifit, UK). This 
was coupled to a lIP4500 ICP-MS system (lIP, USA). 
Flow injection analysis (FIA) has been a popular sample introduction technique 
since the 1970S182• In flow injection ICP-MS a discrete, reproducible volume of 
the sample, is transported via a closed circuit by a continuously flowing carrier to 
the ICP-MS. The main benefits of such a sample introduction system are low 
limits of detection. good precision. small sample volume and rapid analysis time. 
FIA is a well-established technique; a typical system is comprised of a peristaltic 
pump, rotary flow-injection valve and an interface to the analyser. The sample is 
loaded into the sample loop, then injected into the ICP-MS via a continuously 
flowing carrier stream. The size of the sample loop can be varied as can the flow 
rate of the carrier. Both these parameters affect the sensitivity of the technique 
2.4.2 Experimental Procedure 
Optimisation of carrier flow rate and sample volume, the two main parameters 
effecting signal response, was carried out using a platinum enriched solution. 
Both parameters were altered individually and the effect on signal response was 
noted. The flow rate and sample volume giving the most sensitive response were 
used throughout. 
The carrier solution used for flow injection ICP-MS analysis of protein samples 
was 0.1 % Triton XI00. Memory effects can occur when gold is analysed by ICP-
MS and so a wash out step using 2 %HCI / 2 %HN03 was performed at the end of 
each analysis run. 
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Chapter 3: Characterisation of Platinum Enriched 
Gels 
3.1 Introduction 
Despite being one of the rarest elements in the earth's crust (-1 nglg)IS3, platinum 
has been widely used for the past hundred years. Known as a 'noble' metal, 
platinum actually forms a wide variety of complexes with inorganic compounds 
and biological systems making it of interest not only in terms of mineral 
exploration, but also in microbiology and clinical medicine. Levels of platinum 
occurring in the environment, foodstuff and in living organisms are extremely low 
and, unlike most other heavy metals, platinum is generally regarded as non-toxic. 
However, in certain situations where platinum is handled, it can pose an 
occupational hazard. Excessive exposure to soluble platinum compounds can lead 
to platinosis, and so knowledge of the bio-availability, bio-accumulation and 
toxicity of platinum is becoming increasingly important. Platinum baseline levels 
in humans were found to be 0.8-6.9 ngIL in blood and 0.5-14.3 ngIL in urinelS4. 
These levels are found to be significantly higher in workers exposed to 
platinum11O• 
Since its discovery in 1735 platinum has found a number of applications including 
jewellery, thermocouples, electrodes, fuel cells, surgical implants, corrosion 
resistant wares, heterogeneous and homogeneous catalysts and cancer 
chemotherapy. All these applications are potential sources of anthropogenic 
platinum emission. There has been a rapid increase in use and, as a result, 
emission of platinum in recent years. This increase can be attributed to two 
specific sources, the introduction of catalytic converters for the exhaust system of 
motor cars in 1974 and the first use of platinum chemotherapeutic drugs in 1971. 
Platinum is widely used in the automobile industry as an exhaust catalyst that 
oxidises harmful combustion by-products. Surface abrasion of the catalyst results 
in the emission of platinum into the environment; this is usually in the form of 
platinum metal or oxide particulateslss. Platinum emissions can be detected in the 
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aerosol from the car exhaustl86. Once airborne, platinum can contaminate plant 
lifel87. The platinum content of road dust in areas of south London has been found 
to be 0.42-29.8 nglgl88, significantly higher than crustal levels. A correlation was 
found between platinum concentration in roadside dust and traffic flow, hence, 
even higher platinum concentrations might be detected alongside motorways and 
in inner city areas. The presence of chemical and biological agents in soil can 
result in the emitted platinum being transformed into bio-available speciesl89. 
There is evidence of platinum uptake by plants growing on contaminated roadside 
SOilI90, thus providing a mechanism by which platinum can enter the food chain. 
Platinum(II) drugs are widely used in the treatment of various cancers. These are 
also known to contribute to the problem of platinum emission into the 
environment. Studies show elevated platinum levels in hospital waste water and 
sewage sludge 191 due to the use of such platinum drugs. Increased emissions of 
platinum in recent years make in necessary to determine its effect on living 
organisms and the environment. To achieve this aim, analytical techniques 
capable of determining the trace and ultra-trace levels of platinum present in the 
environment need to be developed. Platinum speciation is also required to help 
elucidate metabolism reaction pathways and products. The detection limits of the 
traditional techniques for determining platinum, such as fire assay, are too high 
for such measurements and so instrumentation with lower detection limits is 
employed. Being relatively cheap and versatile, GF-AAS is the method of choice 
for the routine determination of platinum in biological fluids. ICP-MS, however, 
is more sensitive, (see Table 3.1). High sensitivity, combined with rapid, 
simultaneous multi-element capability makes ICP-MS the preferred technique for 
ultra-trace analysis. Ahernative techniques offering comparable detection limits, 
such as NAA and PIXE, are costly and require highly specialised equipment in 
comparison. 
FlameAAS GF-AAS ICP-OES ICP-MS 
LOD (JlgIL) 60.0 1.50 7.00 0.08 
Table 3.1: Limits of detection for platinum. Table adapted from 95 
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There are a number of naturally occurring platinum isotopes, their masses and 
relative abundances are; 
I90Pt _ 0.01 % 
195Pt _ 33.8 % 
192Pt _ 0.79 % 
196Pt _ 25.3 % 
194Pt _ 32.9 % 
198Pt _ 7.2 % 
ICP-MS is capable of detecting all of these isotopes. In order to obtain the highest 
sensitivity, however, the most abundant mass is normally monitored, i.e. 195Pt. 
Examples of platinum studies involving ICP-MS are numerous, with a high 
proportion ofthe samples analysed being biological, in particular urine192, 193, and 
blood \08, \09, 194. 
Besides contributing to platinum emissions into the environment platinum based 
drugs, such as cisplatin and carboplatin, can also pose a potential health risk to 
those undergoing therapy. Once in the body Pt(II) tends to bind to sulphur rich 
amino acids found in proteins when the tertiary structure of the proteins makes 
this possible. Such interactions are particularly relevant to the toxic side effects of 
the drugs, especially those involving the kidneys. Cisplatin is known to bind 
extensively to albumin36 and to transferrin to a lesser degreel95 • An understanding 
of the molecular mechanism of such interactions may help optimise cisplatin 
therapy, making platinum speciation knowledge of clinical, as well as 
environmental, interest. 
Most of the current clinical research concerning platinum focuses on interactions 
occurring between platinum drugs and DNA. In contrast the results in this chapter 
focus on the interactions between platinum and serum proteins. PAGE coupled 
with LA ICP-MS was used to detect and speciate platinum anti-cancer drug 
metabolites in human serum. Other work in this area done using similar 
technologyJS5, 156 experienced problems with high platinum blank concentration 
levels. This platinum contamination was probably due to the use of a flat bed 
electrophoresis system utilising sheet type platinum electrodes with large surface 
areas. No such contamination problems were observed using the vertical Bio-Rad 
electrophoresis system. 
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3.2 Method Development 
Before embarking on the analysis of 'real ' samples it was necessary to perform 
initial feasibility studies. The aim of which was to demonstrate the suitability of 
utilising gel electrophoresis followed by LA ICP-MS for metal speciation in 
biological samples. The studies were also used to identify some of the key 
operational parameters. This optimisation of the system was essential to ensure 
representative sampling of the biological samples (important to maintain metal-
protein binding) and to demonstrate adequate species resolution and sensitivity. 
3.2.1 Flow Injection - ICP-MS 
To obtain quantitative data on the platinum content of serum and protein samples 
analysis was carried out using flow injection - ICP-MS. Optimisation of operating 
parameters was necessary prior to analysis. The key parameters affecting signal 
response are the volume of sample injected and the sample flow rate. 
3.2.1.a Sample Volume 
To determine the optimal sample volume replicate injections were made using a 
Pt standard solution (PtC4, 50 J..I.g/L Ptt. The sample volume was altered with 
each injection. The ion time responses are given in Figure 3.1. 
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Figure 3.1:195 Pt Ion time responses for FI of various sample volumes of PI 
standard (PtCI4, 50 Jig/L PI) 
C Platinum species in Pt standard solutions referred to as PtC4 but more likely to exist as PtCI? 
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As the sample volume was increased so the peak height increased until a threshold 
height was reached. Increasing the sample volume further led to peak broadening. 
The sample volume of 0.1 mL was decided upon as the optimal sample volume 
giving both well formed peaks and a suitable sensitivity. 
3.2.1.b Flow Rate 
To determine the optimal flow rate replicate injections were made using a Pt 
standard solution (PtC4, 50 J.lg/L Pt). The flow rate was increased with each 
injection. The ion time responses are given in Figure 3.2. 
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Figure 3.2: 195 PI Ion time responses for FI of various sample flow rates of Pt 
standard (PtCh 50 pglL PI) 
As the flow rate was increased the resulting peaks became narrower. The peak 
height also increased until a threshold value. Increasing the flow rate beyond this 
led to a reduction in peak height due to insufficient sampling times. The flow rate 
of 84 J..lLlmin, corresponding to a pump speed of 0.3 rps was decided upon as the 
optimal flow rate giving both well formed peaks and a suitable sensitivity. 
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3.2.2 Laser Ablation of Gels 
To ascertain the applicability of the combined strategy a serum sample, enriched 
to contain inorganic platinum (PtC4, 5 J.lg/mL Pt), was subjected to 
electrophoresis and the dried gel was analysed by LA ICP-MS. The Pt distribution 
profile obtained, Figure 3.3, showed that platinum did bind to serum proteins and 
also that the system was suitably sensitive to detect platinum in the gel. 
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Figure 3.3: 195pt Ion time response for laser interrogation of gel following 
electrophoresis of enriched serum (PtCh 5 pglmL Pt) 
After verifying the applicability of the approach, the next stage in method 
development was to study the gel interrogation strategy. In particular it was 
necessary to determine whether the sample ablated, could then be analysed by the 
ICP-MS, to give representative, reproducible results. To investigate this various 
operating parameters were examined with a view to signal optimisation. 
When considering with laser ablation, there are several laser parameters that affect 
the laser coupling efficiency and transfer of ablated product to the ICP. These 
include; laser energy, laser shot rate, beam size and number of laser shots per site. 
The efficiency of laser coupling is dependent also upon the sample matrix. To 
establish the best laser parameters for the analysis of dried electrophoresis gels a 
matrix matched enriched gel was prepared (see section 2.2.3). 
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A gel was cast containing inorganic Pt (PtC4, I ~g/mL Pt). After drying, a section 
of the enriched gel was mounted in the ablation chamber. The gel was then 
interrogated whilst monitoring mJz 195 (Pt). The laser parameters were 
systematically altered until the optimal laser parameters had been determined. As 
the dried gel has a finite depth of 0.2 mm, the amount of sample available for 
ablation and hence the analyte signal achievable is finite. If the sample is ablated 
excessively the paper supporting the dried gel then undergoes ablation. The 
optimal laser parameters are those which will give the most sensitive signal 
without ablating through the gel, whilst at the same time maintaining the inherent 
resolution of electrophoresis. 
In order to determine the optimal laser energy a section of Pt enriched gel (PtC4, 
1 ~glmL Pt) was interrogated repeatedly. For the initial interrogation the 
following parameters were used; laser energy level 20 (4.6 mJ), laser shot rate 20 
Hz, beam size 300 ~m and 20 shots per site. For subsequent interrogations the 
laser operating parameters were kept constant, with the exception of the laser 
energy. This was systematically reduced from level 20 (4.6 mJ) to level 1 (0 mJ). 
The ion time responses obtained can be seen in Figure 3.4. It was noted that as the 
laser energy decreased so the observed signal decreased. This was as a direct 
result of a decrease in the amount of sample ablated. Figure 3.4 shows a linear 
relationship between laser energy and the observed signal intensity. Visual 
assessment of the ablated gel highlighted excessive ablation when energy levels 
exceeding 1.7 mJ were used. The optimal laser energy was identified as the laser 
energy at which maximum analyte signal was achieved without excessive ablation 
of the gel, as such the optimal laser energy of the LSX-200 was found to be 1.7 
mJ. This energy was used for all further gel interrogations, unless otherwise 
stated. The optimal laser shot rate was determined by repeatedly interrogating a 
section of Pt enriched gel (PtC4, 1 ~g/mL Pt), whilst systematically altering the 
shot rate from an initial shot rate of 20 Hz to 1 Hz. In each case equal areas of gel 
were ablated. Figure 3.5 shows the ion time response obtained. As the shot rate 
was decreased so the total number of laser shots fired decreased and the signal 
intensity was also found to decrease. The optimal shot rate for gel interrogation 
was found to be 20 Hz as this gave the greatest sensitivity. 
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Figure 3.4: 195 Pt Ion time responses for Pt enriched gel (PtCh 1 J..lg/mL PI) at 
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Figure 3.5: 195 Pt Ion time responses for Pt enriched gel (PtCh 1 J..lg/mL PI) at 
various laser shot rates Inset: Integrated Pt peak area vs laser shot rate 
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The LSX200 laser ablation facility can afford a variety of laser beam diameters by 
varying the aperture settings, i.e. 10 Ilm - 300 Ilm. To investigate the effect of 
aperture size a section of Pt enriched gel (PtC4, 1 Ilg/mL Pt), was interrogated 
whilst gradually increasing the aperture size. Figure 3.6 shows the ion time 
response obtained and also the effect of aperture size on signal intensity. It was 
found that as the aperture size decreased the amount of sample ablated decreased 
and so the signal intensity decreased. Little or no signal was obtained using 
apertures below 100 Ilm (aperture 4). When choosing an aperture size for gel 
analysis the two main considerations were the sensitivity and maintaining the 
protein resolution. Since the aperture size is so small relative to the protein band 
resolution all further work was carried out using the 260 Ilm aperture. 
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Figure 3.6: 195 Pt Ion time responses for Pt enriched gel (PtCh 1 ",g/mL Pt) at 
various laser aperture sizes Inset: Integrated Pt peak area vs laser aperture size 
The LSX-IOO laser ablation system controls crater size by varying the focus of the 
laser on the sample. This is achieved by altering the height of the laser above the 
sample, see Figure 1.23. This is not an ideal situation as variations in the surface 
of the gel can alter the crater size and so alter the sensitivity of the system. As 
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such, variations in the surface nature can lead to variations in the ICP-MS 
response. The resulting 'peaks' may simply be the result of fluctuations in laser 
focus, not variations in analyte concentration. To minimise this effect the gel 
surface was kept as smooth as possible whilst drying and was mounted in the 
ablation chamber using doubled sided tape. The best laser focus for the 
interrogation of gels was determined by analysing a section of Pt enriched gel 
(PtC4, 1 !lglmL Pt), whilst systematically altering the laser focus. 
Figure 3.7 shows the ion time response obtained. The distances quoted for laser 
defocus are relative to the focal point of the CCD camera, not the laser. It can be 
seen that the lasers focal point is ~ -3000!lm from that of the monitor. As the 
laser was moved away from its focal point the diameter of the laser beam hitting 
the sample increased. This, in turn, led to larger craters being produced and so 
more intense signals were detected. A distance of -1000 !lm defocus with respect 
to the focal point of the CCD camera (equivalent to ~ +2000 )..lm with respect to 
the focal point ofthe laser) was used for gel analysis. 
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When interrogating gels in a shot-wise manner there is a need to optimize the 
number of laser shots fired per site. Figure 3.8 shows the ion time response 
obtained when a Pt enriched gel (PtC4, I J..1g/mL Pt) was interrogated repeatedly 
whilst gradually altering the number of shots per site. The more laser shots fired 
per site, the greater the amount of material ablated and so the greater the resultant 
signal. The finite thickness of the gel limits the amount of material available for 
ablation, and so an excessive number of shots in one site would result in ablation 
of the gel support. 
Visual examination of the ablated gel indicated that excessive ablation occurred 
with >20 shots per site. The plot of peak area against number of laser shots per 
site is linear even when the gel has been excessively ablated, this is probably due 
to platinum being absorbed by the paper support before drying. At such high shots 
per site the resultant signal is not representative of the platinum concentration in 
the gel. For all further work done in the point ablation mode of operation, 20 shots 
were fired per site. 
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Figure 3.8: 195 Pt Ion time responses for Pt enriched gel (PtCh 1 f.LglmL Pt) for 
various laser shots Inset: Integrated Pt peak area vs laser shots 
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The previous experiments were all based on the point ablation mode of operation. 
An alternative mode of interrogation involves firing the laser at the gel 
continuously whilst slowly scanning along the length of the gel lane, this was 
referred to as line rastering. Before interrogating in this manner the translation rate 
for the gel needed to be optimised. The translation rate was gradually increased 
from 10 Jlmls to a maximum value of 1000 Jlmls, all other laser operating 
parameters being kept constant. In each case equal areas were ablated. 
Figure 3.9 shows the ion time responses obtained when a Pt enriched gel (PtC4, 1 
Jlg/mL Pt) was repeatedly ablated at different translation rates. Each ablation 
covered a section of the gel approximately 4000 Jlm in length. Since interrogation 
time is given by the distance scanned divided by the scan rate, the time taken for 
successive interrogations decreased. When scanning at 12.5 /lmls the interrogation 
took 320 s, this decreased to just 4 s when scanning at 1000 Jlmls. Figure 3.9 also 
shows the effect oftranslation rate on the Pt counts/s detected. 
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Figure 3.9: 195 Pt Ion time response for Pt enriched gel (PtCh 1 pg/mL Pt) at 
various translation rates Inset: Pt counts per second vs translation rate 
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To determine the optimal scan rate for line rastering of the gels three factors need 
to be considered, the counts/s obtained, the analysis time and the spatial 
resolution. Increasing the scan rate can be seen to increase the counts/s until a 
maximum signal is achieved (similar in nature to the effect of flow rate in FIA). 
Increasing the scan rate still further results in a decrease in counts/s as the amount 
of material ablated decreases. The sensitivity of the system was shown to be 
maximised at a scan rate of -200 Jlmls. Increasing the translation rate decreased 
the analysis time (linear relationship) but resulted in the loss of spatial resolution 
which is essential for metal speciation in gel electrophoresis. A translation rate of 
50 Jlmls was found to satisfy the three criteria. Whilst the counts/s were not as 
high as might have been achieved with a faster translation rate, spatial resolution 
was maintained. This translation rate give a typical analysis time of -20 minutes 
(1200 s) for a gel lane (- 60 mm) which was found to be acceptable. Thus the 
compromise translation rate of 50 Jlmls was adopted for all further work. 
Once the optimised laser parameters for the two modes of laser interrogation 
(point ablation and line rastering) had been determined it was necessary to decide 
which mode was best suited to gel analysis. Laser optimisation was carried out 
using a Pt enriched gel (PtC4, 1 Jlg/mL Pt) with a uniform Pt distribution across 
the surface of the gel. To determine which mode of interrogation was most suited 
to metal-protein speciation it was necessary to compare not only the sensitivity 
and analysis times obtained but also the spatial resolution achieved in each case. 
To do this a Pt enriched serum sample (PtC4, 5 Jlg/mL Pt) was electrophoresed 
using native PAGE. A section of the gel was then interrogated by the two modes 
in tum, using the optimised parameters previously described. Figure 3.10 shows 
the Pt profiles obtained. Both modes give the same Pt distribution profile. 
However, continuously firing the laser (line rastering) whilst scanning along the 
length of the gel was found to be much more sensitive (note the different Pt signal 
scales used) than analysing discrete areas of the gel (point ablation). Line rastering 
also gave a shorter analysis time (-20 minutes per lane) compared with that 
needed for point ablation (typically 1 hour per lane), whilst maintaining spatial 
resolution. Thus for all future work the line raster mode of laser interrogation was 
employed. 
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Figure 3.10: 195 Pt Ion time responses for PI enriched serum (PtCh 5 pg/mL Pt) 
interrogated by a) point ablation and b) line rastering 
a)Point Ablation (Parameters, 20shots/site, 1. 7 mJ, -1000pm defocus,) 
b) Line Rastering (Parameters; 1.7 mJ, 50 J.Unls, 20 Hz, 260 pm aperture) 
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3.2.3 Electrophoresis 
When separating proteins, especially in the case of complex protein mixtures such 
as blood serum, it essential that the appropriate conditions are used. The degree of 
protein separation depends on a number of parameters such as the length of time 
of electrophoresis, the type of electrophoresis, gel composition, the buffer system 
used, and the amount of protein loaded on the gel. Once optimised conditions had 
been identified further studies were needed to examine the possibility of cross 
contamination between gel lanes and also the effect, if any, of deviation from the 
central lane axis when interrogating gels. 
3.2.3.0 Electrophoresis Time 
The length of time of electrophoresis affects the degree of protein separation. For 
a given system there is an optimal electrophoresis time at which point the proteins 
are separated and can be characterised by their migration distance along the gel. If 
the sample is electrophoresed for too short a time the proteins may not be fully 
resolved. If the sample is electrophoresed for too long the proteins will over-run 
their characteristic position and will begin to merge again. If left to run for 
excessive lengths of time the proteins may eventually run off the end of the gel 
and mix with the buffer solution. 
The optimal electrophoresis time usmg native PAGE was determined by 
electrophoresis of a serum sample enriched with Pt (PtC4, 5 f.!glmL Pt). The 
sample was electrophoresed for 1, 5, 10, 30, and 60 minutes, the experiment being 
run in duplicate. One set of the resulting gel lanes were stained using Coomassie 
Blue to give a visual indication of the protein migration. The remaining set of 
lanes were dried without staining and interrogated by LA ICP-MS monitoring m1z 
195 (Pt). The entire procedure was then repeated using an albumin sample (45 
mg/mL) enriched with Pt (PtC4, 5 f.!g/mL Pt). 
The stained lanes containing the serum and albumin samples are shown in Figure 
3.11. In each case the sample was loaded at the top of the lane and as 
electrophoresis progressed the proteins migrated down the lane. It can be seen that 
the migration distance of the proteins increased with increasing electrophoresis 
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time. Based on the positioning of the stained proteins it can be seen that after 1 
minute of electrophoresis the sample was just entering the gel and no protein 
separation had occurred. From 5-30 minutes of electrophoresis the proteins in the 
serum migrate further into the gel and separate according to their mass/charge 
ratio (m/z) resulting in the appearance of a number of bands. After 60 minutes of 
electrophoresis the serum was found to have over run. Such an excessive 
electrophoresis time caused the protein bands to migrate further but this was at the 
expense of protein resolution as the protein bands began to broaden and run into 
each other. Similar behaviour was observed with the albumin samples. The 
multiple bands observed in the albumin lanes correspond to albumin polymerising 
to form dimers and trimers etc, possibly promoted by the presence of platinum. 
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Figure 3.11: Pt enriched albumin and serum samples, (PtCh 5 f.lg/mL Pt), 
Stained after electrophoresed/or a) 1 min b) 5 min c) 10 min d) 30 min e) 60 min 
Figure 3.12 and Figure 3.13 show the Pt signal responses for laser ablation rep-
MS of the Pt enriched serum samples and albumin samples, respectively. It is 
immediately obvious that some degree of platinum-protein binding occurs in both 
the pure albumin samples and the serum samples. This is demonstrated by the 
appearance of platinum peaks along the length of the gels. The platinum peaks 
progress along the length of the gel as the electrophoresis time is increased in the 
same way the protein bands were seen to progress along the stained gel. Since 
charged platinum species are known to migrate with the solvent front during 
electrophoresis 196, it is fair to assume that any platinum present on the gel 
following an 'adequate' electrophoresis time is, therefore, protein bound. 
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Figure 3.13:195 Pt profiles for Pt enriched albumin samples (PtCh 5 JiglmL Pt) 
electrophoresed for a) 1 min b) 5 min c) 10 min d) 30 min e) 45 min j) 60 min 
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By comparing the platinum profiles from the serum and albumin samples it can be 
seen that platinum binds to albumin. This occurs not only in the pure protein but 
also in the presence of other proteins such as those present in human serum. The 
presence of multiple platinum peaks in the albumin sample can be explained by 
the presence of albumin polymers. This would account for some of the platinum 
peaks present in the serum sample, but not all. Platinum appears to bind to a 
number of serum proteins found near the top of the gel following electrophoresis. 
These would typically be large proteins but assumptions concerning the molecular 
mass of proteins based solely on migration distance is not feasible with native 
PAGE. 
It was noted that, for both the serum and the albumin, the initial Pt signal intensity 
(after 1 minute) is not as high as the Pt signal obtained after 5 minutes. This is due 
to fact that after only 1 minute of electrophoresis not all the sample has had 
sufficient time to enter the lane fully. Once all the protein has entered the gel (5 
minutes) the Pt signal is at a maximum (note the different scales used in Figures 
3.12 and 3.13). Continued electrophoresis causes the Pt signal to diminish since 
the protein bands are becoming more resolved and so the platinum is being 
speciated. The Pt signal can be seen to diminish even more as electrophoresis is 
maintain for 60 minutes. This would imply that extensive electrophoresis, despite 
the mild conditions employed, leads to the loss of some protein bound platinum. 
Further evidence of this is the presence of the platinum peak at the end of the gel 
when platinum enriched albumin was electrophoresed for 60 minutes. This 
corresponds to platinum migrating with the solvent front, that is to say unbound 
platinum, which is greatly increased in longer electrophoresis runs. 
The optimal time for electrophoresis was found to be around 45 minutes, although 
this can vary slightly depending upon the condition of the running buffer. Based 
on these results it was decided to electrophorese gels until the solvent front 
(indicated by the leading band of bromophenol blue) had reached the lower edge 
of the gel, without running off the end. 
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3.2.3.b Protein Loading 
The amount of protein a gel can tolerate and successfully separate is limited by 
the gel dimensions. The Mini-Protean electrophoresis system accommodates gels 
10 cm x 8 cm x 1 mm (thick) in size. The gels have 10 sample wells, each well 
being 5 mm wide. Using these gels a range of protein concentrations were 
electrophoresed to determine the optimal protein loading. Continuous gels were 
used, made up solely of resolving gel. Discontinuous gels also contain a stacking 
gel, which acts to focus the samples. The absence of a stacking gel in the 
continuous system means care must be taken when loading samples. The loaded 
sample should be in the form of as narrow a plug as is possible to maximise 
protein resolution. The mini gel wells will hold a sample volume of up to 30 J.1L, 
but sample volumes of only 5 J,lL were loaded to keep the sample band narrow. 
Smaller volumes were avoided due to the difficulty of accurate pipetting. Serum 
samples (5 J,lL, -70 mg protein ImL), enriched with Pt (PtC4, 5 J,lglmL Pt), were 
loaded at the following concentrations; neat, x2 dilution, x5 dilution, xlO dilution, 
and x20 dilution. After electrophoresis the lanes were stained. The process was 
then repeated with albumin samples (5 J1L, 45 mg albumin ImL) enriched with Pt 
(PtC4, 5 J,lglmL Pt). 
The stained samples, shown in Figure 3.14, highlight the effect protein 
concentration has on protein resolution. Since the metals of interest are at very 
low levels in real serum samples, especially after speciation, it was necessary to 
maximise sensitivity. This was achieved by loading the highest protein 
concentration possible without disrupting protein resolution. Low protein 
concentrations were seen to resuh in better protein resolution, but this was at the 
expense of metal ion concentration and so a compromise protein concentration 
was needed. By comparing the stained lanes it can be seen that as the amount of 
protein loaded per lane was increased the protein bands became broader. It was 
decided that x2 dilution of serum was a practically realistic protein loading as it 
gave a high metal ion concentration without losing too much protein resolution. 
Loading neat serum is not advisable as this overloads the gel and causes albumin 
to smear across the gel (the sample is no longer contained within lane width). 
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Figure 3.14: Pt enriched albumin and serum samples (PtCh 5 f-lglmL Pt) loaded 
at i, x20 dilution ii, xlO dilution iii, x5 dilution iV,x2 dilution v, neat 
3.2.3.c Gel Composition 
The composition of the gel used in electrophoresis has a large impact upon the 
degree of protein resolution achieved. Choice of gel composition depends upon 
the proteins of interest. A low T % gel, with a relatively large pore size, might be 
well suited to separation of high molecular mass protein mixtures, whilst a high T 
% gel, with a relatively small pore size, might be more suited to separating low 
molecular mass mixtures. However, no single T % gel is ideal for the complex 
mixture of proteins found in serum. Gels are available which have a linear T % 
gradient increasing along the length of the gel. The gradually decreasing pore size 
of gradient gels has a sieving effect upon the proteins, thereby increasing 
resolution in some instances. Three different gels were compared to determine the 
best gel composition for separating the proteins found in serum. Four different 
protein samples at physiological concentrations, enriched with Pt (PtC4, 5 llg/rnL 
Pt), were run on each gel to show the effect of gel composition on protein 
migration. The samples run were albumin (relative molecular mass (RMM) ~ 69 
kDa), transferrin (RMM ~ 75 kDa), a-2-macroglobulin (RMM ~ 820 kDa) and 
serum. All samples were run in duplicate, one set was stained and the other 
analysed by LA ICP-MS. 
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From the stained samples, shown in Figure 3.15, it is evident that different 
migration rates occur for a protein depending on the composition of the gel. The 
proteins were seen to migrate further in the 7.5 % gel compared to the 15 % gel, 
due to the large pore size. Sharp protein bands were seen in the 15 % gel but they 
were not very well resolved. The protein bands in the 7.5 % gel, by comparison, 
were much broader but protein resolution was better. The gradient gel was seen to 
give the best overall performance when separating a serum sample, made up of 
proteins with a wide range of mass/charge ratios. The protein resolution was better 
than that achieved with the 15 % gel, with much narrower protein bands than 
those achieved using the 7.5 % gel. The Pt ion responses achieved from laser 
interrogation of the corresponding protein samples are shown in Figures 3.16-
3.19. The platinum profiles also show gradient gels to be the gels most suited to 
separation of the complex mixture of proteins found in serum. 
-
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Figure 3.15: Pt enriched protein samples (PtCh 5 J.ig/mL Pt) run on 7.5 %, 15 % 
and 4-15 % gels. 
Protein samples; i, a2-macroglobulin ii, transferrin iii, albumin iv, serum 
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Figure 3.16: 195 Pt profiles for Pt enriched a2-macroglobulin (PtCh 5 f..IglmL Pt) 
electrophoresed on 7. 5 %, 15 % and 4-15 % gels. 
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Figure 3.17:195pt profiles for Pt enriched transferrin (PtCh 5 j.Ig/mL pt) 
electrophoresed on 7. 5 %, 15 % and 4-15 % gels. 
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Figure 3.18:195 Pt profiles for Pt enriched albumin (PtCh 5 flglmL Pt) 
electrophoresed on 7. 5 %, 15 % and 4-15 % gels. 
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Figure 3.19: 195 Pt profiles for Pt enriched serum (PtCh 5 Jlg/mL PI) 
electrophoresed on 7. 5 %, 15 % and 4-15 % gels. 
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The platinum profiles show that each of the protein samples studied will bind 
platinum to some degree. The peak corresponding to Cl2-macroglobulin bound 
platinum can be seen to migrate further into the gradient gel than the 7.5 % gel 
due to the larger pore size. The small pore size of the 15 % gel in combination 
with the large size and molecular mass of the a2-macroglobulin prevent it from 
entering the gel at all. Not all of the platinum added is bound to the 
az-macroglobulin with unbound platinum migrating with the solvent front, this is 
indicated by the platinum peak at the foot ofthe gel. 
Platinum bound to transferrin can also be seen to migrate different distances 
depending on the composition of the gel used. The migration distances observed 
for 7.5 % and gradient gels are very similar. With the small pore 15 % gel, 
transferrin (molecular mass - 75 kDa) hardly enters the gel. Again not all of the 
platinum added to the protein samples is protein bound, a large fraction can be 
seen to migrate with the solvent front. 
Albumin is very effective at binding platinum. The relatively small albumin 
molecule (69 kDa) almost passes through the 7.5 % gel due to the large pore size. 
With the gradient gel the albumin can be seen to migrate just over half way along 
the gel. The small pore size of the 15 % only allows the albumin to migrate about 
one third of the way into the gel. In each case multiple bands can be seen 
corresponding to peaks from polymerised albumin. The amount of platinum 
migrating with the solvent front is much lower than with the previous protein 
samples indicating that more of the platinum is protein bound. This is probably 
just a reflection of the high concentration of albumin relative to the transferrin and 
a2-macroglobulin (all proteins at physiological concentrations). 
The platinum enriched serum samples shows platinum bound to a range of serum 
proteins. As with the albumin samples, virtually all the platinum is protein bound 
(very little platinum migrating with solvent front). The gradient gel gives the best 
protein distribution, covering about three-quarters of the gel. The 7.5 % gel covers 
the whole gel but as a result is less sensitive whilst the 15 % gel only uses the fIrst 
third ofthe gel and so protein resolution is poor. 
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3.2.3.d Nature of Electrophoresis 
The type of electrophoresis system employed to run gels can have a huge impact 
on the results obtained. Using the Mini-Protean system (Bio-Rad) it is possible to 
run vertical gels under native, denaturing and IEF conditions. Alternative 
commercial flatbed systems are available where the gels are held horizontally. 
Native electrophoresis separates proteins according to a combination of protein 
size and charge. Reasonable protein resolution may be achieved using native 
PAGE but protein identification can be difficult. With denaturing electrophoresis, 
using SDS, protein resolution is improved and protein identification is simplified 
due to the direct relationship between the migration rate and the molecular mass 
of the protein. IEF electrophoresis separates proteins according to their isoelectric 
point. IEF can, therefore, be useful in resolving proteins of similar molecular mass 
and is often combined with SDS electrophoresis to give 2D electrophoresis. 
To show the effect of various electrophoresis styles on protein resolution a 
number of pure proteins, albumin, transferrin and a.2-macroglobulin, were run 
along with serum under both native and denaturing conditions. In each instance 4-
15 % gradient gels were used. After electrophoresis the gels were stained, see 
Figure 3.20. By comparison of the protein distributions achieved using the two 
systems it is apparent that the SDS system produces narrower protein bands than 
those achieved using native PAGE. There were significantly more discrete protein 
bands with the stained SDS gel than with the equivalent sample run under native 
conditions, an indication of the better resolving power ofSDS electrophoresis. 
Closer examination of the stained gels shows a difference in migration rates for 
proteins under the two systems. Using native PAGE, transferrin and albumin have 
very different migration rates, with albumin travelling much farther into the gel. 
Under denaturing conditions albumin and transferrin migrate at similar rates due 
to their similar molecular masses. Albumin is the most abundant protein in human 
serum, and transferrin is known to bind to a variety of metals so resolution of 
these two proteins in particular is essential when studying metal speciation in 
human serum. As a result native PAGE is more suited to this purpose than SDS 
PAGE. 
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Figure 3.20: Protein samples electrophoresed by native and SDS PAGE 
i, a2-macroglobulin ii, transferrin iii, albumin iv, serum 
Under native conditions u2-macroglobulin (molecular mass ~ 820 kDa, 4 sub-
units) gives a single band. The large size of u2-macroglobulin, along with the 
sieving effect of the gradient gel, means the protein band only migrates a little 
way into the gel. When run under denaturing conditions u 2-macroglobulin gives a 
number of bands that migrate further into the gel than is the case with native 
PAGE. A possible explanation for this behaviour is the breaking of sulphydryl 
bonds during the denaturation of the protein, which could result in separation of 
the u2-macroglobulin sub-units. 
Despite the superior resolution of SDS it was decided that native conditions 
should be used to help maintain protein-metal bonds existing within the serum. 
SDS acts by binding to the proteins and opening out the protein structure. The 
effect of this on an existing metal-protein bond is not known. Two detrimental 
possibilities exist; the opening out of the protein can expose binding sites 
previously hidden to the metals. This could result in the occurrence of metal-
protein binding not present under native conditions. Alternatively the SDS may 
bind to the proteins at the expense of existing metal-protein bonds. 
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Figure 3.21 shows the Pt profiles obtained from analysis of Pt enriched serum 
samples (PtC4, 5 IlglmL Pt) run under native and SDS conditions. The Pt levels 
detected for the serum electrophoresed under SDS conditions are significantly 
lower than the levels detected for the sample run under native conditions. Both 
serum samples were enriched with an equal concentration of Pt prior to 
separation, and identical protein concentrations were loaded in each instance. It 
was, therefore, deduced that such differences in the levels of protein bound 
platinum must arise through the denaturation of the serum proteins. As a result 
native PAGE was used for all serum speciation studies. 
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Figure 3.21:J95Pt profiles for Pt enriched serum (PtCh 5 j.Jg/mL Pt) 
electrophoresed under native and denaturing conditions. 
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IEF involves the setting up of a pH gradient. When performing IEF separations on 
the Mini Protean system the sample is loaded at the top of the gel. As a result, if 
the pH range is 3-10, proteins may be exposed to pH levels up to 7 pH units away 
from their isoelectric point. Exposure to such extreme pH levels is highly likely to 
disrupt the metal-protein bonds of interest. Metal speciation studies were not, 
therefore, carried out by IEF separation on the Mini-Protean system. 
An alternative system for carrying out IEF separation is the flat bed system 
produced by Pharmacia. Exposure of proteins to extreme pH levels can be avoided 
by loading the sample in the centre of the gel (- pH 6.5 in a 3-10 pH range) 
making the system more suited to metal speciation. However, analysis of a Pt 
enriched serum sample (PtC4, 5 J.Lg/mL Pt) separated on such a system showed a 
high Pt background over the entire gel. This is most likely due to the design of the 
system. In the upright Mini-Protean system the gel comes into very little contact 
with the electrodes. The thin platinum wire electrodes are immersed in the buffers, 
which only come into contact with the very top of the wells and the very bottom 
of the gel. With a flat bed system the gel is sandwiched between, and so is 
exposed to, two platinum electrodes. The run time for IEF is greater than for 
native PAGE which also increases the likelihood of Pt contamination of the gel. 
Figure 3.22 shows the very low platinum background obtained for a blank gel run 
on a vertical native PAGE system. Note particularly the very low background 
counts compared to Pt signals previously detected. 
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Figure 3.22: 195 PI profile o/blank gel lane/rom verticall-D native PAGE 
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3.2.3.e Buffer System 
The sample buffer commonly used in native PAGE contains glycerol to make the 
sample more dense than the running buffer, thus causing the sample to sink in the 
sample well. It also contains the tracking dye bromophenol blue, which travels 
with the solvent front and so can be used to monitor the progression of 
electrophoresis. In some instances 2-mercaptoethanol is added to break di-
sulphide bonds. When performing native PAGE the bromophenol blue of the 
tracking dye was seen to migrate with the albumin band as well as the solvent 
front, as shown in Figure 3.23. 
albumin 
band 
solvent 
front 
Figure 3.23: Un-stained gel showing bromophenol blue bound to albumin band 
This would indicate that some degree of albumin-bromophenol blue binding is 
occurring. To determine the effect of bromophenol blue on metal-protein binding, 
Pt enriched serum and albumin (PtC4, 5 J.lg/rnL Pt) were run using sample buffers 
with and without bromophenol blue. Samples were also run using sample buffers 
with and without 2-mercaptoethanol. The Pt profiles obtained, Figure 3.24, were 
compared to determine whether bromophenol blue adversely affects Pt binding. 
Mercaptoethanol breaks disulphide bonds and in our studies was shown to affect 
Pt-protein binding. As a result mercaptoethanol was not used in the sample buffer. 
In no instance did bromophenol blue appear to affect Pt-protein binding. This is to 
be expected since albumin has a vast number of binding sites available and so 
competitive binding is unlikely to occur. As a result bromophenol blue was added 
to the sample buffer for all further studies. 
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Not only does bromophenol blue help to indicate the end point of electrophoresis, 
but the fact that it travels with the albumin band means that 89Br can be monitored 
using ICP-MS to help locate the albumin peak. This is more reliable than 
comparing profiles with stained gels as the dimensions of the gels tend to alter as 
a result of the staining process where the gel is fIrst dehydrated then rehydrated 
prior to drying. 
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Figure 3.24:195 Pt profiles for Pt enriched albumin and serum (PtCh 5 jLglmL PI) 
electrophoresed using various sample buffers. 
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3.2.3/ Additional Studies 
After determining the optimal conditions a few additional studies were necessary 
to check the validity of the technique for metal speciation in biological samples. 
First the effect of the laser interrogation position within the gel lane upon signal 
intensity was examined. To perform this experiment a serum sample enriched 
with Pt (PtC4, 5 llg/mL Pt), was interrogated in a lateral manner, shot-wise across 
a section of the lane known to contain protein bound Pt (perpendicular to the 
direction of protein migration). The results obtained are shown in Figure 3.25. 
These results show the exact positioning of the ablation path along the gel lane is 
not critical within a central 3 mm region of the 10 mm gel lane. This can be 
readily achieved given that stepper motor control positional accuracy is of the 
order ± 2 Ilm. 
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Figure 3.25: 195pt profile for lateral interrogation of gel lane containing Pt 
enriched serum (PtCh 5 J..LglmL Pt) electrophoresed under naJive conditions. 
The possibility of cross contamination between gel lanes was studied by 
interrogation of a Pt enriched serum sample (PtC4, 5 llg/mL Pt) and the adjacent 
blank lane (no sample loaded). The results obtained are shown in Figure 3.26. By 
comparison with the background platinum profile it can be seen that cross 
contamination between lanes is insignificant when Pt enriched serum is loaded at 
2 x dilution, 5 ilL/lane. 
108 
500 
II 
I 
450 
400 
350 
Oi 
300 
= ~ 250 
~ 
200 
ISO 
100 
SO 
0 
0.05 4.31 8.56 12.8 17.1 21.3 25.6 29.8 34.1 38.4 42.6 46.9 51.1 55.4 
Migration Distance (mm) 
_ Pt enriched serum - Blank lane adjacent to Pt enriched serum 
- Blank lane 
Figure 3.26: /95 Pt profile for Pt enriched serum (PtCh 5 pg/mL Pt), for adjacent 
blank lane and for blank lane run in isolation. 
3.2.4 Basic Analytical Performance 
Once systematic studies concernmg FI, LA and electrophoresis had been 
performed basic analytical performance studies for complete PI ICP-MS and LA-
ICP-MS analysis were undertaken. The performance data for Linearity of signal 
response, limit of detection, measurement precision and accuracy are reported. 
3.2.4.a Flow Injection ICP-MS 
1. Concentration Dependence 
The relationship between signal response with analyte concentration was 
determined by injecting 0.1 mL injections of aqueous Pt standard solutions at the 
0, 10, 50, 100 and 500 )lg/L levels (including Rh as an internal standard (IS) at 20 
)lg/L). Serum samples enriched with the same Pt concentrations were also injected 
and analysed by PI ICP-MS. The transient 195Pt signals are shown in Figure 3.27. 
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Figure 3.27: 195 Pt time response profiles for various Pt standards (0.1 mL 
injection volume) 
The resulting peak areas were integrated and normalised using the IS, the results 
were plotted against Pt concentration. The linearity of the line is indicated by the 
R2 value, the closer the value is to 1 the better the linearity of the systems 
concentration response. Figure 3.28 shows that the calibration curves obtained 
both exhibit good linearity, R2 = 0.998 and R2 = 0.997. 
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Figure 3.28: Calibration curvesfrom FIICP-MS of Pt standards (0-500 J.1glL) 
II. Limit of Detection 
The sensitivity of the technique is generally described using the parameter limit of 
detection (LaD). The LaD is the lowest analyte concentration above which the 
analyte content may be reliably quantified. The lower the LOD of a system the 
more sensitive the system is. A number of different mathematical definitions are 
in use. However, the most common defmition, and the one we shall use here, is 
the concentration of 3 times the standard deviation (30-) of the blank 
measurements. This defmition gave values of 0.32 /lglL and 0.89 /lgIL for 
aqueous standards and serum standards, respectively. 
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III. Measurement Precision 
Precision is a measure of the reproducibility of a system. The most widely used 
value to express precision is the relative standard deviation (RSD) which gives a 
percentage value. In general an RSD of < 4 % is deemed acceptable. RSD is 
calculated using the equation; 
RSD = standard deviation / mean x 100 
Figure 3.29 shows the ion time response for a 50 Ilg/L Pt sample (aqueous) 
injected and analysed 5 times. Using the above equation an RSD of 1.31 % was 
calculated. 
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Figure 3.29: Time response profile/or injection 0/50 J-lg/L Pt standard solutions 
IV. Accuracy 
Accuracy describes the closeness of the result obtained to the true value. The 
accuracy of the system was obtained by determining the % recovery of spiked 
samples. Six enriched samples (50 IlglL Pt) were injected and analysed using FI 
ICP-MS. Percentage recovery was calculated using the following equation; 
% Recovery = (Concnspiked sample-Concnblank)/ConcDenriched X 100 
Table 3.2 shows the percentage recoveries obtained. The average recovery IS 
101.57 ± 1.25 %, showing a slight positive bias to the system. 
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Sample % Recovery 
99.19 
2 101.41 
3 101.90 
4 102.10 
5 101.99 
6 102.81 
Table 3.2: Percentage recoveries for 50 j.Lg/L Pt spiked samples 
3.2.4.b Laser Ablation ICP-MS 
I. Concentration Dependence 
To determine the relationship between signal response and analyte concentration 
gels were cast (see section 2.2.3) containing 0, 0.1, 0.25, 0.5, 1, 2 and 4.45 ).lg/mL 
of Pt. Each gel also contained the IS Rh (0.5 ).lg/mL Rb). The dried gels were 
interrogated using laser ablation in the raster mode. Respective signal responses 
are shown in Figure 3.30 
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Figure 3.30:195 Pt time response profiles/or laser interrogation of Pt enriched gels 
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The resulting peak areas were integrated and normalised using the IS, the results 
were plotted against Pt concentration Figure 3.31 shows the calibration curve, 
which exhibits good linearity R2 = 0.9983. 
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Figure 3.31:Calibration graphjor LA lCP-MS ojPt enriched gels (0-4.45 f-LglmL) 
II. Limit of Detection 
The sensitivity of the technique is generally described using the parameter limit of 
detection (LOD). Using 3 times the standard deviation (3cr) of the blank 
measurements to determine LOD gives a value of 0.005 Jlg/mL for Pt. 
III. Measurement Precision 
The precision of measurement was determined by interrogating a Pt enriched gel 
(PtC4, 0.5 Jlg/mL Pt) 5 times. The time response signals obtained are shown in 
Figure 3.32. Using the equation given previously an RSD of2.15 % was obtained. 
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Figure 3.32: /95 Pt time response profile for interrogation of a Pt enriched gel 
(PtCh 0.5 f.JglmL Pt) 
IV. Accuracy 
Accuracy describes the closeness of the result obtained to the true value. The 
accuracy of a system is best determined using an appropriate certified reference 
materials (CRM), unfortunately these are not always available. Accuracy can also 
be determined by analysing spiked samples and determining spike recovery but 
this approach was not appropriate for the present studies. 
3.2.4.c Variability of Gel Interrogation 
Having identified a reliable measurement process experiments were conducted to 
assess the variability / imprecision associated with gel preparation. Pt enriched 
serum (PtC4, 5 IlglmL Pt) was used throughout this study. The sample separation 
step needs to be reproducible for the speciation results to be meaningful. Thus 
there was a need to determine the reproducibility of the electrophoresis step: 
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a) Intra-Sample Reproducibility 
An enriched serum sample should give the same Pt response when subjected to 
electrophoresis and laser ablation ICP-MS. Figure 3.33a shows the results 
obtained for a sample run on two different lanes on the same gel. These results 
show sample loading to be reproducible. 
b) Inter-Sample Reproducibility 
Two identically enriched serum samples should give the same Pt response when 
analysed. Figure 3.33b shows the results obtained for two such samples run 
simultaneously on the same ge1. These results show serum enrichment to be 
reproducible. 
c) Inter-Gel Reproducibility 
An enriched serum sample should give the same Pt response when run on two 
separate gels. Figure 3.33c shows the results obtained for such a sample run 
simultaneously on two separate gels. These results show gels to be reproducible. 
d) Inter-Run Reproducibility 
A sample should give identical results when electrophoresed under identical 
conditions, even if not run simultaneously. Figure 3.33d shows the results 
obtained for a sample run on two separate gels at different times. These results 
show electrophoresis to be reproducible. 
e) Inter-Ablation Reproducibility 
Ablating a gel lane twice should give the same results. Figure 3.33e shows the 
results obtained when the same lane was ablated. These results show gel ablation 
to be reproducible. 
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Figure 3.33: 195pt profiles for Pt enriched serum (PtCh 5 j.J.g/mL PI) 
electrophoresed under native conditions. 
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3.3 Application of FI ICP-MS to Clinical Samples 
Flow injection ICP-MS was initially used to determine whether a significant 
degree of platinum-protein binding could be detected in human serum. FIICP-MS 
was also used to determine the levels of platinum (total, free and bound) typically 
found in serum samples taken from patients undergoing platinum therapy and to 
compare the levels with those found in serum taken from control sources. 
3.3.1 In Vitro Studies 
3.3.1.a Liquid IEF Fractions 
A serum sample enriched with platinum (PtC4, 5 J.lglmL Pt) was separated using 
the Rotofor system, which separates proteins according to their pI whilst in a 
liquid state (no gel involved). After separation the proteins were ' harvested' into 
20 discrete fractions. The pH of each fraction recovered was noted to check how 
well the pH gradient had been established; this is essential for good protein 
resolution. The values obtained are shown in Table 3.3. The 20 fractions harvested 
from the Rotofor system were then analysed by FI ICP-MS to determine the 
concentrations of platinum in each fraction. The procedure used is described in 
Chapter 2. The values obtained are shown in Table 3.3, and are plotted in Figure 
3.34. 
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Figure 3.34: 195 Pt concentration in fractions harvested following liquid IEF 
separation of Pt enriched serum sample (PtCI4, 5 Jig/mL Pt) 
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Figure 3.34 shows that most of the protein bound platinum in the enriched serum 
sample can be found in fractions 3-6, which cover the pH range of 4.8-5.6. This 
would correspond to the pI of human serum albumin (see Appendix 1.3). A 
second peak is visible centred around fraction 7, pH 5.8, which is probably due to 
platinum-transferrin binding as transferrin has a pI of 5.9. Much of the platinum 
present in fractions 3-10 is probably bound to albumin. The concentration of 
albumin in serum is too great to fit in the fractions of the appropriate pH and so it 
is likely to over-spill into adjacent fractions. The fractions harvested were 
electrophoresed using native PAGE to gain extra insight into the proteins present 
in the various fractions, see section 3.4.l.d. 
Fraction pH Run 1 (flg/L) Run 2 (flWL) Mean (flg/L) 
1 -4.5 590.13 469.40 529.76 
2 -4.7 481.35 475.68 478.51 
3 -4.8 873.59 874.15 873.87 
4 -5.0 2058.30 1995.75 2027.02 
5 -5.3 2597.90 2587.20 2592.55 
6 -5.6 1238.34 1162.21 1200.27 
7 -5.8 1591.50 1589.85 1590.68 
8 -6.1 1253.09 1212.57 1232.83 
9 -6.3 1157.40 1084.04 1120.72 
10 -6.4 974.32 888.31 931.32 
11 -6.6 711.29 577.69 644.49 
12 -6.6 452.83 436.77 444.80 
13 -6.7 459.33 440.08 449.71 
14 -7.0 316.09 290.45 303.27 
15 -7.2 438.84 446.76 442.80 
16 -7.5 290.84 280.44 285.64 
17 -8.0 327.63 307.61 317.62 
18 -8.5 324.73 309.51 317.12 
19 -9.0 333.26 338.46 335.86 
20 -11.0 277.79 287.62 282.70 
Table 3.3: 195 Pt concentration in fractions harvested following liquid IEF 
separation of Pt enriched serum sample (PtCI4. 5 jlg/mL Pt) 
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The actual platinum concentrations found in the fractions are not as high as might 
be expected. Platinum in serum has been found to be >90% protein bound in 
under 2 hours 77. Whilst the conditions in liquid phase IEF electrophoresis are 
milder than those experienced in IEF PAGE, they are still harsher than those in 
native PAGE. These harsh conditions may explain the low levels detected by 
causing metal-protein bonds to break. Further optimisation of operating 
parameters would be needed before reliable platinum concentrations could be 
achieved. However, the platinum profile obtained gives some idea of the nature of 
platinum-protein binding occurring in human serum enriched in vitro. 
3.3.1.b Electro-elution Samples 
Serum enriched with inorganic platinum (PtC4, 5 J.1g/mL Pt) was electrophoresed 
using a 2DIPrep gel as described in Chapter 2. After electrophoresis the gel was 
electro-eluted and the 14 resulting fractions were collected. Staining of the 
2DIPrep gel after electro-elution showed that a large proportion of the protein was 
still associated with the gel. The fractions recovered from the electro-elution of 
the platinum enriched serum sample were analysed using FI ICP-MS to determine 
the amount of platinum in each fraction. Unfortunately due to the use oflarge flat 
bed platinum electrodes in the electro-elution system the background platinum 
levels were too high to obtain meaningful results. 
3.3.1.c Samples Enriched with Platinum Compounds 
In order to get some idea of the platinum binding potential of serum proteins a 
serum sample was enriched with inorganic platinum (PtC4), to 0, 1,5, 10 and 25 
J.1g/mL Pt. After 3 hours of equilibration at room temperature the samples were 
filtered using ultrafiltration. The ultra-filtrates were collected and analysed using 
FI ICP-MS to determine the levels of free (unbound platinum). The results 
obtained are shown in Table 3.4. The amount of bound platinum was calculated 
using the equation below; 
Total [Pt] = Free [Pt] + Bound [Pt] 
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Enrichment ultrafiltrate 1 ultrafiltrate 2 mean free Pt mean bound Pt bound Pt 
(Ilg/L) (Ilg/L) (Ilg/L) (Ilg/L) (Ilg/L) % 
0 0.32 0.27 0.30 N/A N/A 
1000 3.06 3.02 3.04 997 99.7 
5000 18.5 17.6 18.0 4980 99.6 
10000 45.0 43.7 44.4 9960 99.6 
25000 10.4 9.62 10.0 25000 99.6 
Table 3.4: Pt concentrationsfor enriched serum samples after filtration (3 sigfig) 
It would appear that there is a vast number of potential platinum binding sites in 
serum. Even at the 25 IlglmL level over 99.6 % of the platinum exists in the 
bound state, shown in Figure 3.35. As such it is unlikely that there will be 
saturation of platinum protein binding sites at the levels of platinum occurring in 
human serum, even at the elevated levels present in serum of patients receiving 
platinum therapy. 
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Figure 3.35:Free and bound PI in enriched serum samples (PtCI4, 0-25 pg/mL PI) 
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3.3.2 In Vivo Studies 
Control and platinum patient serum samples were analysed in triplicate using FI-
ICP-MS to detennine the total platinum levels Free platinum levels were 
detennined by ultrafiltration of samples prior to analysis. Bound platinum levels 
were calculated as the difference between the total platinum concentration and the 
free platinum concentration. The results obtained are shown in Table 3.5. 
Total Pt FreePt Bound Pt Bound Pt 
(J.1g1L) (J.1g1L) (J.1g1L) 0/0 
Cisplatin Patient 162.34 14.58 147.76 91.0 
Cisplatin Patient 107.19 12.61 94.58 88.2 
Carboplatin Patient 722.21 111.47 610.74 84.6 
Control! 0.72 0.37 0.35 48.3 
Control 2 0.89 0.38 0.51 56.8 
Enriched Control 47.33 0.77 46.56 98.4 
Table 3.5: /95 Pt concentrations for control and patient serum samples 
By comparison of the total Pt concentrations obtained by PI ICP-MS analysis of 
the serum samples, it can be seen that the platinum levels in the serum of cisplatin 
and carboplatin patients are significantly higher than the platinum levels present in 
the control serum. Control serum 3 is a control serum sample that has been 
enriched with platinum (PtC4, 50 J.1g/L Pt). Using the platinum concentration 
found for control 3 the % recovery for the system was found to be 94.7 %, 
showing a slight negative bias. 
The total platinum concentration in the carboplatin patient's serum is, somewhat 
surprisingly, higher than that found in the cisplatin patients' serum. Comparing 
platinum-protein binding in each of the patient's samples it can be seen that the 
actual percentage of bound platinum is slightly lower in the carboplatin patient 
(84.6 %) than for the cisplatin patients (91.0 % and 88.2 %). Such a difference in 
protein binding could help account for the differences in toxicity between the two 
platinum drugs. In itself these data do not tell us anything about the platinum-
protein species being formed in the serum. 
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3.4 Application of LA ICP-MS to Clinical Samples 
Flow injection studies can determine total and, in combination with ultrafiltration, 
free levels of platinum present in serum samples. However, it can not tell us 
anything about the platinum-species present in the serum. To look at this a more 
sophisticated separation technique, such as electrophoresis, is needed. The 
suitability of laser ablation ICP-MS for the speciation of platinum in biological 
samples separated using PAGE was established during method development. The 
next step was to apply the technique to 'real' samples. In vitro studies were 
carried out initially to gain some insight into the nature of Pt-protein binding. The 
binding of inorganic platinum with different proteins was investigated as well as 
the behaviour of different platinum species in serum. The effect of equilibration 
time on protein binding was also studied. 
Next in vivo studies were carried out comparing the platinum-protein binding 
occurring in control serum with that found in serum taken from patients 
undergoing platinum therapy. When studying serum samples knowledge of the 
behaviour of other metals in serum can be helpful, transferrin, for example, is 
known to be the major protein responsible for iron transport in serum. Human 
serum typically contains 2-3.2 mg/mL transferrin, which is capable of binding two 
Fe atoms per molecule197. By monitoring the distribution of s7Fe the location of 
transferrin in the gel can be inferred. e7Fe is monitored despite the greater 
abundance ofs6pe due to potentiaI 4°Ar160+ interference) 
3.4.1 In Vitro Studies 
3.4.1.a Pure Proteins Enriched with Inorganic Platinum 
Initial studies were carried out in vitro in order to gain a basic understanding of 
the interaction of platinum with serum proteins. Albumin (50 Jlg/JlL), transferrin 
(3.0 J.1g/J.1L) and <X2-macroglobulin (4.0 Jlg/J.1L), all at physiological 
concentrations, were enriched with inorganic platinum (PtC4, 5 J.1g/mL Pt). After 
a 24 hour equilibration period the samples were electrophoresed and then analysed 
by laser ablation ICP-MS. 
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The platinum distribution profiles obtained are shown in Figure 3.36. It was 
assumed throughout the study that proteins and metal ions found in the same 
region of the gel are bound. This is not an unreasonable assumption since 
unbound platinum was found to migrate with the solvent front (migration distance 
-55 mm). In all three cases some degree of platinum-protein binding can be 
observed. 
Since all three protein samples were enriched with the same concentration of 
platinum the degree of protein binding is reflected by the amount of platinum 
migrating with the solvent front. Hardly any platinum is present at the solvent 
front of the albumin sample indicating that virtually all the platinum is protein 
bound. Platinum binding to transferrin and <l2-macroglobulin is not as abundant, 
hence the large proportion of platinum migrating with the solvent fronts. This 
does not, however, imply albumin has a greater afftnity for platinum than 
transferrin and <l2-macroglobulin. The high degree of platinum-albumin binding 
may simply reflect the high concentration of albumin present in the sample 
compared to the other protein samples. 
The platinum band for the albumin sample is broad, due to the high concentration 
of albumin. The band appears to be made up of a number of peaks, this is due to 
the presence of albumin polymers. The enriched transferrin profile shows 
platinum binding. The location of the transferrin on the gel (migration distance -
22 mm) is confirmed using the s7Fe profile. All three platinum profiles are plotted 
on identical y axes and so the platinum peak heights can be directly compared to 
compare the amount of platinum in each protein band. It can be seen that much 
less platinum is bound to transferrin than is found bound to albumin. 
The platinum profile for enriched <l2-macroglobulin shows some platinum binding 
occurs, at a level comparable with transferrin. The occurrence of multiple bands is 
hard to explain, it may be that on binding platinum the quaternary structure of 
<l2-macroglobulin is disrupted causing the constituent sub-units to separate. 
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Figure 3.36: 195pt &57Fe profiles for Pt enriched proteins (PtCh 5 f.1g/mL Pt) 
electrophoresed under native conditions. 
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3.4.1.h Serum Enriched with Platinum Compounds 
Serum was enriched with different platinum compounds individually to study the 
effect of platinum species upon protein binding. Control serum samples were 
enriched with inorganic platinum (PtC4, 5 .... g/mL Pt), cisplatin (5 .... g/mL Pt), and 
carboplatin (5 .... g/mL Pt). The enriched samples, along with a control sample 
(unspiked) were equilibrated for 3 hours then electrophoresed using native PAGE. 
The dried gels were analysed using laser ablation ICP-MS. The platinum profiles 
obtained are shown in Figure 3.37. The platinum profile for the unspiked serum 
sample shows that, as expected, there is no significant Pt-protein binding naturally 
occurring in serum. Extensive Pt-protein binding can be seen to occur when serum 
is enriched with inorganic platinum (note the different y-axis scales used with the 
different serum samples). 
When serum was enriched with inorganic platinum extensive Pt-protein binding 
was observed. As might be expected from the results of the previous study 
platinum was seen to bind to albumin (- 35 mm). The s7Fe profile shows an iron 
peak coincidental with a platinum peak at - 22 mm, which indicates the presence 
of transferrin-bound platinum. Again this is in agreement with the earlier study. A 
large proportion of the protein bound platinum in serum appears to be bound to 
serum proteins that do not migrate very far into the gel, implying they have high 
mass/charge ratio or that they are simply too large to migrate further into the 
gradient gel. Unfortunately a positive identification is not possible with the 
existing apparatus since protein identification based on migration distance is not 
straightforward with native PAGE. The platinum distribution resulting from 
enrichment differs according to the platinum species used. When serum is 
enriched with cisplatin the platinum present is predominantly bound to albumin, 
with a small amount bound to high mass/charge ratio proteins. In contrast, 
carboplatin appears to be bound mainly to high mass/charge ratio proteins with 
hardly any of the platinum appearing in the albumin region. It can be concluded 
that the nature of the platinum species has a strong effect on the protein binding 
occurring in serum. These apparent differences in the proteins binding cisplatin 
and carboplatin may relate to the differences in their relative toxicities. 
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Figure 3.37: 195 Pt profiles for control serum and serum enriched with inorganic 
platinum, cisplatin and carboplatin (5 p.g/mL Pt) after 3 hours of equilibration 
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3.4.J.e Time Studies Involving Platinum Compounds 
To get some idea of the pharmacokinetics of the different platinum drugs samples 
were analysed at different times after enrichment to see the effect on platinum 
distribution. To achieve this, serum was enriched with inorganic platinum (PtC4, 
5 f.1g1mL Pt), cisplatin (5 f.1g1mL Pt), and carboplatin (5 f.1g1mL Pt), in duplicate. 
One set of samples was allowed to equilibrate for 3 hours before electrophoresis, 
the other set of samples was allowed to equilibrate for 24 hours. The platinum 
profiles obtained for the 3 hour samples are shown in Figure 3.37, the platinum 
profiles obtained for the 24 hour samples are shown in Figure 3.38. Again 
different y-axis scales have been used to maximise platinum profile examination. 
First the degree of platinum-protein binding was examined. All platinum species 
showed an increase in the degree of platinum-protein binding observed as the 
equilibration time increased from 3 hours to 24 hours. The degree of platinum-
protein binding observed varied according to the enrichment species. Inorganic 
platinum was seen to bind most readily with serum proteins, cisplatin showed the 
next highest degree of platinum-protein binding with carboplatin showing very 
little platinum-protein binding in serum. 
Next differences in the actual platinum distribution profiles were examined. For 
serum enriched with inorganic platinum the distribution pattern remained 
unaltered with increasing equilibration time, only the signal intensity was seen to 
increase. The story is not so simple for the serum enriched with platinum drugs. 
The platinum distribution of the two drugs altered with equilibration time. As the 
equilibration time increased the proportion of platinum bound to the albumin 
fraction increased for both drugs, although more markedly with cisplatin. After 3 
hours of equilibration cisplatin was bound to a range of serum proteins. After 24 
hours the cisplatin was predominantly bound to albumin. Equilibrating carboplatin 
with serum for 3 hours resulted in very little carboplatin-protein binding. After 24 
hours of equilibration a small amount of carboplatin-albumin binding could be 
observed. This is consistent with the theory that the coplanar structure of 
carboplatin delays degradation and so slows down the rate of protein binding 
relative to cisplatin. 
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platinum, cispiatin and carbopiatin (5 pg/mL PI) after 24 hours of equilibration 
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These observed differences in the serum protein binding behaviour of cisplatin 
and carboplatin in vitro may go some way to explaining the differences in toxicity 
of the two drugs. Protein bound platinum drugs are regarded as non-active. The 
effect protein binding has on the behaviour of the drug will depend to some 
degree on the nature of the protein involved and the nature of the binding. If 
tightly bound to a protein, assuming no essential role of the protein is being 
disrupted, a metal is unlikely to cause a toxic effect. as it is unlikely to be released 
for example to the kidneys. A metal loosely bound to a protein will be more labile 
making its transport to vital organs more probable, thereby increasing the 
potential toxicity of the metal. 
Cisplatin undergoes a high degree of protein binding (relative to carboplatin). As a 
result of this it is likely to remain in the blood stream for longer periods. Whilst 
protein bound in this way cisplatin is known to be inactive. A high proportion of 
the cisplatin can be seen to bind to albumin, a high concentration serum protein 
with many potential metal binding sites. Once protein bound a metal may be 
transported to the organs of the body, once there undesirable interactions may 
result in toxic side effects. Carboplatin undergoes a relatively low degree of 
protein binding and so resides in the serum for a shorter time, as a result the 
dosage is often higher than with cisplatin. Only a small fraction of the protein 
bound carboplatin is bound to albumin, this may lead to its relatively low toxicity. 
3.4.I.d Liquid IEF Analysis 
Liquid IEF was used together with native PAGE in an attempt to improve on the 
protein resolution A serum sample enriched with inorganic platinum (PtC4, 5 
J.lg/mL Pt), was separated using the Rotofor system, which separates proteins 
according to their pI. After separation the serum was 'harvested' into 20 discrete 
fractions. The harvested fractions were run on ID native PAGE gels. This 
effectively gave 2D separation of the serum proteins, with IEF as the fIrst 
dimension and native PAGE as the second. The gels were run in duplicate, one set 
was ablated and the second set stained and dried. The stained gels are shown in 
Figure 3.39. Collected fractions were also analysed using FI ICP-MS as described 
in section 3.3. La. 
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Figure 3.39: Stained gels of Rot of or fractions run on native PAGE 
The stained gel shows that IEF separation using the Rotofor system was not 
perfect. The concentration of albumin in the serum was too high despite dilution 
and as a result albumin was present in virtually every lane. However, a higher 
degree of protein separation was achieved compared to the use of native PAGE in 
isolation. 
Pt profiles were obtained by interrogation of the 20 gel lanes. To determine how 
representative the Rotofor harvest was of the original sample the Pt profiles for all 
20 lanes were combined. The resultant profile is given in Figure 3.40. By 
comparing the resultant profile with a Pt profile obtained from analysis of a serum 
sample enriched with inorganic platinum (such as in Figure 3.37) it can be seen 
that the distribution profile is almost identical. This shows the harvested fractions 
are representative of the serum sample being studied. The Pt distribution profiles 
were also used to construct a 2D contour plot. Platinum signal intensity was 
plotted against position on the gel. The resultant plot is shown in Figure 3.41. Six 
discrete regions of high Pt intensity can be made out, further work would be 
needed to positively identify the associated proteins, but it gives some indication 
of the complexity of platinum binding. 
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3.4.2 In Vivo Studies 
To look at the effect of platinum therapy on protein bound platinum species in 
serum, serum from a control source was electrophoresed alongside serum samples 
taken from patients undergoing platinum therapy. The serum samples of the 
patients were taken 1-2 hours after drug infusion. Following electrophoresis the 
samples were interrogated using laser ablation ICP-MS. The Pt profiles obtained 
are shown in Figure 3.42. 
No significant degree of platinum-protein binding was observed with the control 
serum. The levels of platinum detected in the serum from the patients are 
significantly higher than the level detected in the control serum, this is as might be 
expected. 
The protein bound platinum in the cisplatin patient's serum is mainly associated 
with albumin, there is also some binding to higher mass/charge ratio proteins. The 
platinum in the carboplatin patient's serum is bound to albumin, but a greater 
proportion is bound to other high mass/charge ratio proteins. In vitro studies 
showed cisplatin bound more readily to serum proteins than carboplatin. The 
reverse appears to be the case with the patients' serum. The absolute level of 
protein bound platinum is higher in the serum of the carboplatin patient 
However, it is not justifiable to draw conclusions based on these fmdings alone. 
The FI ICP-MS results (Section 3.3.2) show that the absolute level of bound 
platinum to be higher in the carboplatin patient's serum compared with cisplatin 
patients' serum. However, when taken as a percentage of the total platinum in the 
serum sample it was noted that a slightly greater percentage of platinum was 
protein bound in the case of the cisplatin patients' serum than was the case in the 
carboplatin patient's serum. Other external factors need also to be taken into 
consideration before reading too much into these results, such factors include the 
patients general health, the dosage administered and the duration ofthe therapy. 
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3.5 Main Findings 
The results show LA ICP-MS combined with native PAGE provides a new and 
novel strategy for platinum speciation. Initial studies indicated the experimental 
conditions were such that the integrity of platinum-protein species was 
maintained, unlike with SDS PAGE. The technique did not suffer from high 
platinum background levels as observed with flat bed systems. The LOD for 
platinum in gel is 0.005 Jlg/rnL. The sensitivity of the technique was such that 
small sample volumes could be used (2.5 J.Ll serum loaded per gel lane) with little 
sample preparation. both very important factors in the analysis of clinical samples. 
Results conflI1Jled the significantly higher levels of platinum in serum from 
patients undergoing Pt therapy compared with the control serum samples. A high 
percentage of this platinum was protein bound in both the cisplatin and 
carboplatin patients' serum. In vitro studies showed that serum has a high 
platinum binding potential with platinum-protein binding >99 % for enriched 
serum (25 Jlg/rnL inorganic platinum spike). As such, saturation of platinum 
binding sites should not be an issue when considering patient serum samples. 
Given the lower toxicity associated with carboplatin therapy it was rather 
surprising to find that the Pt concentration in the carboplatin patient's serum was 
higher than that detected in the cisplatin patients' serum. However, a number of 
external factors influence the levels of platinum found in the serum of patients 
undergoing platinum therapy such as the duration of the therapy, level of drug 
administered and general health of patient. The degree and nature of platinum-
protein binding is more pertinent to the toxicity of a drug than the absolute levels 
present in the serum samples and so the nature of platinum-protein binding was 
studied. 
In vitro studies enriching control serum with cisplatin and carboplatin show both 
drugs bind with a range of proteins. It was observed that cisplatin bound more 
readily to albumin than was the case for carboplatin. When time studies were 
carried out with the two drugs differences were observed in the pharmacokinetics 
of protein binding. Levels of protein bound cisplatin were seen to increase with 
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time, with proportion bound to albumin increasing. The platinum distribution 
pattern for carboplatin enriched serum was also seen to alter with time as the 
proportion of platinum bound to albumin increased. Such a difference in the 
nature of the protein binding and the observed differences in the mechanistic 
pathway of the two drugs could go some way to explaining the differences in their 
associated toxicities. It would appear that Pt-albumin binding is associated with 
drug toxicity rather than drug efficacy, such a fmding is consistent with the fact 
that albumin bound platinum drugs are known to lose their anti-tumour activity. 
LA ICP-MS interrogation of serum samples obtained from cisplatin and 
carboplatin patients reflects the differences observed between the drugs in vitro. 
The main difference between the profiles obtained is the proportion of platinum 
bound to albumin. The carboplatin patient's serum contained the highest 
concentration of protein bound platinum, however, only a small fraction of the 
protein bound platinum was bound to albumin relative to the cisplatin patients' 
serum. 
Overall the new hyphenated technique developed proved successful in the 
speciation of platinum species in human serum, in particular clinical samples 
obtained from patients undergoing platinum therapy. The main limitation of the 
technique is sufficient protein resolution given the complex nature of the sample, 
serum typically contains over 100 different proteins 198. The use of liquid IEF, in 
the form of the Bio-Rad Rotofor followed by native PAGE was shown to improve 
protein resolution by the addition of a second separation parameter. The main 
protein component of serum is albumin (- 35-45 mglmL). Such high albumin 
concentrations can pose problems when trying to study metal binding to other, 
lower concentration proteins. One way in which such problems can be overcome 
would be to remove the serum albumin prior to protein separation. The protein 
concentration of the sample would then be greatly reduced. This would mean 
serum could be electrophoresed without prior dilution, effectively increasing the 
sensitivity of the technique as well as improving the potential protein resolution. 
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Chapter 4: Characterisation of Gold Enriched Gels 
4.1 Introduction 
The noble metal gold is one of the few metals to exist in nature in the elemental 
state. Pure gold is a soft, yellow metal with the highest ductility and malleability 
of any element I 99. Because of its relative inertness gold does not tarnish on 
exposure to air and so retains its lustre. Such properties meant gold was an 
unsuitable material from which to make implements, and so primitive man used 
gold purely for ornamental purposes. Today gold finds more widespread usage. 
Whilst retaining its ornamental value in coinage and jewellery, gold is also used in 
the electronics industry, in heterogeneous catalysts, in dental alloys and in modern 
medicine. 
Whilst metallic gold is chemically inert, gold has six discrete oxidation states -I, 
0, I, II, III, & V. There is no evidence for the occurrence of states -I, II or V in the 
environment, whilst the states 0 (metallic gold), I and III are all biologically 
significant, despite the high toxicity of gold III. 
The average concentration of gold in the earth's crust is very low, -5 J.lg/kg200, 
although gold is widely dispersed throughout the environment. Levels of gold 
released into the environment by man are very low, mainly due to the inertness of 
gold and the economic incentives. Very low levels of gold naturally occur in plant 
and animal tissue, although as yet gold has not been identified as an element 
essential for life20I . Concentrations of gold in the human body are usually very 
low, with blood levels of gold in man around 0.35 J.lg/L202, elevated gold levels 
can result from wearing gold jewelleri°3, however, or in chrysotherapio4• Gold 
has a long medical history dating back to ancient China. By the late 19th century it 
was being used to treat tuberculosis (TB) and syphilis. The use of chrysotherapy 
to treat rheumatoid arthritis (RA) was quite fortuitous from the treatment of TB 
patients. 
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Treatment ofRA is the main application of gold therapy today. All gold drugs are 
Au(I) compounds since Au(III) is so much more toxic to humans. Gold drugs for 
the treatment of RA fall into two main groups, oral and parenteral. Auranofin is 
the only modern orally administered gold drug to have found widespread 
acceptance. There is a number of parenteral gold drugs available of which the 
most widely used is Myocrisin. 
Chrysotherapy has been used to treat the many millions of people suffering from 
RA for well over fifty years and is known to induce remission. Despite such 
widespread usage the exact mode of action of gold drugs in still unknown. It is 
known, however, that the pharmacokinetics of parenteral and oral gold drugs 
differ greatly. 
The use of all gold therapy is limited by the occurrence of toxic side effects. Such 
side effects are more common in patients receiving parenteral drugs than with 
those receiving oral drug treatment. Such toxic side effects are thought to be due 
to the formation of Au(lII) compounds, although this has yet to be proven. Gold 
levels in the serum and urine of chrysotherapy patients are routinely monitored 
due to the toxicity associated with the accumulation of high gold levels in the 
bloodstream. 
Gold drugs are difficult to study in solution as gold does not have an observable 
NMR or ESR spectra Gold is mono-isotopic, that is to say 197Au has an 
abundance of 100 %. ICP-MS uses the detection of individual isotopes to 
determine analyte concentrations and offers high sensitivity for gold 
determination. Coupled with the low incidence of isobaric and oxide 
interferences, ICP-MS is a suitable means of gold determination in clinical 
samples. This is especially true when coupled with flow injection or laser 
ablation, which minimise the amount of sample pre-treatment needed. Some 
techniques require extensive sample pretreatment when analysing biological 
samples, for examples the presence of proteins can lead to matrix effects when 
using AAS20S • 
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In this chapter the applicability of laser ablation ICP-MS to gold analysis is 
described and analytical performance documented. Flow injection studies are 
performed to detennine the total and free (unbound) concentrations of gold in 
serum from chrysotherapy patients and controls. In vitro studies have also been 
carried out to determine the effect of different gold species on protein binding. 
These studies involved enriching serum samples with inorganic gold (Au(l», 
Myocrisin (Au(I» and colloidal gold (Au(O». 
Au(O) is of interest since there is speculation that it may be the active form of gold 
in the treatment of RA206. Differences between the protein binding of this gold 
species and inorganic gold may go some way towards explaining the toxic side 
effects observed with conventional gold drugs. Colloidal gold is known to bind to 
proteins and is widely used as a protein dye. However, the binding of colloidal 
gold with proteins is considered non-specific and is very pH dependent20'. When 
Au(O)-protein bonds occur they are non-covalent electrostatic interactions. As a 
resuh any such interactions occurring in serum should interfere with protein 
reactivity only minimally. Ion layers around gold colloid particles compress in the 
presence of strong electrolytes and so they can approach each other closely. 
Flocculation of the solution can occur once a critical distance is reached. This 
being the case it is unlikely that colloidal gold will interact with proteins under 
physiological conditions. 
In vivo studies were also performed comparing gold distribution in control serum 
with that observed in serum from patients receiving chrysotherapy. 
4.2 Method Development 
In general the operating parameters determined in the course of the platinum 
studies were used throughout. PI ICP-MS was identical to that described 
previously as were the laser parameters utilised to interrogate the gels, as shown 
in Table 4.1. The electrophoresis time study was repeated using gold enriched 
serum samples (H(AuC4), 2 ).1g/mL Au) to check on the overall effectiveness of 
electrophoretic separation. 
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Parameter LSXlOO LSX200 
Laser Energy 0.65 mJ 0.8mJ 
Laser Shot Rate 20Hz 20Hz 
Aperture Size N/A 260 Jlm 
Laser Defocus -3000 JUIl N/A 
Scan Rate 50~s 50~s 
Table 4.1: Optimised laser ablation parameters for gel interrogation 
4.2.1 Electrophoresis 
Figure 4.1 shows the Au signal response for laser ablation ICP-MS of serum 
samples enriched with Au (H(AuC4), 2 J..I.g/ml Au) and electrophoresed for 
varying times. Based on the Au distribution it can be seen that after 1 minute the 
serum is just entering the gel and no separation has occurred. From 5-30 minutes 
the proteins in the serum migrate further into the gel and begin to separate 
according to their mass/charge ratio. After 30 minutes a leading peak due to 
unbound gold present in the solvent front can be observed. After 60 minutes of 
electrophoresis the sample has over-run, the solvent front is off the end of the gel 
and the protein bands begin to broaden and run into each other. As with the 
platinum studies the optimal time for electrophoresis was found to be around 45 
minutes, although this time varied depending on the condition of the running 
buffer. Based on these results it was decided to run the gels until the solvent front 
(indicated by the leading band of bromophenol blue) had reached the lower edge 
of the gels, without running off the end of the gel. 
Figure 4.2 shows the Au signal response for laser ablation ICP-MS of the albumin 
samples enriched with Au (H(AuC4), 2 J..I.g/ml Au) and electrophoresed for 
various times. The results are similar to those obtained with serum, with the 
optimal electrophoresis time being - 45 minutes. It can be seen from the two sets 
of results that inorganic gold binds to albumin. When serum is enriched with 
inorganic gold the majority of it is found with the albumin fraction, with a small 
amount found in two proteins peaks near the top of the gel. Further identification 
of these proteins was not possible using the system available. 
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It was noted that, for both the serum and the albumin, the initial Au signal 
intensity (after 1 minute) is not as high as the Au signal obtained after 5 minutes. 
This is due to fact that after only 1 minute of electrophoresis not all the sample 
has had sufficient time to enter the lane fully. Once all the protein has entered the 
gel (5 minutes) the Au signal is at a maximum (note the different scales used in 
Figures 4.1 and 4.2). Continued electrophoresis causes the Au signal to diminish 
since the protein bands become more resolved and so the gold is speciated. The 
Au signal can be seen to diminish even more as electrophoresis is maintain for 60 
minutes. This would imply that extensive electrophoresis, despite the mild 
conditions employed, leads to the loss of some of the protein bound gold. 
4.2.2 Basic Analytical Performance 
4.2.2.a Flow Injection ICP-MS 
I. Concentration Dependence 
The relationship between signal response and analyte concentration was 
determined by making 1.0 mL injections of aqueous Au standard solutions at the 
0, 10,50, 100,500 and 1000 J.1g/L levels (including Rh as an IS at 20 J.1g/L). Serum 
samples enriched with the same Au concentrations were also injected and 
analysed by FI ICP-MS. The resuhing peak areas were integrated and the results, 
normalised using IS, were plotted against Au concentration. Figure 4.3 shows that 
the calibration curves obtained both exhibit good linearity R2 = 0.9999 and R2 = 
0.9998. 
II. Limits of Detection 
The sensitivity of the technique is generally described using the parameter limit of 
detection (LaD). Using 3 times the standard deviation (30) of the blank 
measurements to determine LaD gave values of 0.77 J.l.g/L and 0.89 J.l.g/L for 
aqueous and serum standards, respectively. 
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Figure 4.3: Calibration curves for FIICP-MS of Au standards (0-1000 )J.g!L Au) 
III. Measurement Precision 
Precision is a measure of the reproducibility of a system. The most widely used 
value to express precision is the relative standard deviation (RSD) which gives a 
percentage value. The precision of the measurement was determined by injecting 
an aqueous standard solution (50 J.lg/L Au) five times. Using the equation given 
previously an RSD of 1.55 % was calculated. 
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IV. Accuracy 
The accuracy of the system was obtained by detennining the % recovery of spiked 
samples. Six serum samples enriched at the 100 J..lg/L level were analysed by FI 
ICP-MS. Table 4.2 shows the percentage recoveries obtained. the mean 
percentage recovery was found to be 100.58 ± 1.65 % showing a very slight 
positive bias for the system. 
Sample % Recovery 
100.91 
2 100.75 
3 99.09 
4 103.42 
5 98.80 
6 100.52 
Table 4.2: Percentage recoveries for 100 Jig/L Au spiked serum samples 
4.2.2.b Laser Ablation ICP-MS 
I. Concentration Dependence 
To determine the relationship between signal response and analyte concentration 
enriched gels were analysed. These standards were polyacrylamide gels enriched 
with varying levels of the analyte of interest, inorganic Au in this instance. 
Enriched gels were cast (see Section 2.2.3) containing 0, 0.1, 0.25, 0.5, 1.0, 2.0 
and 4.45 J..lglmL of Au (including internal standard Rh at 0.5 J..lglmL in all gels). 
The gels were then interrogated using laser ablation in the raster mode. 
The resulting peak areas were integrated and the results, normalised using IS, 
were plotted against Au concentration. The linearity of the line is indicated by the 
R2 value, the closer the value is to 1 the better the linearity of the systems 
concentration response. Figure 4.4 shows the calibration curve obtained, which 
exhibits good linearity with an R2 value of 0.9976. 
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Figure 4.4: Calibrationfor LA ICP-MS of Au enriched gels (0-4.45 pglmL Au) 
II. Limit of Detection 
The sensitivity of the measurement is generally described using the parameter 
limit of detection (LOD). Using 3 times the standard deviation (30") of the blank 
measurements to determine LOD gave a value of 0.0034 fJ.g/mL for Au. 
III. Measurement Precision 
The precision of the measurement was determined by interrogating an enriched 
gel (0.5 fJ.g/mL Au) five times. Using the equation given previously, an RSD of 
2.78 % was calculated. 
IV. Accuracy 
Accuracy describes the closeness of a result to the true value. The accuracy of a 
system is best determined using appropriate certified reference materials (CRM), 
unfortunately these are not always generally available. Accuracy can also be 
determined by analysing spiked samples and determining spike recovery but this 
approach was not appropriate for present studies. 
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4.3 Application of FI ICP-MS to Clinical Samples 
Flow injection ICP-MS was initially used to determine whether a significant 
degree of gold-protein binding could be determined in an in vitro enriched human 
serum sample separated using native PAGE. FI ICP-MS was also used to 
determine the levels of gold (total, free and bound) typically found in serum 
samples taken from chrysotherapy patients and to compare them with the levels 
found in serum taken from control sources. 
4.3.1 In Vitro Studies 
Serum enriched with gold (H(AuC4), 5 J.1g1mL Au) was electrophoresed using a 
native 2DIPrep gel as described in Chapter 2. After electrophoresis the gel was 
electro-eluted and the 14 resulting fractions were collected. Staining of the 
2DIPrep gel after electro-elution showed that a large proportion of the protein was 
still associated with the gel. The fractions were analysed using FI ICP-MS to 
determine the amount of gold present in each fraction. The procedure was 
repeated with an unspiked serum sample. Table 4.3 shows the results obtained. 
Fraction Gold Enriched Serum (J.1g/L) Unspiked Serum (J.1g/L) 
1 4.536 0.114 
2 2.143 0.096 
3 1.552 0.134 
4 1.928 0.119 
5 0.904 0.154 
6 0.635 0.131 
7 1.302 0.202 
8 3.497 0.151 
9 6.614 0.209 
10 0.764 0.018 
11 0.139 0.041 
12 0.263 0.004 
13 0.177 0.014 
14 0.294 0.008 
Table 4.3: Au concentrations in electro-elution fractions for Au enriched serum 
(H(AuCI4). 5 j.iglmL Au) and un-enriched serum 
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In order to make the electro-elution results meaningful, the protein concentration 
of each fraction was determined. The protein concentrations for the fractions were 
calculated using the Bio-Rad protein assay (see Appendix 2.1). The enriched 
serum (H(AuC4), 5 J..lg/ml Au) was diluted 1:1 with sample buffer, of this 75 J..lL 
were loaded onto the gel. A further 100 fold dilution of the serum occurred during 
electro-elution. This would result in a fmal gold concentration of 25 J..lg/L 
(assuming all protein eluted from gel). Figure 4.5 shows a graphical representation 
of the result obtained. Based on the average protein concentration of serum (70 
mg/ml before dilution) the protein recovery from the gel by electro-elution is only 
25.74 %. This recovery might be improved on by altering the buffer systems and 
operating parameters, but care must be taken to maintain the metal-protein bonds 
of interest. 
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Figure 4.5: 197 Au concentration profile and protein distribution for FIICP-MS 
analysis of electro-elution fractions collected following PAGE of Au enriched 
serum (H(AuCI4) , 5 j.Jg/mL Au), and un-enriched serum 
The horizontal positioning of the fractions in Figure 4.5 correlates directly with 
the position of the fraction along the gel lane. As a result the plot can be directly 
compared to the gold profiles obtained using laser ablation rep-MS. It can be seen 
that the fractions 8-10 contain the albumin fraction. The plot also shows that 
hardly any protein bound gold is present in the unspiked serum. This is consistent 
with other experimental fmdings (see Figure 4.7). 
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4.3.2 In Vivo Studies 
Control serum samples and serum samples taken from chrysotherapy patients 
were analysed in triplicate using FI-ICP-MS. Total and free gold levels were 
determined by the use ofuhrafiltration (as described in Ch2). Using these results 
levels of bound gold were calculated in each case. The results obtained are shown 
in Table 4.4. 
Total Au Free Au Bound Au Au Bound 
(fJ.gIL) (J.LgIL) (J.LgIL) % 
Myocrisin Patient 1 468.74 295.73 173.01 36.91 
Myocrisin Patient 2 952.40 296.29 656.12 68.89 
Controll 307.80 295.22 12.58 4.09 
Control 2 299.86 295.25 4.61 1.54 
Enriched Control 737.05 294.43 442.62 60.05 
Table 4.4: 197Au concentrations obtained for control and patient serum samples 
analysed using FIICP-MS 
Significantly higher levels of gold were observed in the serum from myocrisin 
patients compared with the control serum. Of this a high proportion was found to 
be protein bound although the degree of protein binding varied greatly between 
the two patients. Very little of the gold present in the control serum was protein 
bound, this is possibly due to the soW'Ce of the gold in the control serum. Control 
3 was a control serum sample enriched with gold (H(AuC4), 500 J.1g/L Au). The 
percentage recovery for the system was 85.40 % and so as such the results show a 
slight negative bias. 
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4.4 Application of LA ICP-MS to Clinical Samples 
4.4.1 In Vitro Studies 
In vitro studies were carried out initially to gain some insight into the 
complexation pattern for Au in serum. In an initial study the binding of different 
gold species with pure proteins was studied. The effect of equilibration time on 
protein binding was also studied. 
4.4.1.0 Pure Proteins Enriched with Inorganic Gold 
Physiological concentrations of albumin (50 mglmL), transferrin (3.0 mglml) and 
(l2-macroglobulin (4.0 mglmL), were enriched with inorganic gold (H(AuC4), 50 
J.lglmL Au). After a 24 hour equilibration period the samples were 
electrophoresed. The dried gels were then analysed using laser ablation ICP-MS. 
The gold distribution profiles obtained are shown in Figure 4.6. 
The level of gold added to the proteins was extremely high, much higher than 
normal physiological levels encountered, - 0.35 J.lgIL202. By using such a high 
gold concentration the relative affinities of the proteins for gold can be studied. 
By studying the gold profiles obtained it can be seen that both albumin and (lr 
macroglobulin exhibit a high degree of gold binding. The levels of gold found in 
serum are unlikely to exceed the number of potential binding sites available on the 
serum proteins. The muhiple gold peaks in the albumin profile can be explained 
by the presence of albumin polymers. 
Some form of transferrin-gold interaction can also be observed but to a much 
lesser degree than that observed with albumin and {X2-macroglobulin. In the 
absence of other proteins competing for gold binding only a low level of gold-
transferrin binding occurs. It is, therefore, unlikely that a significant degree of 
gold-transferrin binding will occur in serum where many other proteins are 
present. Albumin, which is present in serum at high concentrations and readily 
binds gold, is one such competing protein. 
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Figure 4.6: 197Au profiles obtained for pure proteins enriched with inorganic 
gold, (H(AuCI4), 50 f-iglmL Au). 
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4.4.1. b Serum Enriched with Gold Compounds 
The effect of different gold species on gold distribution in serum was studied next. 
Serum samples were enriched with inorganic gold (H(AuC4), 2 JlglmL Au), 
colloidal gold (2 J.1g/mL Au) and the gold drug myocrisin (2 Jlg/mL Au). After 24 
hours of equilibration the samples were electrophoresed using native PAGE along 
with an unspiked serum sample. The dried gels were analysed using laser ablation 
ICP-MS. The gold profiles obtained are shown in Figure 4.7. 
The gold profile obtained from analysis of the unspiked serum sample shows that 
no significant gold-protein binding occurs naturally in the control serum. When 
the serum was enriched with inorganic gold, gold-protein binding was observed. 
The gold was found to bind to albumin. as might be expected from the previous 
study. Two peaks formed by gold binding to serum proteins other than albumin, 
which do not migrate so far into the gel. were also observed. One of these peaks 
might be due to urmacroglobulin binding with gold as it is found in the region of 
the gel previously shown to correspond to u2-macroglobulin. If this is the case the 
degree of gold binding to u2-macroglobulin in serum is much lower than that 
observed for the pure protein in isolation. This could imply that gold binds 
preferentially to albumin, or may simply reflect the relative concentrations of the 
proteins in serum. The occurrence of gold binding to other proteins in the 
presence of albumin at levels below albumin-gold saturation would imply that any 
preferential binding occurring between gold and albumin is not at the exclusion of 
other gold-protein interactions. 
Serum enriched with myocrisin yields a similar gold profile to that obtained from 
inorganic gold enrichment. Once again most of the gold was found to be in the 
region of the albumin peak whilst other, lesser, gold-protein interactions were also 
observed. A positive identification of these other gold binding proteins was not 
possible with the system. The gold peak at -40 mm has migrated further than 
albumin indicating a smaller protein (gradient gel restricts the migration of large 
proteins). A possible protein associated with this peak is pre-albumin which has a 
molecular mass of61 kDa. 
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Figure 4.7: J97Au profiles obtained for profiles for control serum and serum 
enriched with inorganic gold, colloidal gold and myocrisin (2 pg/mL Au). 
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Colloidal gold gives a very different profile from the other enriched serum 
samples. A single peak was seen at the start of the lane. The amount of gold in 
this peak was much higher than the peaks observed with the other enriched serum 
samples. There is a number of possible explanations for this; 
i, the colloidal gold binds to a protein with a high mass/charge ratio 
ii, the colloidal gold binds to a protein and causes it to polymerise or change 
conformation and so prevents the protein entering the gel fully 
lll, the colloidal gold flocculates and so is prevented by size limitations from 
passing through the gel. 
In order to determine which of these possible explanations is the most probable 
cause for the distribution of the colloidal gold in serum it was necessary to carry 
out further studies. 
4.4.1.c Proteins Enriched with Gold Compounds 
Albumin and transferrin, both at physiological concentrations, were enriched with 
colloidal gold and myocrisin (2 J.1g/mL as Au) to help explain the gold peaks 
observed in the corresponding enriched serum samples. The gold profiles obtained 
are shown in Figure 4.8. 
The profiles for colloidal gold with albumin and transferrin are the same as those 
observed with serum Since there is no single protein common to all three samples 
the peak can not be attributed to protein binding. It is, therefore, most probable 
that the large gold peak is due to flocculation of the colloidal gold. This rmding is 
consistent with the theory that Au(lII) is toxic, through protein interaction, whilst 
Au(O) such as colloidal gold, is non-toxic (efficacious even) through the absence 
of protein interactions. 
Myocrisin can be seen to bind extensively to albumin but only sparingly to 
transferrin. In neither instance does a gold peak appear near the top of the lane as 
is the case for myocrisin enriched serum. It can be deduced from this that the gold 
peak occurring in the serum sample is due to gold binding to some protein other 
than albumin and transferrin. 
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Figure 4.8: 197 Au profiles for albumin and transferrin enriched using colloidal 
gold and myocrisin (2 f.J.glmL, Au) 
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4.4.1.d Time Studies Involving Gold Compounds 
To get some idea of the mechanism of gold protein binding, samples were 
analysed at different times after enrichment to see the effect on gold distribution. 
To achieve this serum was enriched with inorganic gold (H(AuC4), 2 J.1g/mL Au) 
in triplicate. One sample was allowed to equilibrate for 24 hours before 
electrophoresis, one sample was allowed to equilibrate for 3 hours before 
electrophoresis and the third sample was allowed to equilibrate for just 5 minutes 
before electrophoresis. The gold profiles obtained are shown in Figure 4.9. 
Gold-albumin binding occurred almost immediately following serum enrichment, 
with the associated peak visible after only 5 minutes of equilibration. No other 
gold-protein interactions occur so rapidly. After 3 hours of equilibration the 
degree of gold-albumin binding had not ahered and no other gold-protein 
interaction was noted. The protein bound gold still appeared to be exclusively 
bound to albumin. 
When the enriched serum sample was allowed to equilibrate for 24 hours it was 
noted that gold-albumin was still the major gold-protein species present in the 
serum. The level of gold-albumin appeared to stay fairly constant regardless of 
equilibration time. After 24 hours of equilibration other gold-protein species could 
be seen in the gold profile. These species consisted of gold bound to proteins with 
electrophoretic mobilities lower than albumin under native conditions. The degree 
of gold binding to these proteins was much lower than that observed for albumin. 
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Figure 4.9: 197 Au profiles for Au enriched serum (H(AuCI4) , 2 f.JglmL Au) 
following various equilibration times 
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4.4.2 In Vivo Studies 
To look at the effect of chrysotherapy on protein bound gold species in serum, 
control serum was electrophoresed alongside serum samples taken from two 
patients undergoing chrysotherapy. The serum samples of the patients were taken 
1-2 hours after drug infusion. Following electrophoresis the samples were 
interrogated using laser ablation ICP-MS. The Au distribution profiles obtained 
are shown in Figure 4.10. 
No significant degree of gold-protein binding was observed with the control 
serum. The levels of gold detected in the serum of both chrysotherapy patients are 
significantly higher than the level detected in the control serum, as might be 
expected. Both the patients were being treated with myocrisin and as a result their 
gold profiles are virtually identical. In both instances the gold is mainly found 
bound to albumin. Very little gold binding to proteins other than albumin was 
observed. This is what we might expect from previous findings given the short 
equilibration time. 
The main difference between the two patient profiles is the absolute level of 
protein bound gold. This is in agreement with the FI ICP-MS results which found, 
173.01 J.1g/L bound gold in serum from patient 1 and 656.12 J.1g/L bound gold in 
serum from patient 2. No inferences can be made about the different levels of 
protein bound gold based purely on these resuhs. There is a number of external 
factors that could influence gold-protein binding, such as: the gold dosage 
administered, the duration of gold therapy and the overall state of health of the 
patients. 
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Figure 4.10: 197 Au profiles from analysis of in vivo samples. 
a) Control serum, b) Myocrisin patient 1, c) Myocrisin patient 2 
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4.5 Main Findings 
The results show LA ICP-MS combined with native PAGE to be a suitable 
technique for gold speciation work using serum samples from patients undergoing 
chrysotherapy. Initial studies indicated the experimental conditions were such that 
the integrity of gold-protein species was maintained and the technique did not 
suffer from high gold background levels. The LOD for gold in the gels was 
0.0034 J.l.glmL, which is adequate for analysis of patient's serum. The sensitivity 
of the technique was such that small sample volumes could be used (2.5 J.l.L serum 
loaded per gel lane) with little sample preparation, both very important factors in 
the analysis of clinical samples. 
In vitro studies enriching control serum with different gold species showed that 
the degree and nature of gold-protein binding was very dependent on the gold 
species. Inorganic gold (Au(III)) was seen to bind most abundantly with albumin. 
A similar gold distribution profile was observed when serum was enriched with 
myocrisin (Au(l)) although an additional gold peak was observed which may be 
due to gold binding to pre-albumin. When serum was enriched with colloidal gold 
(Au(O)) no protein binding was observed, instead the gold flocculated and did not 
enter the gel. In vitro time studies showed gold-albumin binding to be almost 
instantaneous « 5 minutes) whilst other gold-protein interactions took a longer 
time to occur. The profiles obtained from analysis of clinical samples reflect these 
fmdings, the serum samples were acquired from chrysotherapy patients 1 hour 
after drug administration. Gold is seen to be predominantly bound to albumin as 
was the case in the time study. 
Initial studies carried out using FI ICP-MS show typical gold concentrations of 
300 J.l.g/L in control serum. Significantly higher gold concentrations (469-952 
J.l.g/L) were detected in serum obtained from patients undergoing chrysotherapy. 
Ultrafiltration of the serum samples showed a significantly higher degree of gold-
protein binding in the serum of the chrysotherapy patients (31-69 %) compared to 
that observed in the control serum (-2 %). 
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The source of serum gold is a possible explanation for the observed differences in 
the degree of gold-protein binding. In the control, serum gold is likely to result 
from the subject wearing gold jewellery. Gold in the jewellery is solubilised and 
absorbed through the skin as AuC4-. In the patient's serum samples 
administration of Au(l) drugs is likely to be the main source of gold. It would 
appear the absorbed gold species is less inclined to protein binding than the gold 
drugs. 
The large variation in the levels of serum gold and the degree of protein binding in 
patient's serum can be put down to differences in the length of chrysotherapy, 
which can, unlike platinum therapy, go on indefinitely. These finding imply 
absolute gold levels are of little diagnostic use when trying to assess adverse 
reactions to gold. The degree of protein-bound gold, however, may be more 
relevant to such studies. 
Overall the technique proved successful in the speciation of gold species in human 
serum, in particular clinical samples obtained from patients undergoing 
chrysotherapy. It would be interesting to carry out extensive trials into colloidal 
gold therapy, a study to which this technique could be applied directly. 
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Chapter 5: Multi-Element Studies 
5.1 Introduction 
Metals have always been present in mans environment without necessarily posing 
any health risks. However over the last 200 years man has managed to alter the 
relative availability and the form in which these metals occur through 
industrialisation. Two key areas of industrialisation can be used to highlight the 
emission of metals into the environment. The use of fossil fuels to generate energy 
creates acid rain, which in turn mobilises aluminium. The mining industry has led 
to metals being released from their ore deposits into the ambient environment. 
The human body functions under homeostatic control, which is to say there is a 
balanced system of elements present in the cells. Any foreign compounds are a 
potential risk to this delicate balance. Even otherwise innocuous compounds pose 
a risk if they are present at excessive concentrations. This means that as a result of 
anthropogenic emissions health problems can arise caused by elements with 
significant biological roles as well as those with no apparent biological roles. In 
1980 a critical evaluation was written regarding the 'normal levels' of trace 
elements in human blood and plasma208• 
Over the last 60 years an enormous effort has been made to investigate the role of 
trace metals in the biochemical and physiological processes occurring within the 
human body. In order achieve this it is necessary to determine how different metal 
species interact with biological molecules and also to determine how different 
metal species interact with one another within such systems. A wide variety of 
speciation methods (see Section 1.4) can be used to determine metal metabolites 
occurring in biological systems. Metals of interest can be roughly grouped 
according to their naturally occurring concentration in the human body. 
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The first group of metals of interest are those which occur naturally in the body at 
trace levels. These metals are usually essential to humans and so a deficiency of 
such metals can lead to health problems. 
The second group of metals of interest includes those that may be present in 
humans at unnaturally elevated levels. Such an excess of metal can be due to the 
failure of an intrinsic control mechanism or through unusual environmental 
exposure. These metals may have some essentiality, but at excessive levels health 
problems occur. Metal ion antagonism is one example of how these health 
problems can arise. An example of such an element is cobalt. In the form of 
Vitamin BJ2 cobalt is essential to man. Metal workers are a group particularly at 
risk of excessive exposure to cobalt. Inhalation of cobalt containing dusts has been 
found to damage lungs, heart and skin and is an occupational carcinogen. 
Assessing the total body status of a particular metal will involve determining its 
concentration in serum. However, such measurements may not be clinically 
relevant without further knowledge of the degree and nature of protein binding in 
the serum sample. In this chapter we look at the speciation of some naturally 
occurring trace metals in serum using the technique developed in earlier chapters. 
This technique was also used to detect protein bound metal species in serum 
sample enriched in vitro with metal ions of interest. 
5.2 Application of LA ICP-MS to Clinical Samples 
It was established in earlier studies that laser ablation ICP-MS was a suitable 
technique for the speciation of metals in biological samples separated using 
PAGE. Using the parameters determined in this earlier work, (see chapters 3 and 
4) serum samples were analysed to determine the distribution of a variety of 
metals. The first section of this study looked at metals naturally occurring at trace 
levels in human serum. Next serum samples were enriched in vitro with some 
metals of interest through anthropogenic emission. Finally serum samples were 
enriched in vitro with multi-element solutions to see how metals interact in serum. 
163 
5.2.1 Essential Metals Naturally Occurring in Serum 
There are a number of metals that naturally occur in serum at trace levels. These 
elements are essential to life and carry out a number of important roles in 
metalloenzymes and proteins. Unfortunately for analysis using ICP-MS, most of 
these elements have relatively low atomic masses «80) and so fall in the mass 
region where interference from molecular ions poses a common problem. A 
classic example of this is calcium, an essential element performing a number of 
different functions in the body. The most abundant calcium isotope with 96.9 % 
abundance has a mass of 40 and so is isobaric with Ar used to produce the plasma. 
Another problem faced when analysing biological samples for such elements is 
the problem of contamination since these elements are so commonplace. 
To get an idea of the distribution of some essential metals in serum a few of the 
elements more readily detected by ICP-MS were investigated. Care was taken 
when choosing which mass to monitor bearing in mind any likely interferences. 
As a result the masses monitored were not necessarily the most sensitive masses 
available, but were thought to be those with the least interferences associated. 
5.2.1.a Iron 
Iron is the most abundant transition metal on earth, and with regard to its 
biological activity it is the most versatile of all the elements209• In the adult human 
body there are 3-4 g of functional and stored iron. Less than 0.1 % of total body 
iron is transferrin bound. 
Transferrin is a serum protein used in iron transport and exchange between body 
tissues. Transferrin has a molecular mass of -75 kDa and a typical concentration 
in serum of2 mg/mL. Each transferrin molecule has two iron binding sites and in 
general serum transferrin is only 40 % saturated with iron. This gives a rough 
value of 1.2 J.1g/mL transferrin bound iron in serum, see Appendix 2.2 for the 
calculation Transferrin is known to bind a number of other metals as well as iron 
and so is of interest in metal speciation. 
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A control serum sample was made up as described in Section 2.2.2. The serum 
sample then underwent native PAGE as described in Section 2.2.3. Figure 5.1 
shows the Fe distribution profile obtained when the serum sample was 
interrogated using LA Iep-MS. 57Fe was monitored despite the relatively low 
abundance (2.2 %) due the potential interference on 56Fe (91. 7 % abundant) from 
4°ArI60+. 
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Figure 5.1: 57 Fe profile for unspiked serum 
The large iron peak present at ~23 nun corresponds with the position of 
transferrin, the second iron peak (at ~53 mm) corresponds with the position of the 
solvent front. This would indicate that most of the iron present in human serum is 
bound to transferrin. The remainder of the iron in human serum passes through the 
gel with the solvent front showing it to be free-iron, that is to say not protein 
bound (may be bound to low molecular mass fractions of serum). This is 
consistent with the literature. 
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5.2.l .b Copper 
Despite being as inherently toxic as non-essential heavy metals, copper is 
essential to life. Nature has minimised the potential toxicity of copper by 
developing processes to eliminate excess ingested copper, by utilising copper only 
as a prosthetic element tightly bound to specific copper proteins and by 
interactions with zinc, molybdenum and iron. Copper toxicity seems to be wholly 
due to free copper ions altering the physiological functions of new copper proteins 
by combining with them. 
The mean concentration of copper in serum from a healthy subject is 1.19 J..I.g/mL. 
Elevated serum copper levels can be indicative of diseases such as RA and 
carcinomas. Once absorbed 95 % of the copper in serum is bound to 
ceruloplasmin, a protein that tightly binds 6-8 Cu atoms. Serum copper has also 
been found to bind to arglycoprotein (132 kDa), transcuprein (270 kDa) and 
albumin which transports the copper. A control serum sample was made up as 
described in Section 2.2.2. The serum sample then underwent native PAGE as 
described in Section 2.2.3. Figure 5.2 shows the Cu distribution profile obtained 
when the serum sample was interrogated using LA ICP-MS. 65CU was monitored 
despite the relatively low abundance (30.8 %) due the potential interference on 
63CU (69.2 % abundant) from 4°Ar23Na+. 
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Figure 5.2: 65Cu projilejor unspiked serum 
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A number of copper peaks can be seen in the profile. The peak at -54 mm 
corresponds to the solvent front whilst the peak at -35 mm corresponds with the 
position of the albumin peak. Three other copper peaks are also present at; -22 
mrn, 16 mm and 4 mm. The fIrst of these peaks is very close to the transferrin 
peak but does not quite overlap with the position of the iron-transferrin peak. This 
could be due to the fact that copper binds with transferrin resulting in a slightly 
different migration rate than for the iron-transferrin species. Alternatively the peak 
could be due to copper binding to a protein of a similar mass/charge to transferrin. 
It is possible that these peaks correspond to the copper binding proteins found in 
serum as mentioned in the literature. In order to positively identify the proteins 
corresponding to the three copper peaks further work would need to be done. 
5.2.I.e Zinc 
Zinc is an essential component of over 70 metallo-enzymes. Zinc defIciency can 
affect growth and reproduction. Typical healthy zinc concentrations in serum are 
in the range 0.7-1.8 mgIL. AAS can be used to determine total plasma zinc levels 
but this information is insufficient for the diagnosis of marginal cases of zinc 
defIciency. There is clearly a need for better understanding of zinc speciation in 
serum. 
Of the zinc in serum 65 % has been found to bind to albumin and 35 % to 
armacroglobulln21o. In vitro zinc has been found to form fairly stable complexes 
with transferrin. as well as other proteins211 . 
A control serum sample was made up as described in Section 2.2.2. The serum 
sample then underwent native PAGE as described in Section 2.2.3. Figure 5.3 
shows the Zn distribution profile obtained when the serum sample was 
interrogated using LA ICP-MS. 66Zn was monitored despite the relatively low 
abundance (27.9 %) due the potential interference on 64Zn (48.6 % abundant) 
from 32S32S+. 
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Figure 5.3: 66Z n profile for unspiked serum 
Unlike the studies involving iron and copper no significant zinc-protein binding 
was observed in the control serum. The zinc peak at - 55 mm corresponds to 
unbound Zn passing through the gel with the solvent front. These fmdings could 
imply that Zn-protein bonds naturally occurring in serum are relatively weak or 
labile and are broken down through electrophoresis. 
5.2.2 Anthropogenically Enriched Metals 
There are a number of metals that occur in serum at ultra-trace levels. These 
elements are not necessarily essential to healthy life. In general these elements 
have a higher atomic mass than those elements with biological roles and are not as 
readily available in the biosphere. Anthropogenic emissions have resulted in 
humans being exposed to elevated levels of some of these elements. Industrial 
exposure and metallo-drug therapy are among potential sources of such metals. In 
order to gain an insight into the distribution of some of these enriched metals in 
serum, studies were carried out using serum samples enriched (at levels much 
higher than those found physiologically) in vitro. As previously described the 
samples were analysed using LA Iep-MS. 
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An array of metals were studied in this way. The most interesting profiles are 
shown in this Section. the distribution profiles for the other metals studied can be 
found in Appendix 2.3. As with previous studies care was taken when choosing 
the atomic mass to monitor for elements suffering from isobaric or spectral 
interferences. 
5.2.2.a Cadmium 
Cadmium is widely used in pigment stabilisers, batteries, fuels, fertilisers, and 
smehing. There has been an acceleration in the number of problems associated 
with Cd since 1950 as a resuh of an eight-fold increase in Cd consumption which 
has led to increasing Cd concentrations in the environment. 
Cadmium has no proven essentiality in man but is known to interfere with the 
normal metabolism of zinc. Cadmium poisoning as a result of industrial exposure 
is not uncommon. toxicity is thought to be due to competition between Cd and Zn 
for zinc enzyme cofactor sites. Normal serum Cd levels of 1.1 J.lg/L - 3.3 J.lg/L 
have been reported212, whilst levels in workers serum has been reported as eight 
times highe~l3. Cadmium reacts readily with proteins and other biological 
molecules. Stored cadmium is thought to bind to the cysteine rich protein 
metallothionein. Occurrence of low affmity albumin binding214 and high affmity 
armacroglobulin binding21S has been reported. 
A control serum sample was enriched using a Cd standard solution (5 J'g/mL, Cd) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.4 shows the Cd 
distribution profiles obtained when the Cd enriched serum sample and a control 
serum sample are interrogated using LA ICP-MS. 1\ICd was monitored despite the 
relatively low abundance (12.8 %) due to the potential isobaric interference on 
114Cd (28.7 % abundant) from 114Sn. 
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Figure 5.4: J J I Cd profile for serum enriched with inorganic cadmium 
The Cd distribution profile shows a single, very intense Cd peak at - 19 mm 
migration distance. This does not coincide with the two main metal binding 
proteins in serum, albumin (- 33 mm) and transferrin (- 23 mm). It could be due 
to Cd binding to the cysteine rich metallothionein as the literature suggests. 
Further work would be necessary to confirm the identity of this protein. Virtually 
all of the cadmium is protein bound as none migrates with the solvent front (- 52 
rom). 
5.2.2.b Cobalt 
Cobalt is a component of alloys made to resist high temperatures and stresses. It is 
used in the glass industry to colour glass and is also used as a chemical catalyst. 
Exposure of metal workers to elevated levels of cobalt can damage lungs, heart 
and skin, it is also thought to be an occupational carcinogen. 
Cobalt is classed as essential, forming a vital part of Vitamin B 12• The mean 
whole blood concentrations of Co were found to be 0.09 ~g!L in unexposed 
subjects and 1.42 ~g!L in exposed subjects. The presence of Co can antagonise Fe 
uptake and so it has been assumed that some binding with transferrin can occur2 16. 
Co(ll) ions bind preferentially to albumin2 17. 
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A control serum sample was enriched using a Co standard solution (5 ~g/mL, Co) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.5 shows the Co 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA rCP-MS. 59CO is mono-isotopic, that is 
100 % abundant. 
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Figure 5.5: 59CO profile/or serum enriched with inorganic cobalt 
From the cobalt distribution profile it can be seen that virtually all the cobalt is 
protein bound as indicated by the small cobalt peak corresponding to the solvent 
front (~52 mm). The majority of the protein bound cobalt is associated with 
albumin (~34 mrn). A number of other cobalt peaks are present of which the peak 
at ~23 mm is likely to correspond to transferrin bound cobalt. The profile shows 
cobalt protein binding in serum to be extensive and quite complex, unfortunately 
it is not possible to positively identify the other proteins binding cobalt from this 
data alone. 
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5.2.2.c Lanthanum 
Lanthanum is used to strengthen steel and to produce superconductors. In exposed 
workers lanthanum has been found to accumulate in the liver and bone. 
Lanthanum concentration does not decrease with time after exposure indicating a 
long biological half-life2Is . 
Lanthanum has no known essentiality. It is known to replace Ca in a number of 
Ca mediated biological processes, but is not considered toxic. Few studies have 
been published on La-protein binding in serum to date. Interest in La speciation in 
biological samples is increasing due to the introduction of a new La containing 
metallodrug (Shire Pharmaceuticals) used to control P043- levels in kidney 
disease. 
A control serum sample was enriched using a La standard solution (5 J..I.g/mL, La) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.6 shows the La 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA ICP-MS. The most abundant isotope of 
lanthanum e39La, 99.9 % abundant) was monitored as no interference likely to 
occur. 
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Figure 5.6: 139La profile/or serum enriched with inorganic lanthanum 
172 
The lanthanum profile shows extensive protein binding in serum with very little 
lanthanum present in the solvent front (- 52 nun). None of the peaks appear to 
correspond with the position of the albumin band (- 35 mm), unless the 
lanthanum is causing the albumin to polymerise on binding. One of the peaks 
coincides with transferrin (- 23 nun) but unfortunately positive identification of 
the other lanthanum binding proteins is not possible from data obtained alone. 
5.2.2.d Nickel 
Nickel is used in stainless steel. jewellery, electroplating, batteries, dental 
prosthetics, data storage and chemical catalysis. Nickel emissions result from 
mining, refining, metal consumption in industrial processes and waste 
incineration. Atmospheric nickel levels are directly linked to fossil fuel and petrol 
consumption. 
Whilst nickel is generally regarded as toxic it has some essentiality at trace levels. 
The toxicity of nickel depends on the nature of the nickel compound exposed to. 
Contact dermatitis is a common complaint especially among women with nickel 
containing jewellery. A typical serum level of 0.28 J..lg/L 219 has been reported in 
unexposed subjects. 
In plasma Ni2+ transport is facilitated by binding to albumin and ultra-filterable 
ligands220• A major fraction of plasma nickel is also known to bind to 
nickeJoplasmin, an a-macroglobulin. This nickel fraction, however, is not readily 
exchangeable and so does not appear to play any role in nickel transport221 • 
A control serum sample was enriched using a Ni standard solution (5 J..lg/mL, Ni) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.7 shows the Ni 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA ICP-MS. ~i was monitored despite the 
relatively low abundance (26.1 %) due to the isobaric overlap of s~i (68.3 % 
abundant) by slFe. 
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Figure 5.7: 60Ni profile for serum enriched with inorganic nickel 
From the nickel profile it can be seen that a large portion of the nickel is bound to 
a single protein which coincides with the albumin band (- 32 mm) and the rest of 
the nickel migrates with the solvent front (- 53 mm). This is consistent with the 
literature. 
5.2.2.e Lead 
Lead has a wide variety of uses, a few of which include batteries, petrol, paints 
and glassware. Over the past 50 years there has been an increase in the amount of 
lead extracted, used and so emitted into the environment by man. As a result lead 
levels are now many times higher than they used to be which has in turn led to 
increased health risks. 
Lead has no known essentiality, and is found to interfere with several enzymes 
involved in haeme synthesis. Once absorbed by the body lead enters the blood 
stream. Typical lead levels in blood are 5-20 f.lg/100 mL for unexposed subjects, 
of this >95 % is bound to erythrocytes. In plasma almost all the lead is protein 
bound, in particular to albumin and some high molecular mass globulins. 
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A control serum sample was enriched using a Pb standard solution (5 j..lglml, Pb) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.8 shows the Pb 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA ICP-MS. Since molecular interferences 
are unlikely at such high masses the most abundant isotope of lead e08Pb, 52.4 % 
abundant) was monitored. 
2500 208Pb 
2000 
.. 1500 
'" 
= Q Q, 
~ 
~ 1000 
Q. 
500 
o 
0.1 6.2 12.4 18.6 24.8 31.0 37.1 43.3 
Migration Distance (mm) 
Figure 5.8: 208Pb profile for serum enriched with inorganic lead 
49.5 55.7 
From the lead profile it can be seen that a small fraction of the lead migrates with 
the solvent front, whilst the remainder of the lead appears in a very broad band 
(from - 15-35 mm) with the main peak at - 15 mm. Given these migration 
distances it is possible albumin and transferrin are involved to some degree, 
however, it is difficult to say what protein binding is actually occurring within the 
serum from these results alone. It does show that protein-lead binding occurs in 
serum and so may be of clinical interest. 
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5.2.2/ Chromium 
Chromium is used in stainless steel productio~ metal finishing, paint, tanning, 
chemical catalysis and data storage. Increased quantities of chromium have been 
used by man and released into the environment over several decades. Welders are 
exposed to chromium via inhalation as well as running the risk of allergic contact 
dermatitis. Normal concentration range of chromium in human blood is found to 
be 0.1-1 J.lg/L 222. There is a danger wlatile chromium species may be lost when 
using analytical techniques requiring sample digestio~ this is not an issue with 
LA ICP-MS. Chromium is known to be essential, Cr(lll) is thought to potentiate 
the action of insulin in promoting the utilisation of glucose. The oxidation state of 
chromium influences the rate of Cr-uptake as well as its toxicity. Hexavalent 
chromium is 100-1000 times more toxic than the trivalent form. Absorbed 
chromium is transported by the blood, Cr(VI) is accumulated in the red blood 
cells where it is rapidly reduced to the less toxic Cr(lII). Cr(III) is bound to 
Jas .. . lar c.. 223 b also alb . p rna protems, m partlCU translerrm ut umm. 
A control serum sample was enriched using a Cr standard solution (5 J.lg/ml, Cr) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.9 shows the Cr 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA ICP-MS. The profiles obtained for Fe are 
also shown to demonstrate the effect of enriched Cr on other metal-protein 
binding in serum. 53Cr was monitored despite the relatively low abundance (9.5 
%) due the potential interference on 52Cr (83.8 % abundant) from 40 ArI2C+. 
The profile shows Cr binding to three proteins in serum, with some Cr migrating 
with the solvent front (-55 mm). The main Cr binding protein is albumin (-34 
mm) closely followed by transferrin (-23 mm). The third Cr binding protein (-2 
mm) is likely to be a large protein or one with a high mass/charge ratio but a 
positive identification can not be made with the data available. It can be seen that 
Fe is lost from transferrin on binding Cr, a process that may be detrimental to 
health. 
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Figure 5.9: 53 Cr and 57 Fe profiles for serum enriched with inorganic chromium 
5.2.2.g Gallium 
Gallium is used as a chemotherapeutic and radio-imaging agent and also as a 
component of super-fast integrated circuits. Technological developments that call 
for the use of more semi-conductors are likely to lead to an increase in gallium 
emissions. 
Gallium has no known essentiality and has toxic effects such as nephrotoxicity, 
When administered intravenously gallium binds rapidly to plasma proteins in 
particular transferrin224 , where it competes with iron, and ceruloplasmin. The level 
of gallium in healthy human plasma was found to be around 0.1 ~g/L225. 
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A control serum sample was enriched using a Ga standard solution (5 J..lglml, Ga) 
as described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.10 shows the Ga 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA ICP-MS. The profiles obtained for Fe are 
also shown to demonstrate the effect of enriched Ga on the protein binding of 
other metals in serum. 69Ga, the most abundant isotope of gallium (60.1 %) was 
monitored as no interferences occurred on this mass. 
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Figure 5.10: 69 Ga and 57 Fe profiles for serum enriched with inorganic gallium 
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From the profile it can be seen that a small fraction of gallium in serum is protein 
bound, the remainder migrates with the solvent front (- 53 mm). A small Ga peak 
is clearly visible at -23 mm coinciding with the transferrin band. A Ga peak at 
-34 mm can just be made out coinciding with the albumin band. By comparing 
the iron profiles of unspiked and Ga enriched serum it can be seen that transferrin 
bound iron is lost on gallium binding. This could be of clinical interest and so 
could for the basis of further research. 
5.2.2.h Vanadium 
Vanadium is used in steel production, in high-strength titanium alloys and in 
chemical catalysis. A possible source of vanadium in the atmosphere is from the 
burning of fossil fuels. Vanadium demand and emission has increased over the 
last 30 years. 
Vanadium is a commonly occurring element assumed to be essential in man. 
Vanadium has a large number of oxidation states, from -1 to +5, but only +4 and 
+5 are of biological importance. Once absorbed, vanadium is transported in serum 
by binding to transferrin. Typical vanadium concentration in human serum from 
unexposed subjects is reported as 0.02-0.9 ~g/L226. 
A control serum sample was enriched using a V standard solution (5 J..I.g/mL, V) as 
described in Section 2.2.2. After 24 hours of equilibration the serum sample 
underwent native PAGE as described in Section 2.2.3. Figure 5.11 shows the V 
distribution profiles obtained when the enriched serum sample and a control 
serum sample are interrogated using LA ICP·MS. The profiles obtained for Fe are 
also shown to demonstrate the effect of enriched V on the protein binding of other 
metals in serum. SIV, the most abundant isotope of vanadium (99.8 %) was 
monitored since no interferences were observed on this mass. 
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Figure 5.11: 5/ V and 57 Fe profiles for serum enriched with inorganic vanadium 
The profile shows that a small degree of vanadium-protein binding occurs in 
serum, with the majority of the V migrating with the solvent front (~55 mm). A 
small V peak can be seen at ~ 22 mm which coincides with the transferrin band. A 
very small V peak is just visible at - 35 mrn which coincides with the albumin 
band. The Fe profile shows transferrin bound iron is lost when V is bound to 
transferrin. Such interactions are unlikely to occur at normal physiological levels, 
but may become more important when serum levels are elevated through 
exposure. 
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5.2.3 Metal Interactions in Serum 
The previous Sections highlighted some instances of metal interactions in human 
serum i.e. Cr and Fe. To briefly illustrate this further a study was conducted where 
serum was enriched with multi-metal standard solutions. The effect the presence 
of other metal ions in serum had on metal-protein binding was observed. Two 
standards were used; 
1) Cu (1.67 f.lg/mL), Cd (1.67 f.lg/mL), and Zn (1.67 f.lg/mL) 
2) Fe (1.67 f.lg/mL), Cd (1.67 f.lg/mL), and Zn (1.67 f.lg/mL) 
The serum samples were enriched and equilibrated for 24 hours before 
electrophoresis. The gels were interrogated in the usual manner. The profiles 
obtained for the two samples are shown in Figures 5.12 and 5.13, respectively. 
By direct comparison of the two sets of s7Fe profiles it can be seen that even when 
serum is not enriched Fe-transferrin binding occurs. When serum was enriched 
with the muhi-metal standard not containing Fe there was an increase in the 
amount of Fe-transferrin binding observed, this is most likely due to iron 
contamination of the metal standard. In the serum sample enriched with Fe a more 
marked increase in the amount of Fe-transferrin binding was observed. 
Copper was seen to behave in a very similar way. Cu-protein binding was present 
in all the samples, even those unenriched. The intensity of the Cu-protein peaks 
increased slightly when the serum was enriched with a multi-metal standard 
containing no copper, this is again most probably due to copper contamination. 
The greatest increase in Cu-protein peak intensity was observed when serum was 
enriched with the muhi-metal standard containing copper. 
No specific Zn-protein binding is evident with the unspiked serum samples. Both 
serum samples enriched with the muhi-metal standard containing zinc showed 
signs of Zn-protein binding. However, despite the two samples being enriched 
with zinc to a concentration of 1.67 f.lg/mL the 66Zn profiles obtained differ. It can 
be seen that the presence of additional copper in the serum sample appears to 
facilitate zinc binding to an unidentified protein, which migrates only a little way 
into the gel (- 8 mm). 
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Figure 5.12: 57Fe, 65Cu, 66Zn and JJ ICd Profiles for Serum Enriched with Cu, Cd 
and Zn (1.67 mg/L) 
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Figure 5.13: 57Fe, 65Cu, 66Zn and llICd Profiles/or Serum Enriched with Fe, Cd 
and Zn (1.67 mg/L) 
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When unspiked serum was interrogated no Cd-protein binding was observed. 
Cd-protein binding was observed when interrogating serum enriched with 
cadmium. The "'Cd profiles for both samples were virtually identical, implying 
cadmium binding is not affected by the presence/absence of iron and copper. 
5.3 Main Findings 
The technique was found to be suitably sensitive for the speciation of certain 
metals at physiological levels. e.g. Fe and Cu. The results obtained from analysis 
of control and enriched serum samples show that different metal species interact 
with serum proteins in different ways. Some metals appear to bind to a wide range 
of serum proteins whist others appear to bind specifically to a single protein. 
Table 5.1 summarises how various metal ions were distributed along the 
polyacrylamide gel following electrophoresis of enriched serum (or unspiked 
serum in the case of Fe. Cu and Zn). The two main proteins which can be 
identified following native PAGE are transferrin at - 24 mm and albumin at - 36 
mm. 
A variety of different metal distribution profiles were observed. In some instances 
very little metal-protein binding was observed. This does not necessarily imply no 
metal-protein binding occurs for these metals. The experimental conditions used, 
although mild. may disrupt existing metal-protein bonds. Alternatively the species 
of metal used in serum enrichment may not be suitable for protein binding. It has 
already been shown in Chapter 4 that the nature of metal-protein binding depends 
greatly on the metal species used. 
This brief study illustrates that some complex interactions occur in serum 
regarding the interaction of various metal ions. These interactions can. in turn. 
affect the degree/nature of metal-protein binding. Such interactions must be 
considered when interpreting metal-protein binding data obtained from the 
analysis of complex biological samples such as serum. 
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Table 5. J: Metal distribution in enriched serum samples. • denotes metal present in 
protein fraction . •• denotes metal signal intensity relatively high 
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Chapter 6: Conclusions and Recommendations for 
Future Work 
6.1 Conclusions 
Certain criteria were outlined in the aImS of the study, which the gel 
electrophoresis/laser ablation combination needed to fulfill in order for it to be 
deemed suitable for metal speciation in biological samples. The four key criteria 
were as follows. 
• Mild conditions to maintain integrity of metal-protein species 
• Selective separation step to separate species 
• High sensitivity metal species detection 
• Small sample volume requirements 
All of these criteria were considered during the method development step. PAGE 
was chosen for its high selectivity in separating serum proteins and the small 
sample volumes required. To ensure sample integrity, serum samples were 
separated under native conditions. ICP-MS was chosen as the detection system 
because of its muhi-element capability as well as its high sensitivity. Laser 
ablation provided a novel route for sample introduction permitting rapid 
interrogation of gels and acquisition of mass spectra. In situ analysis of the gels 
helped to maintain both the metal-protein species integrity and protein resolution. 
LA ICP-MS analysis of native electrophoresis gels was found to compare 
favourably with competitive techniques. Method development studies showed 
both the electrophoresis step and the metal detection step to be robust and have 
good reproducibility. The design of the electrophoresis system meant the 
background platinum signal was suitably low. The muhi-element capability of the 
technique means a variety of elements were monitored simuhaneously, reducing 
the need for replicate gel interrogations. As a result multi-element data from an 
electrophoresed sample can be acquired relatively rapidly at around 20 minutes. 
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Pt-protein binding was observed in serum samples acquired from patients 
undergoing platinum therapy. Analysis of control serum showed no such binding. 
Cisplatin and carboplatin, two popular platinum anti-tumour drugs, were studied. 
LA ICP-MS combined with native PAGE showed there to be differences in the 
protein binding of these two drugs. In vitro studies enriching control serum with 
cisplatin and carboplatin show both drugs binding with a range of proteins. It was 
observed that cisplatin bound more readily to albumin than was the case for 
carboplatin. Time studies carried out with the two drugs highlighted differences in 
their protein binding mechanisms. Levels of protein bound cisplatin were seen to 
increase with time, with the majority of the platinum always bound to albumin. 
The platinum distribution pattern for carboplatin enriched serum was seen to alter 
over time with the proportion of albumin bound platinum increasing. These 
differences in protein binding were also observed in serum samples acquired from 
patients undergoing platinum therapy. Such differences in protein binding and 
mechanistic pathways of the two drugs could go some way to explaining the 
differences in their associated toxicities. It would appear that Pt-albumin binding 
is associated with drug toxicity rather than drug efficacy; such a finding is 
consistent with the fact that albumin bound platinum drugs are known to lose their 
anti-tumour activity. 
The degree and nature of gold-protein binding was found to be very dependent 
upon the gold species present. Au(ITI) and Au(I) were both found to bind almost 
instantaneously with albumin when studied in vitro. However, when serum was 
enriched with colloidal gold (Au(O)) no protein binding was observed, instead the 
gold flocculated and did not enter the gel. The profiles obtained from analysis of 
clinical samples are consistent these findings. 
The FI ICP-MS studies established gold concentrations of 300 J.lg/L in control 
serum whilst significantly higher gold concentrations (469-952 J.lg/L) were 
detected in serum from patients undergoing chrysotherapy. Gold-protein binding 
was found to be significantly higher in the patients' serum (37-69 %) than in the 
control (-2 %), reflecting the source of serum gold. 
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The main source of gold in serum obtained from chrysotherapy patients is the 
administration of Au(I) drugs. Au(I) is thought to disproportionate in serum to 
give Au(O) and Au(III), which has been shown to bind readily with serum 
proteins. With reference to the control serum the majority of the gold has been 
shown not to be protein bound. This fInding would imply inorganic gold is not the 
main source of gold. These fIndings demonstrate how absolute gold levels are of 
little diagnostic use when trying to assess adverse reactions to gold. The degree of 
protein-bound gold, however, may be more relevant to such studies. 
When the technique was applied to serum enriched with a range of multi-elements 
in vitro, a variety of metal distribution profIles was observed signifying extensive 
metal-protein binding. These results are summarised in Appendix 2.4. In some 
instances very little metal-protein binding was observed. This does not necessarily 
imply no metal-protein binding occurs for these metals. The experimental 
conditions used, ahhough mild, may disrupt existing metal-protein bonds. 
Akernatively the species of metal used in serum enrichment may not be suitable 
for protein binding. The study also illustrated some of the complex interactions 
occurring in serum with regards the interactions of various metal ions. Such 
interactions can, in turn, affect the degree/nature of metal-protein binding. The 
possibility of metal-metal interactions must be considered when interpreting 
metal-protein binding data obtained from the analysis of complex biological 
samples such as serum. 
Overall the technique proved suitable for the metal speciation of biological 
samples. It was successfully applied to the detection of metal species in human 
serum enriched in vitro with a variety of metals. The technique was also used to 
speciate metals occurring in serum at trace levels, such as Fe and Cu. Finally the 
technique was successfully used to analyse clinical samples obtained from 
patients undergoing platinum and gold therapy. Meaningful data was obtained 
which could be compared to that obtained from the analysis of control serum. 
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6.2 Recommendations for Future Work 
Recommendations for future work focus firstly upon improving the technique and 
then on further clinical studies. Ahhough the technique met the criteria laid out in 
the aims of the study it still had a number oflimitations, which might be improved 
upon. The main limitations of the technique include: 
• high concentration of albumin in serum obscures other serum proteins and 
so necessitates sample dilution 
• limited protein identification given the use of native PAGE 
• limited protein resolution given the complex nature of the sample, serum 
typically contains more than 100 proteins. 
The main protein component of serum is albumin (- 35 mglmL). Such high 
albumin concentrations can pose problems when trying to look at metal binding to 
other, lower concentration proteins. One way in which such problems can be 
overcome would be to remove the serum albumin prior to protein separation. 
Albumin removal can be achieved by passing the serum through an affmity gel 
such as the one produced by Bio_Rad227• Removal of albumin in this way will 
greatly reduce the total protein concentration of the serum, thus removing the need 
for sample dilution. This would effectively increasing the sensitivity of the 
technique as well as improving the potential protein resolution. Investigation 
would need to be carried out to check if the integrity of the metal species was 
maintained. 
Protein identification is difficuh when using native PAGE as the migration 
distance of the protein is not simply a function of molecular mass. A method of 
protein identification which could be used in conjunction with LA ICP-MS of 
polyacrylamide gels is matrix assisted laser desorption/ionsiation time of flight 
mass spectrometry (MALDI TOF)228. In this process a laser is used to remove 
molecules, intact, from the target and the molecular mass of the molecule is 
determined using time of flight MS. An initial test was carried out using albumin 
on the target and promising resuhs were obtained, see Appendix 2.5. 
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MALDI has been used to analyse proteins directly from the polyacrylamide 
gels229• The process requires the use of a matrix, which allows the sample to be 
desorbed by the laser energy. Investigations into the best matrix for the system 
would be needed. By using MALDI TOF the molecular mass ofa protein. from a 
region of the gel where high metal concentrations were detected, could be 
determined. Such information may help identify the proteins binding metal ions. 
The protein resolution achievable with native PAGE is limited by factors such as 
the gel size and the protein concentration. Albumin removal might go some way 
to improving resolution of the remaining proteins. Increasing the size of the gels, 
whilst it would improve the protein resolution would also increase the 
electrophoretic run time, increasing the likelihood of metal-protein binding loss. It 
would also increase the interrogation time. Another way in which protein 
resolution can be improved is to use a different separation technique. The use of 
liquid IEF, in the form of the Bio-Rad Rotofor followed by native PAGE was 
shown to improve protein resolution by the addition of a second separation 
parameter. This technique was found to work with platinum samples. Its 
applicability to other metals would have to be determined to check sample 
integrity. Another analytical technique for rapid protein separation requiring small 
sample volumes is capillary electrophoresis (CE). Coupling of CE to ICP-MS was 
until quite recently troublesome. Recent advances have made it more easily 
achievable ls4• 230. CE coupled to ICP-MS would combine rapid protein 
identification with sensitive multi-element detection. The main draw back with 
this technique compared with LA ICP-MS of polyacrylamide gels is that the 
sample is totally destroyed by analysis whereas the gel can be re-analysed after 
suitable storage if required. 
Futme work in the applications of the technique to clinical samples should include 
a more extensive time study of both the platinum and gold patients. Analysis of 
samples from colloidal gold trials would also be interesting. Table 1.5 shows a 
sample of the metallo-drugs currently used and so the potential clinical 
applications of this technique are numerous. 
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Appendix 1.1: Elemental Composition of a Reference Person 
Class Element gl70 kg molesl70 kg 
Balk DemeDts C 12600 1050 
H 7000 3500 
N 2100 75 
0 45500 1425 
MaerODatrieDts Ca 1050 26.2 
CI 105 2.96 
K 140 3.58 
Mg 3S 1.44 
Na 105 4.6 
P 700 22.5 
S 175 5.5 
Tnee Elemeatl 
EsseDtial Co 0.003 0.00005 
Cr 0.005 0.0001 
Cu O.ll 0.0016 
F 0.8 0.021 
Fe 4.2 0.075 
I 0.03 0.00024 
Mn 0.02 0.00036 
Mo 0.005 0.00005 
Se 0.02 0.00025 
Zn 2.33 0.036 
Possibly Esseafial Ni 0.01 0.00017 
Si 1.4 0.05 
So 0.03 0.00025 
V 0.02 0.00039 
NOD-Esseatial AI 0.1 0.0037 
As 0.014 0.00019 
B 0.01 0.00092 
Sa 0.016 0.00012 
Cd 0.03 0.00027 
Li 0.0007 0.0001 
Pb 0.08 0.00038 
Rb 1.1 0.013 
Sb 0.07 0.00057 
Sr 0.14 0.0016 
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Appendix 1.2: The Natural Protein Amino Acids 
Name Character Metal-binding Sidechain 
Aspartic acid. Asp Acid M2+, M3+ 
-CH2-COOH 
Glutamic acid. Glu Acid M2+ 
-CH2-CH2-COOH 
Tyrosine, Tyr Neutral Mn3+, Fe3+ 
-CH2-(Q)O-H 
Alanine, Ala Neutral 
-CH3 
Asparagine, Asn NeutraL, -CH2-CO-~2 
Cysteine, Cys Neutral Zn, Cu, Fe, Ni, Mo -CH2-SH 
Glutamine, Gin Neutral -CH2-CH2-CO-~2 
Serine, Ser Neutral M+? 
-CH20H 
Threonine, Thr Neutral M+? 
-CH-CH3 
bH 
Histidine, His Neutral Zn, Cu, Mn, Fe, Ni 
-CH2-C=CH 
Basic anion binding ~r 
Arginine, Arg Basic anion binding -(CH2)3-~-C-~2 
!!rn2+ 
Lysine, Lys Basic anion binding -(CH2)4-~3+ 
Glycine, Gly Non-polar -H 
Isoleucine, lie Non-polar 
-CH-CH2-CH3 I 
CH3 
Leucine, Leu Non-polar /CH3 
-CH2-C~ 
CH3 
Methionine, Met Non-polar Cu, Fe 
-CH2-CH2-S-CH3 
Phenylalanine, Phe Non-polar 
-CH2-(Q) 
Proline, Pro Non-polar amino group replaced 
by cyclic imino group 
Tryptophan, Trp Non-polar 
-CH21fJlPl 
Valine, Val Non-polar /H3 
-CH 
"cH3 
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Appendix 1.3: Metallo-drugs used in Sample Enrichment 
Cisplatin 
Cisplatin injection solution. Concentration 1 mglmL, presented in 10 mL Onco-
Tain™ vials. Each mL contains I mg of cisplatin, 9 mg of sodium chloride B.P. 1 
mg of mannitol B.P. and water for injections B.P. Distributed in UK by Faulding 
Pharmaceuticals pic trading as David Bull Laboratories. 
Carboplatin 
Paraplatin™ injection solution. Concentration 10 mglmL, presented in 15 mL 
vials. Also contains water for injections. Distributed in UK by Bristol-Myers 
Pharmaceuticals. 
Myocrisin 
MyocrisinTM injection solution. Concentration 10 % presented in 0.5 mL 
ampoules. The injection solution also contains phenylmercuric nitrate and water 
for injections. Distributed in UK by JHC Heahhcare Limited. 
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Appendix 1.4: Properties of Serum Proteins 
Protein pI Molecular Mass mg/IOO mL (in serum) 
alAcid glycoprotein 2.7 44100 75-100 
haptoglobulin 4.1 100000 30-190 
ceruloplasmin 4.4 160000 27-63 
prealbumin 4.7 61000 28-35 
albumin 4.9 69000 3500-4500 
az-macroglobu lin 5.4 820000 220-380 
tnnsrerrin 5.9 75000 200-320 
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Appendix 1.5: Metal Standards used in Sample Enrichment 
As 1000 J,lg/mL As in 2 % HN03 
Au 1000 J,lg/mL Au in HCl 
Bi 1000 J,lg/mL Bi in 2 % HN03 
Cd 1000 J,lg/mL Cd in 2 % lIN03 
Co 1000 J,lg/mL Co in 2 % HN03 
Cr 1000 J,lg/mL as (NR.)2Cr2O, in lIN03 
Cu 1000 J,lg/mL Cu in 2 % 
Fe 1000 J,lg/mL Fe in 2 % lIN03 
Ga 1000 J,lg/mL Ga in HN03 
Gd 1000 J,lg/mL as Gd203 in lIN03 
Hg 1000 J,lg/mL Hg in 2 % HN03 
In 1000 J,lg/mL In in 2 % lIN03 
La 1000 J,lg/mL as La203 in lIN03 
Li 1000 J,lg/mL as LhC03 in lIN03 
Lu 1000 J,lg/mL as LU203 in HN03 
Mn 1000 J,lg/mL Mn in 2 % lIN03 
Mo 1000 J,lg/mL Mo in 2 % lIN03 
Ni 1000 J,lg/mL Ni in 2 % HN03 
Pb 1000 J,lg/mL as Pb(N03)2 in HN03 
Pd 1000 J,lg/mL Pd in HC} 
Pt 1000 J,lg/mL Pt in HC} 
Ru 1000 J,lg/mL as RuCh.3H20 in HC} 
Sb 1000 J,lg/mL Sb in 2 % lIN03 
Se 1000 J,lg/mL Se in 2 % HN03 
Sn 1000 J,lg/mL Sn in lIN03 tr. HF 
Sr 1000 J,lg/mL as Sr(N03)2 in HN03 
V 1000 J,lg/mL V in 2 % HN03 
Zn 1000 J,lg/mL Zn in 2 % HN03 
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Appendix 1.6: Laser Ablation Parameters 
LSX 200 Energy Values 
1 OmJ 11 1.9mJ 
2 OmJ 12 2.2mJ 
3 0.1 m.J 13 2.7mJ 
4 0.2 m.J 14 3.1 mJ 
5 0.4 m.J 15 3.3 mJ 
6 0.6 m.J 16 3.4mJ 
7 0.8mJ 17 3.7mJ 
8 1.1 mJ 18 4.0mJ 
9 1.3 m.J 19 4.2mJ 
10 1.7 mJ 20 4.6mJ 
LSX 200 Aperture Diameters 
1 1OJ.U1l 5 200 Ilm 
2 25 J.U1l 6 260 J.1ffi 
3 50 J.U1l 7 300 Ilm 
4 100 J.U1l 
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Appendix 1.7: Composition ofSRM612 
Element Certified Value 
(mglkg) 
Barium (41) 
Boron (32) 
Cerium (39) 
Cobah (35.5) 
Copper (37.7) 
Dysprosium (35) 
Erbium (39) 
Europium (36) 
Gadolinium (39) 
Gold (5) 
Iron 51 
Lanthanum (36) 
Lead 38.57 
Manganese (39.6) 
Neodymium (36) 
Nickel 38.8 
Potassium (64) 
Rubidium 31.4 
Samarium (39) 
Silver 22 
Strontium 78.4 
Thallium (15.7) 
Thorium 37.79 
Titanium (50.1) 
Uranium 37.38 
Ytterbium (42) 
Values in brackets not certified 
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Appendix 2.1: Protein Assay 
The Bio-Rad protein assay is based on a method first developed by Bradford231 • It 
is used to determine the total protein concentration of a sample based on the 
proportional binding of Coomassie® Brilliant Blue 0-250 dye to proteins. The 
binding of the dye to a protein causes a shift in the absorption maximum of the 
dye from 465 run (doubly protonated red form) to 595 run (unprotonated blue 
form). The protein concentration of a sample is determined by comparison of the 
absorbance max at 595 run to a linear absorbance profile produced by a series of 
calibration standards. The micro assay procedure is very sensitive with a working 
range of 5-1 00 J-lg/ml. 
The method is a rapid, simple one-step procedure in which the reagent is added to 
the sample and the absorbance measured at 595 run. This assay has the advantage 
of being faster, involving fewer mixing steps, not requiring heating and giving a 
more stable colorimetric response than other assays commonly used. However, as 
with other assays the results can be influenced by non-protein sources such as 
detergents and response becomes progressively non-linear at the high end of the 
protein concentration range. The procedure also exhibits a significant dependence 
on protein amino acid composition and this has recently been shown to be a 
consequence of the dye binding primarily to basic (especially arginine) and 
aromatic amino acid residues232• 
The system was calibrated using lyophilised bovine serum albumin (BSA) 
reconstituted in deionised water. Five working standards were prepared in linear 
range (1.2-20 J-lg/mL). To 800 J.lL of each standard and sample solution 200 J-lL of 
dye reagent concentrate were added. Samples were mixed using a vortex spinner 
then incubated at room temperature for 5 minutes - 1 hour. The absorbance 
maximum at 595 run was then measured. A calibration graph plotted with 
Absorbance at 595 run vs [protein] for the BSA standard solutions, see Figure 
A2.1. The protein concentrations of the samples were then determined using the 
calibration curve, values obtained shown in Table A2.1. 
200 
1 2 
0.8 
III 
~ 
Q 0.6 0 
0.4 
0.2 
0 
0 2 4 6 7 
Protein Concentration (J.tglmL) 
8 
y = 0.0908x + 0.0539 
R2 = 0.9917 
9 10 
Figure A2.1: Standard Curve for Bio-Rad protein assay using BSA 
Electro-elution Protein Concentration 
Fraction ()lg/mL) 
1 39.93 
2 41.93 
3 35.97 
4 51.28 
5 58.02 
6 39.70 
7 51.51 
8 378.62 
9 306.62 
10 32.46 
11 23.82 
12 25.93 
13 23.32 
14 25.84 
Mean 81.07 
Table A2.1: Protein ConcentratIOns In Electro-elution Fractions 
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Assuming the mean protein concentration in serum is 70 mg/mL then the % 
protein recovery following electro-elution can be carried out as follows; 
[protein] in neat serum = 70mg/mL 
[protein] in enriched serum = 70 xO.9 = 63 mg/mL 
[protein] in sample with buffer = 63 x 0.5 = 31.5 mg/mL 
[protein] in recovered fractions = 31.5 x 0.01 = 0.315 mg/mL 
[protein] recovered (mean) = 81.07 ~g/mL 
% protein recovery = 100/0.315 x 0.08107 = 25.74 % 
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Appendix 2.2: Calculation of Iron Concentration 
Typical concentration of transferrin in serum = 2 mglmL 
Molecular mass of transferrin = -75 kDa 
Atomic mass of iron = 56 
Number of iron binding sites per molecule of transferrin = 2 
Typical saturation of iron binding sites in serum = 40010 
Typical concentration of iron bound to transferrin in serum given by; 
[Fe-transferrin ] = no mo lecules x no Fe atoms x atomic 
in serum transferrin per molecule mass Fe 
0.002 / 75000 x (2 x 40 /100) x 56 
1.194 x 10-6 glmL 
= 1.194 J.1g1mL 
typical amount of Fe-transferrin loaded per PAGE lane is given by; 
Fe-transferrin mass = [Fe-transferrin] in serum x serum volume 
= 1.194 x 0.00225 
= 0.0027 J.1g 
::::: 3 ng Fe-transferrin/lane 
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Appendix 2.3: Metal Profiles for Enriched Serum 
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